Document:

Co-Development and License Agreement, dated September 30, 2002

  
 Exhibit 10.1 
  
 Confidential treatment has been requested for portions of this Exhibit. The copy filed
herewith omits the information subject to the confidentiality request. Omissions are designated as ***. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 EXECUTION COPY 
  
 CO-DEVELOPMENT AND 
  
 LICENSE AGREEMENT 
  
 between 
  
 NEOTHERAPEUTICS, INC. 
  
 and 
  
 GPC BIOTECH AG 
  
 Dated as of September 30, 2002 
  

 1 

 CO-DEVELOPMENT AND 
 LICENSE AGREEMENT 
  
 This
CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), dated as of September 30, 2002, is between Neotherapeutics, Inc., a company duly organized and existing under the laws of Delaware and having offices at 157 Technology Drive, Irvine,
California, USA for and on behalf of itself and its Affiliates (“NEOTHERAPEUTICS”), and GPC Biotech AG, a company duly organized and existing under the laws of the Federal Republic of Germany and having offices at Fraunhoferstrasse 20,
D-82152 Martinsried/Munich Germany, for and on behalf of itself and its Affiliates (together with its Affiliates, “GPC”). 
  
 PRELIMINARY STATEMENTS 
  
 A. NEOTHERAPEUTICS has entered into that certain License Agreement with Johnson Matthey PLC (“J-M”) dated August 28, 2001, pursuant to which
NEOTHERAPEUTICS has been granted a license, with the right to sublicense, to certain patent rights and other know-how and technology owned by J-M. 
  
 B. NEOTHERAPEUTICS wishes to grant a sublicense to GPC, and GPC wishes to take a sublicense from NEOTHERAPEUTICS, under certain rights granted to
NEOTHERAPEUTICS under the J-M License Agreement and under other relevant patent rights and know-how controlled by NEOTHERAPEUTICS, upon the terms and conditions set forth in this Agreement. 
  
 NOW, THEREFORE, in consideration of the foregoing preliminary statements and
the mutual covenants and agreements of the Parties contained in this Agreement, the Parties hereby agree as follows: 
  
 1. DEFINITIONS 
  
 As used in this Agreement, the following terms shall have those meanings set forth in this Section 1 unless the context dictates otherwise. 
  
 1.1. “Affiliate” with respect to either Party, shall mean any
Person controlling, controlled by, or under common control with, such Party. For the purpose of this Section 1.1, “control” shall refer to (i) the possession, directly or indirectly, of the power to direct the management or policies of
such Party, whether through the ownership of voting securities, by contract or otherwise, or (ii) the beneficial ownership (as such term is defined in the 1934 Act) of at least fifty percent (50%) of the voting securities or other ownership interest
of such Party. 
  
 1.2. “Confidential Information” shall
have the meaning assigned to such term in Section 12.1. 
  
 1.3.
“Covered Product” shall mean any Platinum Complexes formulated for administration to humans, the research, development, manufacture, sale or use of which in any country in the Territory is covered by a Valid Claim of any Patent included in
the J-M Licensed Technology or the NEOTHERAPEUTICS Licensed Technology. 
  

 2 

 1.4. “Effective Date” shall mean the date first set forth above. 
  
 1.5. “EMEA” shall mean the European Agency for the Evaluation of
Medicinal Products and any successor thereto. 
  
 1.6.
“FDA” shall mean the United States Food and Drug Administration, or any successor thereto. 
  
 1.7. “Field” shall mean the FIELD, as such term is defined in the J-M License Agreement, as amended from time to time. 
  
 1.8. “First Commercial Sale” shall mean, with respect to any
Covered Product, the first sale for use or consumption by the general public of such Covered Product in a country in the Territory after all required marketing and pricing approvals have been granted, or otherwise permitted, by the governing health
authority of such country. “First Commercial Sale” shall not include the sale of any Covered Product for use in clinical trials or for compassionate use prior to the approval of an NDA. 
  
 1.9. “GPC Development Technology” shall mean all Inventions and
Know-How first developed, reduced to practice or shown to have utility by one or more employees of GPC without the involvement of one or more employees of NEOTHERAPEUTICS in connection with the development of Covered Products, as well as any and all
Patents covering the same. 
  
 1.10. “Invention” shall
mean any new or useful method, process, manufacture, compound or composition of matter, whether or not patentable or copyrightable, or any improvement thereof. 
  

1.11. “J-M License Agreement” shall mean that certain License Agreement dated August 28, 2001, by and between NEOTHERAPEUTICS and J-M, as
amended from time to time. A copy of such Agreement, including all amendments executed prior to the execution of this Agreement, is attached hereto as Exhibit A. 
  
 1.12. “J-M Licensed Technology” shall mean the J-M Patent Rights, the LICENSOR’S INFORMATION and the
LICENSOR’S ONGOING INFORMATION to which NEOTHERAPEUTICS has been granted a license under the J-M License Agreement, as such capitalized terms are defined in the J-M License Agreement, as amended from time to time. 
  
 1.13. “J-M Patent Rights” shall mean the PATENT RIGHTS, as such
term is defined in the J-M Licensed Agreement. A list of all such J-M Patent Rights in existence on the Effective Date is included in Exhibit B attached hereto. 
  

1.14. “J-M Royalty Term” shall mean the period beginning on the Effective Date and ending on the earlier of (i) the expiration of the TERM,
as such term is defined in the J-M License Agreement, as amended from time to time, or (ii) the date on which NEOTHERAPEUTICS is no longer required to make royalty payments to J-M pursuant to the J-M License Agreement. 
  

 3 

 1.15. “Joint Development Committee” shall mean the entity organized and acting pursuant to
Section 4. 
  
 1.16. “Joint Development Technology”
shall mean all Inventions and Know-How first developed, reduced to practice or shown to have utility by one or more employees of GPC and one or more employees of NEOTHERAPEUTICS in connection with the development of Covered Products, as well as any
and all Patents covering the same. 
  
 1.17. “Know-How”
shall mean unpatented technical and other information which is not in the public domain including information comprising or relating to discoveries, inventions, data, designs, formulae, methods, models, assays, research plans, procedures, designs
for experiments and tests and results of experimentation and testing (including results of research or development), processes (including manufacturing processes, specifications and techniques), laboratory records, chemical, pharmacological,
toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses, reports or summaries and information contained in submissions to and information from ethical committees and regulatory authorities. Know-How
includes rights protecting Know-How. The fact that an item is known to the public shall not be taken to exclude the possibility that a compilation including the item, and/or a development relating to the item, is (and remains) not known to the
public. 
  
 1.18. “MAA” shall mean a Marketing
Authorization Application or similar application filed with the EMEA after completion of human clinical trials to obtain marketing approval for a Covered Product in the European Union. 
  
 1.19. “MHW” shall mean the Ministry of Health and Welfare in Japan and any successor agency. 
  
 1.20. “NDA” shall mean a New Drug Application to be filed with the
FDA, or the equivalent thereof in other countries or regulatory jurisdictions. 
  
 1.21. “NEOTHERAPEUTICS Development Technology” shall mean all Inventions and Know-How first developed, reduced to practice or shown to have utility by one or more employees of NEOTHERAPEUTICS without the
involvement of one or more employees of GPC in connection with the development of Covered Products, as well as any and all Patents covering the same. 
  
 1.22. “NEOTHERAPEUTICS Licensed Technology” shall mean the LICENSEE’S ONGOING INFORMATION, as such term is defined in the J-M License
Agreement, as amended from time to time, as well as all Patents owned or controlled by, or licensed to, NEOTHERAPEUTICS, and all Know-How and Inventions developed, owned or controlled by, or licensed to, NEOTHERAPEUTICS, on or after the Effective
Date, other than the J-M Licensed Technology, which, by objective standards, is necessary for or may be useful in the development, manufacture, use or sale of Licensed Products in the Field in the Territory, all to the extent that NEOTHERAPEUTICS
has the right to license or otherwise make available such Patents, Know-How and Inventions to GPC hereunder. A list of all such Patents in existence on the Effective Date is included in Exhibit B attached hereto. 
  

 4 

 1.23. “Net Sales” shall have the meaning ascribed to the term “Net Sales Value” in
the J-M License Agreement, as amended from time to time. 
  
 Notwithstanding the foregoing, in the event a Covered Product is sold in conjunction with another proprietary component so as to be a combination product (whether packaged together or in the same therapeutic formulation), Net Sales shall be
calculated by multiplying the Net Sales of such combination product by a fraction, the numerator of which shall be the fair market value of the Covered Product as if sold separately (determined in accordance with generally accepted accounting
principles), and the denominator of which shall be the aggregate fair market value of all the proprietary active components of such combination product, including the Covered Product, as if sold separately. In the event no such separate sales are
made by GPC or its Affiliates, Net Sales of the combination product shall be calculated in a manner to be negotiated and agreed upon by the Parties, reasonably and in good faith, prior to any sale of such combination product, which shall be based
upon the respective estimated commercial values of the proprietary active components of such combination product. 
  
 GPC’s or any of its Affiliate’s transfer of Covered Product to another Affiliate or a Sublicensee shall not result in any Net Sales, unless such
Covered Product is consumed by such Affiliate or Sublicensee in the course of its commercial activities. 
  
 1.24. “1934 Act” shall mean the U.S. Securities Exchange Act of 1934, as amended, and all regulations promulgated pursuant thereto from time to
time. 
  
 1.25. “Party” shall mean NEOTHERAPEUTICS or
GPC and, when used in the plural, shall mean NEOTHERAPEUTICS and GPC. 
  
 1.26. “Patents” shall mean all letters patent and patent applications throughout the Territory, as well as any and all substitutions, extensions, renewals, continuations, continuations-in-part, divisions, patents-of-addition
and/or reissues thereof. 
  
 1.27. “Person” shall mean
any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or any agency or political subdivision thereof. 
  
 1.28. “Platinum Complexes” shall mean the platinum co-ordination
compounds that are the subject of the J-M Patent Rights. 
  
 1.29.
“Royalty Term” shall mean the period beginning on the Effective Date and ending on the date of the expiration of the last to expire Valid Claim, if any, included in the Joint Development Technology or NEOTHERAPEUTICS Development Technology
that covers the manufacture or sale of Covered Products. If, at the time of expiration of the J-M Royalty Term, there are no Valid Claims included in the Joint Development Technology or NEOTHERAPEUTICS Development Technology covering the manufacture
or sale of a Covered Product, then the Royalty Term with respect to such Covered Product shall expire on the expiration of the J-M Royalty Term. 
  
 1.30. “Satraplatin” shall mean the platinum complex bis(acetato)amminedichloro(cyclohexylamine)platinum(IV). 
  

 5 

 1.31. “Sublicensee” shall mean a Third Party to which GPC has sublicensed rights under the
NEOTHERAPEUTICS Licensed Technology or J-M Licensed Technology for the commercialization of Covered Products. 
  
 1.32. “Sublicense Fees” shall mean all payments made to GPC from a Sublicensee that relate specifically to the sublicense of rights granted to
GPC hereunder, excluding (i) payments made in consideration of research and development efforts undertaken by GPC, (ii) payments made to reimburse GPC for expenses previously incurred by GPC in connection with the development of Covered Products,
(iii) payments made in consideration of the purchase of equity of GPC by a Sublicensee to the extent that such payments do not exceed the fair market value of such equity, (iv) payments made in consideration of the manufacture or supply of Covered
Products by GPC to the extent that such payments do not exceed CPC’s costs of such manufacture and supply, (v) loans made to GPC or (vi) Sublicense Royalties. 
  
 1.33. “Sublicense Royalties” shall mean royalty payments made to GPC based on sales of Covered Products by a
Sublicensee. 
  
 1.34. “Territory” shall mean the entire
world. 
  
 1.35. “Third Party” shall mean any Person who
or which is neither a Party nor an Affiliate of a Party. 
  
 1.36.
“Valid Claim” shall mean (i) a pending claim in any patent application that has not been pending for more than five (5) years, which shall be treated as if such pending claim were issued in then-current form, or (ii) a claim of any issued
letters patent that, in each case, has not been held invalid or unenforceable by final decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that is not
admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 
  
 2. REPRESENTATIONS AND WARRANTIES 
  
 2.1.
Representations and Warranties of Both Parties. Each Party represents and warrants to the other Party that, as of the Effective Date: 
  
 (a) Such Party is duly organized and validly existing under the laws of the jurisdiction of its incorporation and has full corporate power
and authority to enter into this Agreement and to carry out the provisions hereof; 
  
 (b) Such Party has taken all corporate action necessary to authorize the execution and delivery of this Agreement and the performance of
its obligations under this Agreement; and 
  
 (c)
This Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in accordance with the terms of this Agreement, except as such enforceability may be affected by laws affecting creditors’
rights generally and general equitable principles. The execution, delivery and performance of this Agreement by such Party do not conflict with any agreement, instrument or understanding, oral or written, to which such Party is a party or by which

  

 6 

	 	 
such Party may be bound, or violate any law or regulation of any court, governmental body or administrative or other agency having authority over such Party.
All consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by such Party in connection with the execution, delivery and performance of this Agreement have been obtained.

  
 2.2. Additional Representations and
Warranties of NEOTHERAPEUTICS. NEOTHERAPEUTICS represents and warrants to GPC that, as of the Effective Date: 
  
 (a) NEOTHERAPEUTICS and/or its Affiliates are the owner of, or have exclusive rights to, all of the Patents included in the J-M Licensed
Technology (except as expressly provided in the copy of the J-M License Agreement attached as Exhibit A) and the NEOTHERAPEUTICS Licensed Technology in existence on the Effective Date, and have the exclusive right to grant the licenses or
sublicenses, as the case may be, therefor granted under this Agreement; 
  
 (b) All such Patents consist of either patent applications that have been filed and are pending and actively being prosecuted as of the Effective Date, or issued letters patent that are in full force and effect and
have been maintained through the Effective Date; 
  
 (c) NEOTHERAPEUTICS is not aware of any asserted or unasserted claim or demand which it believes can be enforced by a Third Party against any such Patents; 
  
 (d) To the best of NEOTHERAPEUTICS’s knowledge and belief, the practice of such Patents and the
exercise of the rights granted to GPC in Section 7 do not infringe upon or conflict with any patent, copyright or other proprietary right of any Third Party; 
  

(e) NEOTHERAPEUTICS and/or its Affiliates have the right to grant the licenses or sublicenses, as the case may be, granted under this
Agreement for all of the Know-How and Inventions included in the J-M Licensed Technology and NEOTHERAPEUTICS Licensed Technology in existence on the Effective Date; 
  
 (f) Such Know-How and Inventions were not obtained by NEOTHERAPEUTICS, and to the best of
NEOTHERAPEUTICS’s knowledge and belief were not obtained by J-M, in violation of any contractual or fiduciary obligation to which NEOTHERAPEUTICS, J-M or any of their respective employees or staff members are or were bound, or by the
misappropriation of the trade secrets of any Third Party; 
  
 (g) NEOTHERAPEUTICS has not entered into any agreement with any Third Party which is in conflict with the rights granted to GPC under to this Agreement, and the execution and performance of this Agreement by
NEOTHERAPEUTICS do not and shall not violate any agreement or undertaking to which NEOTHERAPEUTICS is a party; and 
  
 (h) To the best of NEOTHERAPEUTICS’s knowledge and belief, all of the data and information that NEOTHERAPEUTICS has provided to GPC
prior to the Effective Date relating to such Patents, Know-How and Inventions, and to Covered 

  

 7 

 
Products in general, are reasonably accurate, and NEOTHERAPEUTICS has not omitted therefrom any material data or information in NEOTHERAPEUTICS’s
possession or control reasonably in advance of the Effective Date concerning the same. 
  
 2.3. Representations and Warranties of GPC. GPC represents and warrants to NEOTHERAPEUTICS that, as of the Effective Date: 
  
 (a) Experience. GPC acknowledges that it can bear the economic risk of its investment in the NEOTHERAPEUTICS
Shares. GPC has by reason of its business or financial experience or the business or financial experience of its professional advisors who are unaffiliated with and who are not compensated by NEOTHERAPEUTICS or any affiliate or selling agent of
NEOTHERAPEUTICS, directly or indirectly, has the capacity to protect its own interests in connection with its purchase of the NEOTHERAPEUTICS Shares. GPC has the financial capacity to bear the risk of this investment. 
  
 (b) Purchase Entirely for Own Account. The NEOTHERAPEUTICS
Shares will be acquired by GPC for investment for GPC’s own account not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and GPC has no present intention of selling, granting any participation in, or
otherwise distributing the same. GPC does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the
NEOTHERAPEUTICS Shares. GPC has not been formed for the specific purpose of acquiring solely the NEOTHERAPEUTICS Shares. 
  
 (c) Disclosure of Information. GPC has received and reviewed information about NEOTHERAPEUTICS, and in particular about the Patents,
Know-How, Inventions and Covered Products, and has had an opportunity to discuss NEOTHERAPEUTICS’s business, management and financial affairs with its management and to review NEOTHERAPEUTICS’s facilities. GPC understands and acknowledges
that such discussions, as well as any written information issued by NEOTHERAPEUTICS (i) were intended to describe the aspects of NEOTHERAPEUTICS’s business and prospects which NEOTHERAPEUTICS believes to be material, but were not necessarily an
exhaustive description (except to the extent described in Section 2.2(h)), and (ii) may have contained forward-looking statements involving known and unknown risks and uncertainties which may cause NEOTHERAPEUTICS’s actual results in future
periods or plans for future periods to differ materially from what was anticipated and that no representations or warranties were or are being made with respect to any such forward-looking statements or the probability of achieving any of the
results projected in any of such forward-looking statements. Nothing contained in this Section 2.3 shall limit in any respect NEOTHERAPEUTICS’s representations and warranties contained in this Agreement. 
  
 (d) Restricted Securities. GPC understands that the
NEOTHERAPEUTICS Shares have not been, and will not, prior to issuance under Section 9.1(c), be, registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration
provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy 

  

 8 

	 	 
of GPC’s representations as expressed herein. GPC understands that the NEOTHERAPEUTICS Shares are “restricted securities” under applicable
U.S. federal and state securities laws and that, pursuant to these laws, GPC must hold the NEOTHERAPEUTICS Shares indefinitely unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration and
qualification requirements is available. GPC acknowledges that NEOTHERAPEUTICS has no obligation to register or qualify the NEOTHERAPEUTICS Shares for resale except as set forth in the Registration Rights Agreement to be entered into as provided in
Section 9.1(c). GPC further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the
NEOTHERAPEUTICS Shares, and on requirements relating to NEOTHERAPEUTICS which are outside of GPC’s control, and which NEOTHERAPEUTICS is under no obligation and may not be able to satisfy. GPC acknowledges that NEOTHERAPEUTICS will make a
notation on its stock books regarding the restrictions on transfers set forth in this Section 2.3 and will transfer securities on the books of NEOTHERAPEUTICS only to the extent not inconsistent therewith. 

  
 (e) Residence. The office or offices of GPC in which its
investment decision was made is located at the address or addresses of GPC set forth in the preamble. 
  
 (f) Further Restrictions on Disposition. GPC agrees not to make any disposition of all or any portion of the NEOTHERAPEUTICS Shares unless
and until: (a) there is then in effect a registration statement under the Securities Act covering such proposed disposition and the disposition is made in accordance with such registration statement; or (b) (i) GPC shall have notified
NEOTHERAPEUTICS of the proposed disposition and shall have furnished NEOTHERAPEUTICS with a statement of the circumstances surrounding the proposed disposition and (ii) if reasonably requested by NEOTHERAPEUTICS, GPC shall have furnished
NEOTHERAPEUTICS with an opinion of counsel, reasonably acceptable to NEOTHERAPEUTICS, that such disposition will not require registration under the Securities Act. 
  
 (g) Legends. GPC understands that the NEOTHERAPEUTICS Shares, and any securities issued in respect of or
exchange for the NEOTHERAPEUTICS Shares, may bear one or all of the following legends until they are no longer required by law or the provisions of this Agreement: 
  
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
(THE “SECURITIES ACT”) PURSUANT TO AN EXEMPTION FROM REGISTRATION CONTAINED IN REGULATION S PROMULGATED UNDER THE SECURITIES ACT, AND MAY NOT BE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S, PURSUANT TO A
REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION. NO HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY BE CONDUCTED EXCEPT IN COMPLIANCE WITH THE SECURITIES ACT.” 
  

 9 

 Any legend required by the Blue Sky laws of any state to the extent such laws are applicable to the
shares represented by the certificate so legended. 
  
 The legend
set forth above shall be removed by NEOTHERAPEUTICS from any certificate evidencing NEOTHERAPEUTICS Shares upon transfer of such NEOTHERAPEUTICS Shares in compliance with Rule 144(k) under the Securities Act or upon delivery to NEOTHERAPEUTICS of an
opinion, in form and substance and by counsel reasonably satisfactory to NEOTHERAPEUTICS, that a registration statement under the Securities Act is at that time in effect with respect to the legended security or that such security can be freely
transferred without such a registration statement being in effect and that such transfer will not jeopardize the exemption or exemptions from registration pursuant to which the securities were issued. 
  
 (h) Foreign Investors. GPC hereby represents that it has
satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the NEOTHERAPEUTICS Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for
the purchase of the NEOTHERAPEUTICS Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that
may be relevant to the purchase, holding, redemption, sale, or transfer of the NEOTHERAPEUTICS Shares. GPC’s subscription and payment for and continued beneficial ownership of the NEOTHERAPEUTICS Shares, will not violate any applicable
securities or other laws of GPC’s jurisdiction and will not require NEOTHERAPEUTICS to obtain any permit, make any filing or take any other action in such jurisdiction. 
  
 (i) Offshore Transaction. 
  
 (i) GPC is not organized under the laws of or is not a citizen or resident of the United States and was not
formed for the purpose of investing in Regulation S securities, does not have any of its securities registered under the Exchange Act, and is not owned by U.S. Persons as defined in Regulation S and herein. 
  
 (ii) At the time the buy order to purchase the
NEOTHERAPEUTICS Shares was originated, GPC was outside the United States. 
  
 (iii) All subsequent offers and sales of the NEOTHERAPEUTICS Shares shall be made in compliance with Regulation S, pursuant to registration of the securities under the Securities Act or pursuant to an exemption from
such registration. 
  
 (iv) GPC agrees that from
the date hereof until after one year after the issuance of the NEOTHERAPEUTICS Shares hereunder (the “Restrictive Period”), GPC agrees, upon any offer, sale, or transfer of the NEOTHERAPEUTICS Shares (including any interests therein), GPC,
or any successor, or any Professional under its direction (as defined below) (except for 

  

 10 

 
sales of any NEOTHERAPEUTICS Shares registered under the Securities Act or otherwise exempt from such registration) (i) will not sell to a U.S. Person or to
an account of or for the benefit of a U.S. Person or to anyone believed to be a U.S. Person; (ii) will not engage in any efforts to sell the NEOTHERAPEUTICS Shares in the United States; (iii) will, at the time the buy order or transfer is
originated, believe the buyer or transferee is outside the United States; (iv) will send to any transferee who is a Professional, whether acting as agent or principal, a confirmation or other notice stating that the Professional is subject to the
same restrictions on transfer to U.S. Persons or for the account of or benefit of U.S. Persons during the Restrictive Period as provided herein; and (v) will not in connection with the common stock of NEOTHERAPEUTICS engage in the United States in
any short selling, option writing, equity swaps, or other types of hedging transactions or derivative transactions. NEOTHERAPEUTICS will not honor or register and will not be obligated to honor or register any transfer in violation of these
provisions. 
  
 (v) For purpose hereof, in
general, a “U.S. Person” means any natural person, resident of the United States; any partnership or corporation organized or incorporated under the laws of the United States or any state or territory thereof; any estate of which any
executor or administrator is a U.S. Person; any trust of which any trustee is a U.S. Person; any agency or branch of a foreign entity located in the United States; any nondiscretionary account or similar account, other than estate or trust, held by
a dealer or other fiduciary organized, incorporated, or (if an individual) resident of the United States; and any partnership or corporation if organized or incorporated under the laws of any foreign jurisdiction and formed by a U.S. Person
principally for the purpose of investing in securities and not registered under the Securities Act unless it is organized and incorporated and owned by “accredited investors,” as defined under Rule 501(a) under the Securities Act, who are
not natural persons, estates or trusts. “U.S. Person” is further defined in Rule 902(o) under the Securities Act. 
  
 (vi) A “Professional” is a “distributor” as defined in Rule 902(c) under the Securities Act (generally any
underwriter, or other person, who participates, pursuant to a contractual arrangement, in the distribution of the Shares); a dealer as defined in Section 2(12) of the Exchange Act (encompassing those who engage in the business of trading or dealing
in securities as agent, broker, or principal); or a person receiving a selling concession, fee, or other remuneration in respect of the sale of the Shares sold. 
  

2.4. Definition of “Knowledge.” As used in this Section 2, the phrases “to the best of” a Party’s “knowledge and
belief,” “known to” or similar phrases are intended to indicate that no information has come to the attention of senior management of the Party making the particular representation which would give such person actual knowledge of the
existence or absence of such facts. 
  

 11 

 3. J-M LICENSE AGREEMENT 
  

3.1. Representations and Warranties of NEOTHERAPEUTICS. NEOTHERAPEUTICS represents and warrants to GPC that, as of the Effective Date:

  
 (a) The J-M License Agreement is in full
force and effect and has not been modified or amended, except that no representation or warranty is made with respect to J-M or matters solely within the control or direction of J-M that are not known to NEOTHERAPEUTICS; 
  
 (b) To the best of NEOTHERAPEUTICS’s knowledge and
belief, neither J-M nor NEOTHERAPEUTICS is in default with respect to a material obligation under, and neither such party has claimed or has grounds upon which to claim that the other party is in default with respect to a material obligation under,
the J-M License Agreement; 
  
 (c) To the best of
NEOTHERAPEUTICS’s knowledge and belief, the rights that J-M has licensed to NEOTHERAPEUTICS pursuant to the J-M License Agreement were not and are not subject to any restrictions or limitations except as set forth in the copy of the J-M License
Agreement attached as Exhibit A; and 
  
 (d)
NEOTHERAPEUTICS has not waived or allowed to lapse any of its rights under the J-M License Agreement, and no such rights have lapsed or otherwise expired or been terminated. 
  
 3.2. NEOTHERAPEUTICS Obligations. NEOTHERAPEUTICS agrees that during the term of this Agreement: 
  
 (a) NEOTHERAPEUTICS will use commercially reasonable efforts
to fulfill its obligations under the J-M License Agreement to the extent such obligations have not been delegated to GPC and to the extent that failure to do so would adversely affect GPC or its rights hereunder; 
  
 (b) NEOTHERAPEUTICS shall not enter into any subsequent
agreement with J-M that modifies or amends the J-M License Agreement in any way that could potentially adversely affect GPC’s rights or economic interest under this Agreement without GPC’s prior written consent, and shall provide GPC with
a copy of all modifications to or amendments of the J-M License Agreement, regardless of whether GPC’s consent was required with respect thereto; provided that, NEOTHERAPEUTICS may redact confidential portions of any such modifications and
amendments, but only to the extent that any such redactions do not impair GPC’s ability to take full advantage of its rights and benefits under this Agreement; 
  
 (c) NEOTHERAPEUTICS shall not terminate the J-M License Agreement in whole or in part, directly or
indirectly, without GPC’s prior written consent; 
  
 (d) NEOTHERAPEUTICS shall promptly furnish GPC with copies of all reports and other communications NEOTHERAPEUTICS receives from J-M that relate to the subject matter of this Agreement; 
  

 12 

 (e) NEOTHERAPEUTICS shall promptly furnish GPC with copies of all reports and other
communications that NEOTHERAPEUTICS furnishes to J-M that relate to the subject of this Agreement, and to the extent any such reports or communications relate to the efforts of GPC under this Agreement, NEOTHERAPEUTICS shall give GPC a reasonable
opportunity to review and comment upon such reports or communications before they are transmitted to J-M; 
  
 (f) NEOTHERAPEUTICS shall furnish GPC with copies of all notices received by NEOTHERAPEUTICS relating to any alleged breach or default by
NEOTHERAPEUTICS under the J-M License Agreement within three (3) business days after NEOTHERAPEUTICS’s receipt thereof and, if NEOTHERAPEUTICS cannot or chooses not to cure or otherwise resolve any such alleged breach or default,
NEOTHERAPEUTICS shall so notify GPC within five (5) days thereafter and allow GPC, in GPC’s sole discretion, to cure or otherwise resolve any such alleged breach or default; and 
  
 (g) NEOTHERAPEUTICS, acting as an intermediary between J-M and GPC, shall allow GPC to enjoy the direct
benefit of all of NEOTHERAPEUTICS’s affirmative rights, to the extent they relate to the J-M Licensed Technology. 
  
 4. JOINT DEVELOPMENT COMMITTEE 
  
 4.1. Members. The Parties shall establish a Joint Development Committee (the “Joint Development Committee”), which shall comprise three
(3) representatives designated by each Party (or such other number as the Parties may agree in writing). The initial members of the Joint Development Committee are set forth on Exhibit C. Any Member of the Joint Development Committee may be
represented at any meeting by a designee who is appointed by such member for such meeting and who has authority to act on behalf of such member, as evidenced by written notice from such Member to the chairperson of the Joint Development Committee.
The chairperson of the Joint Development Committee shall be one of the representatives designated by GPC. The initial chairperson is designated on Exhibit C. Each Party shall be free to replace its representative members with new appointees who have
authority to act on behalf of such Party on the Joint Development Committee, on written notice to the other Party. 
  
 4.2. Responsibilities. The Joint Development Committee shall be responsible for planning, overseeing and directing the development and
commercialization of, and regulatory filings relating to, Covered Products. 
  
 4.3. Meetings. The Joint Development Committee shall meet quarterly until the achievement of the first milestone described in Section 9.2 and, thereafter, as frequently as the Parties deem appropriate, on such
dates and at such times as the Parties shall agree, on ten (10) days’ written notice to the other Party unless such notice is waived by the other Party. The Joint Development Committee may convene or be polled or consulted from time to time by
means of telecommunications, video conferences or correspondence, as deemed necessary or appropriate by the Parties. To the extent that meetings are held in person, they shall alternate between the offices of the Parties unless the Parties otherwise
agree. The chairperson shall be responsible for sending notices of meetings to all members. 
  

 13 

 4.4. Decisions. 
  
 (a) A quorum for a meeting of the Joint Development Committee shall require the presence of at least one
NEOTHERAPEUTICS member (or designee) and at least one GPC member (or designee) in person or by telephone. All decisions made or actions taken by the Joint Development Committee shall be made unanimously by its members, with the NEOTHERAPEUTICS
members cumulatively having one vote and the GPC members cumulatively having one vote. 
  
 (b) In the event that unanimity cannot be reached by the Joint Development Committee with respect to a matter that is a subject of its
decision-making authority within thirty (30) days after the matter is first brought before the Joint Development Committee, then the matter shall be decided by the chairperson of the Joint Development Committee in good faith. 
  
 4.5. Minutes. Within fifteen (15) days after each Joint Development
Committee meeting, GPC shall prepare and distribute minutes of the meeting, which shall provide a description in reasonable detail of the discussions had at the meeting and a list of any actions, decisions or determinations approved by the Joint
Development Committee at such meeting. GPC shall be responsible for circulation of all draft and final minutes. Draft minutes shall be circulated to all members of the Joint Development Committee sufficiently in advance of the next meeting to allow
review and comment prior to the meeting. Minutes shall be approved or disapproved, and revised as necessary, at the next meeting. Final minutes shall be distributed to the members of the Joint Development Committee. 
  
 4.6. Term. The Joint Development Committee shall exist until the
expiration of the Royalty Term for all Covered Products. 
  
 4.7.
Expenses. Each Party shall be responsible for all travel and related costs for its representatives to attend meetings of, and otherwise participate on, the Joint Development Committee. 
  
 4.8. Additional Studies. NEOTHERAPEUTICS reserves the right, subject
to the approval and oversight of the Joint Development Committee, which approval will not be unreasonably withheld, to propose additional studies of Satraplatin at its own expense. 
  
 5. CO-PROMOTION. In the event GPC determines to directly market Covered Products in the United States itself rather than licensing
such Covered Products to a Third Party for commercialization, GPC shall notify NEOTHERAPEUTICS in writing reasonably in advance of the commencement of commercialization of any such Covered Product. If, within ten (10) days after receipt of such
notice from GPC, NEOTHERAPEUTICS indicates in writing to GPC that it desires to co-promote such Covered Product with GPC, the Parties shall negotiate in good faith the terms of such co-promotion of such Covered Product. If GPC proposes to enter into
an agreement with a Third Party that includes a grant of rights to such Third Party to market a Covered Product in the United States, GPC shall use commercially reasonable efforts to obtain co-promotion rights in the United States with such Third
Party that include NEOTHERAPEUTICS. 
  

 14 

 6. OWNERSHIP; PATENT PROTECTION 
  
 6.1. Ownership of GPC Development Technology. Except as otherwise provided in this Agreement, the entire right, title
and interest in and to all GPC Development Technology shall be owned solely by GPC, and all decisions regarding the protection of GPC Development Technology shall remain with GPC. 
  
 6.2. Ownership of J-M Licensed Technology, NEOTHERAPEUTICS Licensed Technology, NEOTHERAPEUTICS Development
Technology. Except as otherwise provided in this Agreement, the entire right, title and interest in and to all NEOTHERAPEUTICS Licensed Technology and NEOTHERAPEUTICS Development Technology and, as between the Parties, J-M Licensed Technology
shall be owned solely by NEOTHERAPEUTICS, and, except as otherwise set forth in this Agreement or the J-M License Agreement, all decisions regarding the protection of J-M Licensed Technology, NEOTHERAPEUTICS Licensed Technology and NEOTHERAPEUTICS
Development Technology shall remain with NEOTHERAPEUTICS. 
  
 6.3.
Ownership of Joint Development Technology. GPC and NEOTHERAPEUTICS shall jointly own all rights, title and interests in Joint Development Technology. 
  
 6.4. Patent Filing, Prosecution and Maintenance. 
  
 (a) Reasonably promptly after the Effective Date the Joint Development Committee, in consultation with the Parties’ respective patent
counsel, shall agree upon a patent filing policy with respect to the NEOTHERAPEUTICS Licensed Technology, the Joint Development Technology and the NEOTHERAPEUTICS Development Technology. In addition, from time to time, the Joint Development
Committee shall determine, in accordance with such policy, whether and in what jurisdictions patent applications should be filed with respect to any Know-How or Inventions included in the NEOTHERAPEUTICS Licensed Technology, the Joint Development
Technology and the NEOTHERAPEUTICS Development Technology. 
  
 (b) Following a determination by the Joint Development Committee that a patent application should be filed with respect to any Know-How or Inventions included in the NEOTHERAPEUTICS Licensed Technology,
NEOTHERAPEUTICS, through outside patent counsel (including, without limitation, foreign patent counsel and agents) reasonably acceptable to GPC, shall promptly file a patent application with respect thereto in the jurisdiction(s) selected by the
Joint Development Committee, and thereafter NEOTHERAPEUTICS shall prosecute such application and maintain any letters patent issuing therefrom. NEOTHERAPEUTICS shall take all such actions in consultation with GPC and its patent counsel and shall
keep GPC apprised as to the status of all pending patent applications. The out-of-pocket costs of filing, prosecuting and maintaining any Patents actually incurred by NEOTHERAPEUTICS under this Section 6.3(b) shall be reimbursed by GPC.
NEOTHERAPEUTICS shall invoice GPC for such costs on a quarterly basis. Such invoices shall be payable forty-five (45) days after receipt thereof. If the Joint Development Committee determines to not have a patent application filed with respect to
any Know-How or Inventions included in the NEOTHERAPEUTICS Licensed Technology, NEOTHERAPEUTICS may, notwithstanding anything else contained herein, file, 

  

 15 

 
prosecute and maintain a patent application and any letters patent issuing therefrom at its own expense. 
  
 (c) The preparation, filing, prosecuting and maintenance of
Patents included in the J-M Licensed Technology shall be accomplished as provided in the J-M License Agreement, subject to the provisions of this Agreement. Furthermore, the Parties’ respective rights and obligations under this Section shall be
subject, in all events, to any superior rights of J-M under the J-M License Agreement regarding the J-M Licensed Technology. 
  
 (d) If J-M elects to abandon the prosecution or maintenance of any J-M Patent Right in any country pursuant to Section 1 of Article VII of
the J-M License Agreement and NEOTHERAPEUTICS elects not to assume the prosecution or maintenance of such J-M Patent Right, NEOTHERAPEUTICS shall so notify GPC. If GPC notifies NEOTHERAPEUTICS that GPC wishes to assume the prosecution or maintenance
of such J-M Patent Right, NEOTHERAPEUTICS shall exercise its right to assume such prosecution or maintenance on behalf of GPC, and NEOTHERAPEUTICS shall assign its rights to such J-M Patent Right in such country to GPC. 
  
 6.5. Termination of Support by GPC. GPC shall have the right to
terminate its obligations, if any, under this Agreement in any country with respect to any Patent included in the NEOTHERAPEUTICS Licensed Technology, from time to time, upon notice to NEOTHERAPEUTICS; provided, however, that no such
notice shall be effective with respect to any such Patent if it is given fewer than sixty (60) days prior to a deadline for taking any action that must be taken in order to preserve the owner’s rights in such Patent. Upon the delivery of any
such effective notice, GPC’s rights, licenses and obligations under this Agreement with respect to such Patent shall terminate in any such country, except those obligations that shall have accrued prior to the delivery of such notice.

  
 7. GRANT OF LICENSES 
  
 7.1. Exclusive Sublicense Grant. NEOTHERAPEUTICS hereby grants GPC an
exclusive royalty-bearing right and sublicense in the Field throughout the Territory, with the right to grant further sublicenses in accordance with the terms of this Agreement, under the J-M Licensed Technology to research, develop, make, have
made, use, sell, offer for sale, have sold, import and export Covered Products. 
  
 7.2. Exclusive License Grant. NEOTHERAPEUTICS hereby grants to GPC an exclusive royalty-bearing right and license in the Field throughout the Territory, with the right to grant sublicenses in accordance with
the terms of this Agreement, under the NEOTHERAPEUTICS Licensed Technology, the NEOTHERAPEUTICS Development Technology and NEOTHERAPEUTICS’s interest in the Joint Development Technology to research, develop, make, have made, use, sell, offer
for sale, have sold, import and export Covered Products. 
  
 7.3.
Scope of Exclusivity. The licenses granted to GPC pursuant to Sections 7.1 and 7.2 shall be exclusive even as to NEOTHERAPEUTICS, except to the extent necessary for NEOTHERAPEUTICS to perform its obligations under this Agreement. 

 

 16 

 7.4. Provisions Regarding Sublicenses. Any sublicense by GPC of the rights granted to GPC
hereunder shall be consistent with the terms of this Agreement and shall include an obligation for the Sublicensee to comply with the applicable obligations of GPC set forth in this Agreement. GPC shall provide to NEOTHERAPEUTICS a copy of any
sublicense agreement of the rights granted herein with any Third Party promptly after entering into such sublicense; provided that, GPC may redact confidential portions of any such sublicense agreement, but only to the extent that any such
redactions do not impair NEOTHERAPEUTICS’ ability to ensure compliance with the provisions of this Agreement. 
  
 7.5. Transfer of Information. Promptly following the Effective Date, NEOTHERAPEUTICS shall coordinate with the Joint Development Committee and
provide copies of and access to all of LICENSOR’S INFORMATION, LICENSOR’S ONGOING INFORMATION and all other information relating to the J-M Patent Rights in its possession. Thereafter, NEOTHERAPEUTICS will continue to provide such
information, as well as NEOTHERAPEUTICS Development Technology, to GPC as it becomes available to or is conceived by NEOTHERAPEUTICS as soon as practicable after it becomes available to or is conceived by NEOTHERAPEUTICS. 
  
 8. DEVELOPMENT AND COMMERCIALIZATION 
  
 8.1. Development Efforts by GPC. GPC shall, either itself or through
its Affiliates or Sublicensees: 
  
 (a) at its
own expense, or at the expense of its Affiliates or Sublicensees, diligently conduct the development of Covered Products within the Field using Platinum Complexes. GPC shall exercise in the performance of such development commercially reasonable
technical skill and competence; 
  
 (b) use its
commercially reasonable endeavors to obtain appropriate regulatory approvals for Covered Products in the United States or any of the countries currently comprising the European Union and Japan and to promote the distribution and sale of Covered
Products in the Field in such countries where such regulatory approval is obtained; 
  
 (c) ensure that all literature prepared by GPC and relating to Covered Products bears an acknowledgement to the effect that they are
subject to a license from J-M and NEOTHERAPEUTICS, and all protocols prepared by GPC and relating to Covered Products bears an acknowledgement to the effect that they are subject to a license from NEOTHERAPEUTICS and attach to all Covered Products a
label quoting relevant patent numbers and stating that such Covered Products are made under license under J-M and NEOTHERAPEUTICS; and 
  
 (d) advise NEOTHERAPEUTICS promptly of all approvals granted with respect to Covered Product. 
  
 8.2. Delegation of IND Authority; Right to Reference. NEOTHERAPEUTICS
acknowledges that a Phase II clinical trial of Satraplatin has been conducted pursuant to an Investigational New Drug Application Number 44,615 filed with the FDA (the “Filed IND”). 

  

 17 

 
Promptly after the Effective Date, NEOTHERAPEUTICS shall prepare for filing with the FDA all documents necessary to designate and delegate to GPC all
exclusive (even as to NEOTHERAPEUTICS) authority to take actions and receive all communications from the FDA with respect to the Filed IND and shall file such documents with the FDA following GPC’s review and approval of such documents.
NEOTHERAPEUTICS shall not take any action to revoke or limit the delegation described in the preceding sentence. In addition, in the event that the FDA, for any reason, fails to recognize and give full effect to the delegation described in this
Section, NEOTHERAPEUTICS shall not take any action with respect to the Filed IND or the clinical trials conducted pursuant to the Filed IND without the prior approval of the Joint Development Committee. In addition to the foregoing, NEOTHERAPEUTICS
hereby grants to GPC an irrevocable right to reference the Filed IND and all other regulatory submissions, approvals, clearances, data and other documents and information related to the Filed IND that NEOTHERAPEUTICS has filed or referenced with the
FDA. Promptly after the Effective Date, the Parties shall begin planning and coordinating the transfer to the Joint Development Committee of all responsibilities regarding clinical trials conducted pursuant to the Filed IND. GPC shall promptly
provide to NEOTHERAPEUTICS copies of all correspondence related to Covered Products delivered to or received from the FDA. 
  
 8.3. Ownership of Regulatory Filings. Except for the Filed IND, all INDs, NDAs and other regulatory filings made or filed by GPC with respect to
any Covered Products shall be in the name of, and be owned solely by, GPC. 
  
 8.4. Reporting. (a) GPC shall promptly notify NEOTHERAPEUTICS concerning any happening or circumstance that GPC understands will result in NEOTHERAPEUTICS’s loss of any of its rights under the J-M License
Agreement, and GPC shall reasonably cooperate with NEOTHERAPEUTICS to prevent any such loss. 
  
 (b) Following any acquisition of or by NEOTHERAPEUTICS (whether through merger, consolidation, acquisition (directly or indirectly) of
stock representing thirty percent (30%) or more of the outstanding voting stock or other of its equity securities, sale of all or substantially all of its assets, or otherwise) by or of any Third Party that is a substantial competitor of GPC, as
determined by objective standards (which shall include, but not be limited to, a determination as to whether such Third Party is developing or marketing a drug of the same chemical class as the Covered Product or whether such Third Party is
developing or marketing a drug targeted to the same tumor type as a any product under development or being marketing by GPC), GPC shall not be required to include in any report furnished by GPC pursuant to this Agreement, or provide to any
representative of NEOTHERAPEUTICS (or any successor thereto), any information that GPC, acting in good faith, determines to be competitively sensitive or enabling information, unless such information is required for compliance with the obligations
to J-M under the J-M License Agreement, in which event NEOTHERAPEUTICS or its successor, as the case may be, and J-M (if it shall receive such information) shall execute a nondisclosure agreement, satisfactory to GPC in form and substance,
concerning all such information. 
  
 8.5. Trademarks. GPC
shall market the Covered Products throughout the Territory under trademarks (collectively, the “Trademarks”) selected by GPC. GPC shall own all right, 

  

 18 

 
title and interest in and to such Trademarks and shall bear all costs and expenses of registering, and maintaining the registration of, same. 
  
 9. MONETARY OBLIGATIONS 
  
 9.1. License Fee. In partial consideration of the rights and licenses granted to GPC under this Agreement, GPC shall
pay to NEOTHERAPEUTICS the following license fees at the times indicated below: 
  
 (a) Within ten (10) days after the execution of this Agreement, or such later date as the First Amendment to the J-M License Agreement
shall have been amended to (x) delete all references in the J-M License Agreement to the form sub-license agreement attached as Exhibit 1 to the J-M License Agreement and (y) change the references in Section (7) of the First Amendment to Paragraph 1
of Article IX in lieu of the references to Paragraph 6 of Article VII, GPC shall pay NEOTHERAPEUTICS a non-refundable, non-creditable, one-time license fee in the amount of US$2,000,000 in cash. 
  
 (b) Within thirty (30) days of the first dosing of the first
patient in the first Phase III or registrational clinical trial of Satraplatin after the Effective Date (such date of dosing, the “Dosing Date”), GPC shall pay NEOTHERAPEUTICS a non-refundable, non-creditable, one time license fee in the
amount of $2,000,000, $1,000,000 of which fee shall be payable in cash and $1,000,000 of which fee shall be payable through the purchase by GPC, for an aggregate payment of $1,000,000, of a number of shares of common stock, par value $.001 per
share, of NEOTHERAPEUTICS equal to the lesser of (i) the quotient obtained by dividing (x) $1,000,000 by (y) one hundred and fifty percent (150%) of the average closing sale price of the NEOTHERAPEUTICS common stock, as reported by the Nasdaq
quotation system for the twenty (20) consecutive trading days ending on the third trading day before the Dosing Date, or (ii) 19.9% of the number of shares of NEOTHERAPEUTICS common stock outstanding as of the Effective Date, or such other number of
shares as Nasdaq may specify as the highest number of shares of common stock that NEOTHERAPEUTICS may issue hereunder without first obtaining stockholder approval (the “NEOTHERAPEUTICS Shares”); provided that, if the number of
NEOTHERAPEUTIC Shares to be issued pursuant to this Section is determined pursuant to clause (ii) above, then, until GPC has purchased the number of shares of NEOTHERAPEUTICS common stock determined pursuant to clause (i) above and subject to
NEOTHERAPEUTICS ability to issue additional shares without first obtaining stockholder approval pursuant to Nasdaq regulations, all milestone payments owed by GPC to NEOTHERAPEUTICS pursuant to Section 9.2 below shall be used to purchase additional
shares of NEOTHERAPEUTICS common stock at the price determined as of the date of the achievement of the applicable milestone in accordance with the formula set in clause (i)(y) above, and such additional shares shall be considered to be
NEOTHERAPEUTICS Shares hereunder. Concurrently with the first issuance of the NEOTHERAPEUTICS Shares, the Parties shall execute a Registration Rights Agreement in the form attached hereto as Exhibit D. GPC agrees that it shall be a condition of the
issuance of the NEOTHERAPEUTICS Shares that GPC make the representations set forth in Section 2.3 as of the date of issuance of the NEOTHERAPEUTICS Shares. GPC represents that it has not engaged in any short selling, option writing, equity swaps, or

  

 19 

 
other types of hedging transactions or derivative transactions with respect to the common stock of NEOTHERAPEUTICS, and GPC further agrees that it will not
engage in any such transaction with respect to the common stock of NEOTHERAPEUTICS at any time during the period commencing on the Effective Date and ending one year after the issuance of the NEOTHERAPEUTICS Shares. 
  
 9.2. Development Milestone Payments by GPC. (a) In partial
consideration of the rights and licenses granted to GPC by NEOTHERAPEUTICS under this Agreement, GPC shall pay NEOTHERAPEUTICS the following milestone payments upon the first occurrence of each event set forth below achieved by GPC or its
Affiliates: 
  
 (i) US$*** upon acceptance by the
FDA of an NDA covering Satraplatin; 
  
 (ii)
US$*** upon acceptance by the EMEA in the European Union of an application for marketing clearance covering Satraplatin; 
  
 (iii) US$*** upon FDA approval of Satraplatin for commercial sale for a first indication; 
  
 (iv) US$*** upon approval by the EMEA in the European Union
of Satraplatin for commercial sale for a first indication; 
  
 (v) US$*** upon first approval by the MHW in Japan of Satraplatin for commercial sale; 
  
 (vi) US$*** upon FDA approval of Satraplatin for commercial sale for a second indication; and 
  
 (vii) US$***upon approval by the EMEA in the European
Union of Satraplatin for commercial sale for a second indication. 
  
 Each
of the foregoing payments shall be made within thirty (30) days after achievement of such milestone. For the avoidance of doubt, after GPC has made any of the foregoing payments with respect to any one Covered Product, GPC shall have no further
obligation to make such payment with respect to any other Covered Product. As used in this Section 9.2, “approval” shall mean approval by the FDA, the EMEA or the MHW of a NDA, MAA or other application for regulatory approval to market and
sell a Covered Product in the United States, the European Union or Japan, and with respect to the European Union shall also include any government pricing or reimbursement approval necessary to market or sell such Covered Product in the European
Union. 
  
 9.3. Royalties. (a) Subject to Section 9.3(b),
in partial consideration of the rights and licenses granted to GPC under this Agreement, GPC shall pay NEOTHERAPEUTICS a royalty on Net Sales of each Covered Product, commencing on the First Commercial Sale of each Covered Product by GPC or its
Affiliates in each country in the Territory, in an amount equal to the applicable percentage of the world-wide Net Sales of such Covered Product by GPC and its 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 20 

 Affiliates throughout the Territory during each calendar year (or portion thereof) during the term of this Agreement:

  
 (i) ***% on worldwide annual Net Sales up to
$*** 
  
 (ii) ***% on worldwide annual Net
Sales between $*** and $*** 
  
 (iii) ***%
on worldwide annual Net Sales above $***. 
  
 Such incremental amounts
shall be reduced on a Covered Product by Covered Product and country by country basis upon the expiration of the J-M Royalty Term and for the remainder of the Royalty Term by a percentage of Net Sales equal to *** of the percentage of Net Sales that
NEOTHERAPEUTICS had paid to J-M with respect to sales of such Covered Product immediately prior to the expiration of the J-M Royalty Term and shall be reduced pro rated accordingly with respect to any partial calendar year during the term of this
Agreement. 
  
 (b) Notwithstanding
the foregoing, GPC’s obligation to make payments with respect to each Covered Product in each country in the Territory under Sections 9.3 and 9.4 shall expire upon the expiration of the Royalty Term with respect to such Covered Product in such
country. 
  
 (c) The obligation to pay royalties
to NEOTHERAPEUTICS under this Section 9.3 is imposed only once with respect to the same unit of a Covered Product, regardless of the number of Patents pertaining thereto. 
  
 9.4. Sublicense Income. 
  
 (a) Subject to Section 9.3(b), GPC shall pay NEOTHERAPEUTICS (i) *** (***%) of all Sublicense Fees and (ii) *** (***%) of all Sublicense
Royalties received by GPC, provided that, until the expiration of the J-M Royalty Term, the payments made by GPC to NEOTHERAPEUTICS under clause (ii) shall in any event not be ***%) of Net Sales of Covered Products by Sublicensees.

  
 (b) Notwithstanding anything else contained
herein, upon receipt by GPC of any payment from a Sublicensee upon the achievement of any applicable milestone (a “Sublicensee Milestone”), (i) if the Sublicensee Milestone is also a milestone described in Section 9.2, GPC shall make the
applicable milestone payment under Section 9.2 to NEOTHERAPEUTICS and (ii) the payment received by GPC from such Sublicensee shall be treated as a Sublicense Fee and subject to Section 9.4(a), provided that GPC may deduct any payment made pursuant
to clause (i) and all other payments previously made by GPC pursuant to Section 9.2 (to the extent not previously deducted pursuant to this clause) from such Sublicense Fee before calculating the percentage owed to NEOTHERAPEUTICS pursuant to
Section 9.4(a) in determining GPC’s obligation under such Section. As an example, if GPC received US$*** from a Sublicensee upon approval by the EMEA in the European Union of Satraplatin for commercial sale for a first indication, GPC would pay
NEOTHERAPEUTICS US$*** pursuant to Section 9.2, and US$*** pursuant to Section 9.4(a) (***% of US$*** (US$*** less US$*** paid pursuant to Section 9.2)), for an aggregate payment of US$***. 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 21 

 9.5. Third Party Payments. (a) GPC, at its sole expense, shall pay all amounts owing to any Third
Party to obtain rights to any Valid Claims of any issued patent or patent application issued to Third Parties determined by the Joint Development Committee to be necessary for GPC’s exercise of its rights hereunder to research, develop, make,
have made, use, sell, offer for sale, have sold, import or export any Covered Product (collectively, “Third Party Payments”). Except as provided in Section 9.5(b), GPC shall not be entitled to any credit under this Agreement on account of
any Third Party Payments paid by GPC. 
  
 (b) GPC
shall be entitled, on a country by country basis, to credit against payments due to NEOTHERAPEUTICS under this Agreement an amount equal to the Third Party Payments paid by GPC; provided, however, that the application of such credit shall not, prior
to the expiration of the J-M Royalty Term, reduce the amounts payable by GPC under this Agreement with respect to any given calendar quarter to less than a percentage of Net Sales equal to *** (***%) above the royalties on Net Sales owed by
NEOTHERAPEUTICS to J-M under the J-M License Agreement and, thereafter, such credit shall not reduce the amount payable by GPC under this Agreement by more than *** (***%). Notwithstanding the foregoing, if GPC is required to pay an award of damages
or a settlement amount in the form of a reasonable royalty based on sales during any period of previous infringement (as opposed to the on-going payment of a running royalty), then such payment shall be allocated to the several calendar quarters
during such period of infringement, and the limits set forth in the previous sentence shall apply to each portion of such payment allocated to a specific quarter and not to such payment as a whole. 
  
 9.6. Payments under J-M License. Notwithstanding anything else
contained herein, NEOTHERAPEUTICS shall remain solely responsible to J-M for all payments due to J-M under the J-M License. 
  
 9.7. Reimbursement of NEOTHERAPEUTICS Development Expenses. Within thirty (30) days of receipt of invoices from NEOTHERAPEUTICS, which invoices
shall be delivered by NEOTHERAPEUTICS no more frequently than quarterly, GPC shall reimburse NEOTHERAPEUTICS for all costs and expenses (including full reimbursement for NEOTHERAPEUTICS personnel) incurred by NEOTHERAPEUTICS in the development of
Covered Products as approved in advance by the Joint Development Committee. 
  
 10. PAYMENTS AND REPORTS 
  
 10.1.
Payment. Except as otherwise provided in this Agreement, all royalty and other payments due hereunder shall be paid quarterly within thirty (30) days after the end of each calendar quarter. Each such payment shall be accompanied by a
statement, Covered Product-by-Covered Product and country-by-country, of the amount of Net Sales during such quarter, the amount of royalties due on such Net Sales, the amount of Sublicense Fees and Sublicense Royalties during such quarter and the
amount owed to NEOTHERAPEUTICS on account of such Sublicense Fees and Sublicense Royalties. 
  
 10.2. Mode of Payment. GPC shall make all payments required under this Agreement as directed by NEOTHERAPEUTICS from time to time, in U.S. Dollars (except as provided in Section 10.6). All royalties due
hereunder shall first be determined in the currency of the country 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 22 

 
in which the Covered Products in question were sold and then converted into equivalent U.S. funds. The exchange rate for such conversion shall be that rate
quoted in The Wall Street Journal on the last business day of the applicable reporting period. 
  
 10.3. Records Retention. GPC and its Affiliates shall keep complete and accurate records pertaining to the sale of Covered Products in the Territory in accordance with the obligations therefor set forth in the
J-M License Agreement. 
  
 10.4. Audit Request. At the
request and expense (except as provided below) of NEOTHERAPEUTICS, GPC and its Affiliates shall permit an independent, certified public accountant appointed by NEOTHERAPEUTICS and reasonably acceptable to GPC, at reasonable times and upon reasonable
notice, to examine no more than once per year those records and all other material documents relating to or relevant to Net Sales in the possession or control of GPC and its Affiliates, for a period of three years after such royalties have accrued.
The results of any such examination shall be made available to both Parties. If, as a result of any inspection of the books and records of GPC or its Affiliates, it is shown that GPC’s royalty payments under this Agreement were less than the
amount which should have been paid, then GPC shall make all payments required to eliminate any discrepancy revealed by said inspection within forty-five (45) days after NEOTHERAPEUTICS’s demand therefor. Furthermore, if the aggregate royalty
payments GPC made were less than ninety five (95%) of the amount which should have been paid made during the period in question, GPC shall also reimburse NEOTHERAPEUTICS for the reasonable out-of-pocket cost of such inspection and shall pay interest
on the deficiency pursuant to Section 10.7. 
  
 10.5.
Taxes. In the event that GPC is required to withhold any tax to the tax or revenue authorities in any country in the Territory in connection with any payment to NEOTHERAPEUTICS due to the laws of such country which payment is credited to
NEOTHERAPEUTICS’s tax liability, such amount shall be deducted from the royalty or other payment to be made by GPC, and GPC shall notify NEOTHERAPEUTICS and promptly furnish NEOTHERAPEUTICS with copies of any tax certificate or other
documentation evidencing such withholding. Each Party agrees to cooperate with the other Party in claiming exemptions from such deductions or withholdings under any agreement or treaty from time to time in effect. 
  
 10.6. Blocked Currency. If at any time legal restrictions prevent
GPC’s prompt remittance of part or all of the royalties due with respect to any country where a Covered Product is sold, GPC shall convert the amount owed to NEOTHERAPEUTICS into U.S. funds and shall pay NEOTHERAPEUTICS directly from GPC’s
U.S. source of funds for the amount impounded. GPC shall then pay all future royalties due to NEOTHERAPEUTICS from GPC’s U.S. source of funds so long as the legal restrictions of this Section 10.6 still apply. 
  
 10.7. Late Payments. In the event that any payment GPC is required to
make hereunder is not made within thirty (30) days after such payment was originally due, GPC shall pay interest on the past due amount as follows: 
  
 (a) If GPC’s late payment pertains to a payment NEOTHERAPEUTICS is required to make under the J-M License Agreement and causes
NEOTHERAPEUTICS to become liable to pay interest with respect to such payment under the J-M License 

  

 23 

 
Agreement, then GPC shall pay interest on the past due amount as provided under the applicable provision(s) of the J-M License Agreement. 
  
 (b) In all other events, GPC shall pay interest on the past
due amount at the rate of twelve percent (12%) per annum, until payment in full is made. 
  
 11. MANUFACTURING. Promptly following the Effective Date, GPC and NEOTHERAPEUTICS shall negotiate in good faith the terms of a Supply Agreement regarding the supply of PLATINUM COMPLEXES (as defined in the J-M
License Agreement) to GPC, which agreement shall provide for payments to NEOTHERAPEUTICS equal to *** and shall contain such other terms as are customary in such an agreement; provided that, nothing shall prevent GPC from approaching J-M directly to
receive PLATINUM COMPLEXES or to receive a grant of rights to have a Third Party supply PLATINUM COMPLEXES, in which case, GPC shall pay to NEOTHERAPEUTICS the ***. If, despite good faith efforts, the Parties are unable to agree on the terms of a
Supply Agreement within forty five (45) days of the Effective Date, then the terms of the Supply Agreement shall be submitted to arbitration pursuant to Section 17.13. Within five (5) days after both parties have appointed an arbitrator pursuant to
Section 17.13, each party shall submit to the panel of arbitrators a form of supply agreement for consideration by the panel; provided that, such forms shall only be for the panel’s consideration, and the panel shall be free to resolve the
dispute in any manner that it deems appropriate. “NEOTHERAPEUTICS’s Costs” shall be determined on a shipment by shipment basis and shall be equal to the amount paid by NEOTHERAPEUTICS to J-M in accordance with Article VI of the J-M
License Agreement. 
  
 12. CONFIDENTIALITY 
  
 12.1. Confidentiality; Exceptions. Except to the extent expressly
authorized by this Agreement or otherwise agreed in writing, the Parties agree that, during the term of this Agreement and for five years thereafter, each Party, its Affiliates and its Sublicensees, if any (collectively, a “receiving
Party”), shall use their best efforts to keep completely confidential, shall not publish or otherwise disclose to any Third Party and shall not use for any purpose other than the performance of this Agreement both the financial terms of this
Agreement and any information furnished to it by the other Party, its Affiliates or its Sublicensees, if any (collectively, a “disclosing Party”) (and shall ensure that its and its Affiliates’ and its Sublicensees’ respective
directors, officers, employees or agents do likewise), except to the extent that it can be established by the receiving Party by competent proof that such information: (i) is, or hereafter becomes, generally available to the public other than by
reason of any default by the receiving Party with respect to its confidentiality obligations hereunder; (ii) was already known to the receiving Party at the time of disclosure by the disclosing Party; (iii) was lawfully disclosed to the receiving
Party by a Third Party who was not in default of any confidentiality obligation to the disclosing Party; or (iv) is independently developed by or for the receiving Party without reference to or reliance upon the information furnished by the
disclosing Party (all such information to which none of the foregoing exceptions applies, “Confidential Information”). The NEOTHERAPEUTICS Licensed Technology and NEOTHERAPEUTICS Development Technology shall be the Confidential Information
of NEOTHERAPEUTICS and 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 24 

 the GPC Development Technology shall be the Confidential Information of GPC. The Joint Development Technology shall be
the Confidential Information of both Parties. 
  
 12.2.
Exclusions to Confidentiality. The restrictions contained in Section 12.1 shall not apply to any Confidential Information in the hands of a receiving Party that (i) is submitted by the receiving Party to governmental authorities to facilitate
the issuance of marketing approvals for a Covered Product, provided that reasonable measures shall be taken to assure confidential treatment of such information, if practicable; (ii) is provided by GPC to any Third Party under appropriate terms and
conditions, including confidentiality provisions equivalent to those in this Agreement, for consulting, manufacturing development, manufacturing, external testing, marketing trials and sublicensing or potential sublicensing; or (iii) is otherwise
required to be disclosed in compliance with applicable laws or regulations (including, without limitation, to comply with any governmental or stock exchange disclosure requirements) or an order by a court or other regulatory body having competent
jurisdiction; provided, however, that if a receiving Party is required to make any such disclosure of the disclosing Party’s Confidential Information such receiving Party shall, except where impracticable for necessary disclosures
(for example to physicians conducting studies or to health authorities), give reasonable advance notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the case of patent applications or otherwise, will
use its best efforts to secure confidential treatment of such Confidential Information required to be disclosed. In addition, any press release or other public announcement permitted by the terms of Section 17.7 hereof shall be excluded from the
provisions of Section 12.1. 
  
 12.3. Injunctive Relief.
The Parties acknowledge that monetary damages alone would not adequately compensate the disclosing Party in the event of a material breach by the receiving Party of this Section 12, and that, in addition to all other remedies available to the
disclosing Party under this Agreement, at law or in equity, it shall be entitled to injunctive relief for the enforcement of its rights under this Section 12, without the posting of a bond or other security. 
  
 13. INTELLECTUAL PROPERTY 
  
 13.1. Patent Enforcement. (a) Each Party shall notify the other
promptly after such Party becomes aware of any alleged infringement of any Patent licensed to GPC under this Agreement in any country in the Territory. Except as provided in Section 13.3, GPC shall have the first right, but not the duty, to
institute patent infringement actions against Third Parties with respect to any such alleged infringement. GPC shall take all such actions under this Section 13.1(a) (other than with respect to a Patent included solely in the GPC Development
Technology) in reasonable consultation with NEOTHERAPEUTICS and shall keep NEOTHERAPEUTICS apprised as to the status of any such infringement action GPC institutes. NEOTHERAPEUTICS shall execute all reasonable, necessary and proper documents and
take such actions as shall be appropriate to allow GPC to institute and prosecute infringement actions under this Section 13.1(a). 
  
 (b) The costs and expenses of bringing and maintaining any infringement action under Section 13.1(a) shall be borne solely by GPC.

  

 25 

 (c) Any award or compensation (including the fair market value of non-monetary
compensation) paid by Third Parties as a result of any infringement action brought by GPC under Section 13.1(a) (whether by way of settlement or otherwise) shall be allocated first to reimbursement of GPC for all expenses incurred by it in
connection with such action. Any remaining award or compensation shall be used to pay NEOTHERAPEUTICS the royalty it would have been entitled to receive had the balance of such recovery or damages, to the extent attributable to sales of such
infringing products, been attributable to sales of Covered Products by GPC hereunder. 
  
 (d) Except as provided in Section 13.3, in the event GPC elects not to, or fails to, exercise its rights under Section 13.1(a) with
respect to any alleged infringement of a Patent licensed to GPC under this Agreement (excluding any Patent included solely in the GPC Development Technology) within one hundred twenty (120) days after receiving notice thereof, NEOTHERAPEUTICS shall
have the right, but not the duty, to institute patent infringement actions against Third Parties with respect to any such alleged infringement NEOTHERAPEUTICS shall take all such actions under this Section 13.1(d) in reasonable consultation with GPC
and shall keep GPC apprised as to the status of any such infringement action NEOTHERAPEUTICS institutes. GPC shall execute all reasonable, necessary and proper documents and take such actions as shall be appropriate to allow NEOTHERAPEUTICS to
institute and prosecute infringement actions under this Section 13.1(d). Any award or compensation (including the fair market value of non-monetary compensation) paid by Third Parties as a result of any infringement action brought by NEOTHERAPEUTICS
under this Section 13.1(d) (whether by way of settlement or otherwise) shall be allocated first to reimbursement of NEOTHERAPEUTICS for all expenses incurred by it in connection with such action. Any remaining award or compensation shall be
allocated equally between the Parties. 
  
 13.2. Infringement
Actions by Third Parties. (a) Each Party shall notify the other Party promptly in writing of any claim of, or action for, infringement of any Patents owned or licensed by Third Parties which is threatened, made or brought against either Party by
reason of either Party’s performance of its obligations under this Agreement or manufacture, use or sale of any Covered Products in the Territory in the Field. 
  
 (b) Except as provided in Section 13.3, in the event that such an action for infringement is commenced
solely against a Party or both Parties jointly and/or any of their respective Affiliates or Sublicensees, as the case may be, with respect to any Covered Product developed and commercialized by GPC, its Affiliates and/or Sublicensees, GPC shall
defend such action at its own expense, and NEOTHERAPEUTICS hereby agrees to assist and cooperate with GPC to the extent necessary in the defense of such suit, in accordance with Section 13.2(c). GPC shall have the right to settle any such action or
consent to an adverse judgment thereto, and NEOTHERAPEUTICS’s consent shall not be required unless such settlement or consent: (i) imposes any material obligation on NEOTHERAPEUTICS (including under Section 13.2(d)), or (ii) materially impairs
NEOTHERAPEUTICS’s rights in or to any J-M Licensed Technology, NEOTHERAPEUTICS Licensed Technology, NEOTHERAPEUTICS Development Technology and/or Joint Development Technology, in which event NEOTHERAPEUTICS’s consent shall not be
unreasonably withheld or delayed. 
  

 26 

 (c) The costs of defending any infringement action with respect to a Covered Product
developed and commercialized by GPC, its Affiliates and/or Sublicensees shall be borne solely by GPC. 
  
 (d) During the pendency of any such action, GPC shall continue to pay all royalties due hereunder. Subject to Section 9.5(b), GPC shall be
fully liable for the payment of any award for damages, or any amount due pursuant to any settlement entered into by GPC, to the extent that any such action pertains to a Covered Product developed and commercialized by GPC and/or its Affiliates or
Sublicensees. 
  
 (e) Except to the extent that
the provisions of Section 13.1 shall apply to any portion thereof, GPC shall retain any award or compensation (including the fair market value of non-monetary compensation) received by GPC as a result of any such action (i.e., as a result of a
counterclaim). 
  
 13.3. Superior Rights of J-M.
Notwithstanding any other provision of this Agreement, the Parties’ respective rights and obligations under this Section 13 shall be subject, in all events, to any superior rights of J-M under the J-M License Agreement regarding the J-M
Licensed Technology. 
  
 14. INDEMNIFICATION 
  
 14.1. By GPC. GPC shall indemnify and hold NEOTHERAPEUTICS and its
Affiliates and their respective directors, officers, employees and agents, harmless from and against any and all liabilities, damages, losses, costs and expenses (including the reasonable fees of attorneys and other professionals and other
reasonable litigation expenses) arising out of or resulting from: 
  
 (i) the negligence, recklessness or intentional misconduct of GPC, its Affiliates or its Sublicensees and their respective directors, officers, employees and agents, in connection with the work performed by GPC in
connection with the development of Covered Products or pursuant to Section 8 or in connection with GPC’s exercise of any of its rights hereunder; 
  
 (ii) any and all product liability claims resulting from the development and/or commercialization of any Covered Product by GPC, its
Affiliates or its Sublicensees; 
  
 (iii) any
warranty claims, Covered Product recalls or any tort claims of personal injury (including death) or property damage relating to or arising out of the manufacture, use, distribution or sale of any Covered Product by GPC, its Affiliates or its
Sublicensees due to any negligence, recklessness or intentional misconduct by, or strict liability of, GPC, its Affiliates or its Sublicensees, and their respective directors, officers, employees and agents, except, in each case, to the comparative
extent such claim arose out of or resulted from the negligence, recklessness or intentional misconduct of NEOTHERAPEUTICS or its Affiliates and their respective directors, officers, employees and agents; or 
  
 (iv) any breach of any representation or warranty made by
GPC in Section 2.1. 
  

 27 

 14.2. By NEOTHERAPEUTICS. NEOTHERAPEUTICS shall indemnify and hold GPC, its Affiliates and its
Sublicensees and their respective directors, officers, employees and agents, harmless from and against any and all liabilities, damages, losses, costs and expenses (including the reasonable fees of attorneys and other professionals and other
reasonable litigation expenses) arising out of or resulting from: 
  
 (i) the negligence, recklessness or intentional misconduct of NEOTHERAPEUTICS or its Affiliates and their respective directors, officers, employees and agents, in connection with the work performed by NEOTHERAPEUTICS
under the development of Covered Products or pursuant to Section 5 or in connection with NEOTHERAPEUTICS’s exercise of any of its rights hereunder; or 
  
 (ii) any breach of any representation or warranty made by NEOTHERAPEUTICS pursuant to Section 2 or 3.1. 
  
 14.3. Notice. In the event that any Person entitled thereto (an
“Indemnitee”) is seeking indemnification under Section 14.1 or 14.2, such Indemnitee shall inform the indemnifying Party of a claim as soon as reasonably practicable after the indemnitee receives notice of the claim, shall permit the
indemnifying Party to assume direction and control of the defense of the claim (including the sole right to settle it at the sole discretion of the indemnifying Party, provided that such settlement does not impose any material obligation on the
indemnitee or the other Party) and shall cooperate as requested (at the expense of the indemnifying Party) in the defense of the claim (including, without limitation, granting the indemnifying Party limited access to pertinent records and making
persons under such Indemnitee’s control available for interview and testimony). 
  
 14.4. Complete Indemnification. As the Parties intend complete indemnification, all costs and expenses incurred by any Indemnitee to enforce this Section 14 shall be reimbursed by the indemnifying Party.

  
 15. TERM; TERMINATION 
  
 15.1. Term. This Agreement shall commence as of the Effective Date
and, unless sooner terminated as provided hereunder, shall expire as follows: 
  
 (a) As to each Covered Product in each country in the Territory, this Agreement shall expire upon the expiration of the Royalty Term with respect to such Covered Product in such country. 
  
 (b) This Agreement shall expire in its entirety upon the
termination of the respective Royalty Terms with respect to all Covered Products in all countries in the Territory. 
  
 15.2. Effect of Expiration. Following the expiration of this Agreement with respect to a Covered Product in a country in the Territory pursuant to
Section 15.1(a), GPC shall have the royalty-free, perpetual right to continue to make, have made, use, sell, offer for sale, have sold and export such Covered Product in such country. Following the expiration of the term of this Agreement in its
entirety pursuant to Section 15.1(b), GPC shall have the royalty-free, perpetual 

  

 28 

 
right to continue to make, have made, use, sell, offer for sale, have sold and export all Covered Products in all countries in the Territory. 
  
 15.3. Termination by Either Party. Each Party shall have the right to
terminate this Agreement, upon notice to the other Party, in the event that: 
  
 (i) Such other Party materially defaults with respect to any of its material obligations under this Agreement and does not cure such default within sixty (60) days after the receipt of a notice from the non-breaching
Party specifying the nature of, and requiring the remedy of, such default (or, if such default cannot be cured within such sixty (60)-day period, if the breaching Party does not commence and diligently continue actions to cure same during such sixty
(60)-day period); provided that, (x) if NEOTHERAPEUTICS is the Party claiming a default by GPC, GPC shall promptly following receipt of such notice of default notify NEOTHERAPEUTICS if it intends to seek to cure such default, (y) if the default
relates to the payment of any amounts owed under this Agreement, the cure period described above shall be fifteen (15) days from receipt of notice of such default, and (z) if any such default is limited to the breaching Party’s obligations with
respect to a particular Covered Product and/or a particular country in the Territory, then any termination of this Agreement under this clause (i) due to such default shall be limited to the breaching Party’s rights under this Agreement with
respect to such Covered Product and/or country. Any termination pursuant to this clause (i) shall be without prejudice to any of the non-breaching Party’s other rights under this Agreement, and in addition to any other remedies available to it
by law or in equity; 
  
 (ii) The other Party
shall have: (i) voluntarily commenced any proceeding or filed any petition seeking relief under the bankruptcy, insolvency or other similar laws of any jurisdiction, (ii) applied for, or consented to, the appointment of a receiver, trustee,
custodian, sequestrator, conciliator, administrator or similar official for it or for all or substantially all of its property, (iii) filed an answer admitting the material allegations of a petition filed against or in respect of it in any such
proceeding, (iv) made a general assignment for the benefit of creditors of all or substantially all of its assets, (v) admitted in writing its inability to pay all or substantially all of its debts as they become due, or (vi) taken corporate action
for the purpose of effecting any of the foregoing; or 
  
 (iii) An involuntary proceeding shall have been commenced, or any involuntary petition shall have been filed, in a court of competent jurisdiction seeking: (i) relief in respect of the other Party, or of its property, under the bankruptcy,
insolvency or similar laws of any jurisdiction, (ii) the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for such other Party or for all or substantially all of its property, or (iii) the
winding-up or liquidation of such other Party; and, in each case, such proceeding or petition shall have continued undismissed for sixty (60) days, or an order or decree approving or ordering any of the foregoing shall have continued unstayed,
unappealed and in effect for thirty (30) days. 
  
 15.4.
Termination by GPC. Notwithstanding any other provision of this Agreement, GPC shall have the right to terminate this Agreement, in its entirety or with respect to any 

  

 29 

 
particular Covered Product and/or country in the Territory, at any time upon six (6) months’ notice (or less, at NEOTHERAPEUTICS discretion) to
NEOTHERAPEUTICS. 
  
 15.5. Effect of Expiration or
Termination. (a) Subject to Section 15.5(b), upon any termination of this Agreement by NEOTHERAPEUTICS pursuant to Section 15.3 or by GPC pursuant to Section 15.4, GPC shall (i) transfer and assign to NEOTHERAPEUTICS all of GPC’s right,
title and interest in and to any GPC Development Technology and all data, reports, records, materials and other intellectual property owned or controlled by GPC that relates exclusively to the Covered Products; (ii) grant NEOTHERAPEUTICS a
non-exclusive license, solely for the purpose of NEOTHERAPEUTICS’s developing, making, having made, using, marketing and selling Covered Products, under GPC’s interest in any Joint Development Technology that does not exclusively relate to
the Covered Products; and (iii) transfer and assign to NEOTHERAPEUTICS ownership of all INDs, NDAs and other regulatory filings made or filed with respect to any Covered Product (or, if such transfer and assignment is not permitted under the laws of
any applicable jurisdiction, GPC shall take such other permitted actions with respect to such filings as may be reasonably requested by NEOTHERAPEUTICS), all upon commercially reasonable, arm’s length financial terms and conditions that the
Parties shall negotiate in good faith and agree upon as soon as practicable after such termination of this Agreement; provided that, if this Agreement is terminated by GPC pursuant to Section 15.4, then NEOTHERAPEUTICS shall not be obligated to pay
any amount for the licenses and transfers described in this sentence. In the event the Parties, despite the mutual use of good faith efforts, are unable to agree upon such terms and conditions, the Parties shall appoint an independent valuation
expert who shall determine such terms and conditions, which determination shall be binding upon the Parties. If the Parties are unable to agree upon the appointment of such an expert, then each Party shall nominate an expert (the cost of whom shall
be borne by such Party), and both experts appointed by the Parties shall jointly appoint the expert who shall make such determination. Any expert appointed pursuant to this Section 15.5(a) shall have at least fifteen (15) years’ experience in
the business of pharmaceutical development and commercialization. Except as provided above, the costs and expenses of any expert acting under this Section 15.5(a) shall be borne equally by the Parties. 
  
 (b) Notwithstanding the foregoing: 
  
 (i) In the event of any termination of this Agreement by
NEOTHERAPEUTICS pursuant to Section 15.3 or by GPC pursuant to Section 15.4 with respect to fewer than all of the Covered Products and/or fewer than all of the countries in the Territory, the rights, licenses and other benefits to be transferred,
granted and otherwise assigned to NEOTHERAPEUTICS under Section 15.5(a) shall be expressly limited to those pertaining to the Covered Products and/or the countries in the Territory to which such termination applies; and 
  
 (ii) At any time prior to any transfer, granting and
assignment of rights, licenses and benefits to NEOTHERAPEUTICS pursuant to Section 15.5(a), NEOTHERAPEUTICS may elect, upon notice to GPC, to waive the application of Section 15.5(a) with respect to such rights, licenses and benefits. Following any
such waiver neither Party shall have any obligation or liability to the other with respect to such rights, licenses and benefits. 
  

 30 

 15.6. Right to Sell Stock on Hand. Provided that GPC is not in material breach of any obligation
under this Agreement at the time of any termination of this Agreement, in whole or in part, GPC shall have the right for one year thereafter to dispose of all Covered Product then in its inventory and to complete manufacture of and dispose of any
work-in-progress then being manufactured, as though this Agreement had not terminated. GPC shall pay royalties thereon, in accordance with the provisions of this Agreement, as though this Agreement had not terminated. 
  
 15.7. Survival of Sublicenses. Upon any termination of this Agreement,
all sublicenses granted by GPC under this Agreement shall be automatically assigned to NEOTHERAPEUTICS, which shall thereafter receive all benefits and have all obligations under the sublicenses as in the place and stead of GPC. 
  
 15.8. Effect of Termination of J-M License Agreement. Upon any
termination of the J-M License Agreement, GPC shall attorn to and accept J-M in place of NEOTHERAPEUTICS such that this Agreement shall be deemed to be an agreement between J-M and GPC. 
  
 15.9. Accrued Rights, Surviving Obligations. (a) Termination, relinquishment or expiration of this Agreement for any
reason shall be without prejudice to any rights which shall have accrued to the benefit of either Party prior to such termination, relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve either Party from
obligations which are expressly indicated to survive termination or expiration of this Agreement. The rights of the Parties upon termination described in this Agreement shall not be exclusive of any other rights or claims at law or in equity that
either Party may have against the other arising out of this Agreement. 
  
 (b) Termination, relinquishment or expiration of this Agreement shall not terminate each Party’s obligation to pay all royalties, milestone payments and other monetary obligations that may have accrued hereunder
prior to such termination. All of the Parties’ rights and obligations under Sections 6.1, 6.2, 8.5, 10, 12, 13 (solely with respect to actions pending at such time), 14, 15.2, 15.5, 15.6, 15.7, 15.8, 15.9, 17.1 (if in effect at such time),
17.3, 17.5, 17.12, 17.13 and 17.14 shall survive termination, relinquishment or expiration hereof. 
  
 16. FORCE MAJEURE 
  
 Neither Party shall be held liable or responsible to the other Party nor be deemed to be in default under or in breach of any provision of this Agreement for failure or delay in fulfilling or performing any obligation under this Agreement
when such failure or delay is due to force majeure, and without the fault or negligence of the Party so failing or delaying. For purposes of this Agreement, force majeure shall be defined as causes beyond the control of the Party, including, without
limitation, acts of God; acts, regulations, or laws of any government; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; labor disturbances; epidemic; and failure of public
utilities or common carriers. In such event NEOTHERAPEUTICS or GPC, as the case may be, shall immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The Party giving such notice shall
thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled 

  

 31 

 
and for thirty (30) days thereafter. To the extent possible, each Party shall use reasonable efforts to minimize the duration of any force majeure.

  
 17. MISCELLANEOUS 
  
 17.1. Relationship of Parties. Nothing in this Agreement is intended
or shall be deemed to constitute a partnership, agency, employment or joint venture relationship between the Parties. Neither Party shall be entitled to, or shall, incur any debts or make any commitments for the other, except to the extent, if at
all, specifically provided herein. 
  
 17.2. Assignment.
(a) Each Party shall be entitled to assign this Agreement to any of its Affiliates upon sixty (60) days’ prior written notice to the other Party; provided, however, that in the event of any such assignment, the assigning Party shall remain
jointly and severally liable with respect to all of its obligations hereunder, and in the event of any default relating to any such obligations, the other Party shall be entitled to proceed against either such Affiliate or directly against the
assigning Party, as such other Party may determine in its sole discretion, to enforce this Agreement. 
  
 (b) Except as provided in Section 17.5(a), neither Party shall be entitled to assign its rights hereunder without the express written
consent of the other Party, except that each Party may assign this Agreement to any assignee of all or substantially all of such Party’s business (or that portion thereof to which this Agreement relates) or in the event of such Party’s
merger, consolidation or similar transaction. 
  
 (c) No assignment contemplated by this Section 17.3 shall be valid or effective unless and until the assignee/transferee shall agree in writing to be bound by the provisions of this Agreement. 
  
 17.3. Disclaimer of Warranties. EXCEPT AS EXPRESSLY PROVIDED IN
SECTIONS 2 AND 3.1, THE PARTIES EXPRESSLY DISCLAIM ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD PARTY RIGHTS, OR ARISING FROM A
COURSE OF DEALING OR USAGE OF TRADE PRACTICE. 
  
 17.4. Further
Actions. Each Party shall execute, acknowledge and deliver such further instruments, and take all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  

 32 

 17.5. Notice. Any notice or request required or permitted to be given under or in connection with
this Agreement shall be deemed to have been sufficiently given if in writing and personally delivered or sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or overnight express courier service (signature
required), prepaid, to the Party for which such notice is intended, at the address set forth for such Party below: 
  
 (i) In the case of GPC, to: 
  
 GPC BIOTECH AG 
 Fraunhoferstrasse 20

 D-82152 Martinsried/Munich 
 Germany 
  
 Attention: Chief Executive Officer

 Facsimile No.: 011-49-89-8565-2610 
  
 With a copy to: 
  
 Ropes & Gray 
 One International Place

 Boston, Massachusetts 
 USA

 Attention: Marc A. Rubenstein, Esq. 
 Facsimile No.: 617-951-7050 
  
 (ii) In the case of
NEOTHERAPEUTICS, to: 
  
 157 Technology Drive 
 Irvine, California 92618 
 USA 

Attention: 
 Facsimile No.: 949-788-6706

  
 or to such other address for such Party as it shall have specified by like
notice to the other Party, provided that notices of a change of address shall be effective only upon actual receipt thereof. If delivered personally or by facsimile transmission, the date of delivery shall be deemed to be the date on which such
notice or request was given. If sent by overnight express courier service, the date of delivery shall be deemed to be the next business day after such notice or request was deposited with such service. If sent by certified mail, the date of delivery
shall be deemed to be the fifth (5th) business day after such notice or request was deposited with the postal
service in the country of mailing. 
  
 17.6. Use of Name.
Except as otherwise provided herein, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or any other trade name or trademark of the other Party (including, without
limitation, any Trademark) for any purpose in connection with the performance of this Agreement. 
  
 17.7. Public Announcements. (a) Except as required by law (including, without limitation, the applicable disclosure requirements of any relevant
regulatory authority or stock exchange) and as permitted by Section 12.2, neither Party shall make any public announcement concerning this Agreement, any Covered Product or any other subject matter hereof without the prior written consent of the
other Party, which shall not be unreasonably withheld or delayed. It shall not be unreasonable for a Party to withhold consent with respect to any public announcement containing any of such Party’s Confidential Information. In the event of any

  

 33 

 
required or proposed public announcement, (i) the Parties shall consult with each other in good faith as to the timing thereof, and (ii) the Party making
such announcement shall provide the other Party with a copy of the proposed text prior to such announcement sufficiently in advance of the scheduled release of such announcement to afford such other Party a reasonable opportunity to review and
comment upon the proposed text. Notwithstanding the foregoing, the Parties agree to prepare a mutually agreeable press release that may be used by either Party in connection with this Agreement, and any further announcement containing substantially
the same information may be used without the need to seek the consent of the other Party. 
  
 (b) Each Party acknowledges and agrees that the other Party needs to communicate with its investors regularly and keep them apprised of
the development status of the products in which such Party has an interest. In order to facilitate this communication, promptly after the Effective Date each Party shall designate, from time to time, one employee who shall have primary
responsibility for reviewing and approving all proposed investor communications of the other Party, to the extent that they pertain to this Agreement, any Covered Product or any other subject matter hereof. Each Party shall instruct such employee to
review the content of such draft communications as expeditiously as possible and otherwise to cooperate with and assist the other Party in connection therewith, so long as the number of such communications and the timing thereof are reasonable.

  
 (c) Following a Party’s consent to or
approval of the public announcement of any information pursuant to this Section 17.7, both Parties shall be entitled to make subsequent public announcements of such information without renewed compliance with this Section 17.7, unless the scope
and/or duration of such consent or approval is expressly limited. 
  
 17.8. Waiver. A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any subsequent breach hereof.
All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative, and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party. 
  
 17.9. Compliance with Law. Nothing in this Agreement shall be deemed
to permit a Party to export, re-export or otherwise transfer any Covered Product sold under this Agreement without compliance with applicable laws. 
  
 17.10. Severability. When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this
Agreement. 
  
 17.11. Amendment. No amendment, modification
or supplement of any provisions of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 
  

 34 

 17.12. Governing Law; English Original; Jurisdiction. (a) This Agreement shall be governed by and
interpreted in accordance with the laws of the Commonwealth of Massachusetts without regard to its choice of law principles. The English original of this Agreement shall prevail over any translation hereof. 
  
 (b) Without prejudice to the rights and obligations of the
Parties under Section 17.13, each Party hereby consents to the in personam jurisdiction of any state or federal court sitting in the Commonwealth of Massachusetts with respect to any matter arising in connection with this Agreement and further
consents to the service of any process, notice of motion or other application to any such court or a judge thereof outside the Commonwealth of Massachusetts by registered or certified mail or personal service, provided that reasonable time is
allowed for appearance. Each Party hereby waives, to the greatest extent it may do so, any defense it may have on the grounds of inconvenient forum with respect to any action or proceeding maintained in any state or federal court in Massachusetts.

  
 17.13. Arbitration. (a) Any dispute arising out of or
relating to any provisions of this Agreement shall be finally settled by arbitration to be held in Boston, Massachusetts, under the auspices and then current commercial arbitration rules of the American Arbitration Association (the “AAA”).
Such arbitration shall be conducted by three (3) arbitrators. Within thirty (30) days after the commencement of any arbitration, each Party shall appoint one arbitrator, and these two arbitrators shall jointly appoint the third arbitrator, who shall
have significant experience in pharmaceutical drug development and commercialization; provided, however, that if the two arbitrators appointed by the Parties are unable to agree upon the third arbitrator within thirty (30) days after
their appointment, then the third arbitrator shall be appointed by the AAA. The Parties shall instruct such arbitrators to render a determination of any such dispute within four (4) months after their appointment. All arbitration proceedings shall
be conducted in English. Judgment upon any award rendered may be entered in any court having jurisdiction, or application may be made to such court for a judicial acceptance of the award and an order of enforcement, as the case may be. 

 
 (b) Section 17.14(a) shall not prohibit a Party from
seeking injunctive relief from a court of competent jurisdiction in the event of a breach or prospective breach of this Agreement by the other Party which would cause irreparable harm to the first Party. 
  
 17.14. No Consequential Damages. IN NO EVENT SHALL EITHER PARTY OR ANY
OF ITS RESPECTIVE AFFILIATES OR SUBLICENSEES BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES OR SUBLICENSEES FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR
OTHERWISE, INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS OR REVENUE, OR CLAIMS OF CUSTOMERS OF ANY OF THEM OR OTHER THIRD PARTIES FOR SUCH OR OTHER DAMAGES. 
  
 17.15. Entire Agreement. This Agreement (together with the Exhibits hereto) sets forth the entire agreement and understanding between the Parties
as to the subject matter hereof and merges all prior discussions and negotiations between them, and neither of the Parties shall be bound by any conditions, definitions, warranties, understandings or representations with respect 

  

 35 

 
to such subject matter other than as expressly provided herein or as duly set forth on or subsequent to the Effective Date in writing and signed by a proper
and duly authorized officer or representative of the Party to be bound thereby. Without limiting the generality of the foregoing, the terms and conditions of this Agreement shall supersede the terms and conditions of any confidentiality,
non-disclosure or similar such agreement that the Parties may have executed prior to the Effective Date. 
  
 17.16. Parties in Interest. All the terms and provisions of this Agreement shall be binding upon, inure to the benefit of and be enforceable by the
Parties hereto and their respective permitted successors and assigns. 
  
 17.17. Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. 
  
 17.18. Counterparts. This Agreement may be executed simultaneously in
two counterparts, any one of which need not contain the signature of more than one Party, but both such counterparts taken together shall constitute one and the same agreement. 
  

 36 

 IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its duly authorized
officer as of the day and year first above written. 
  

			
	 NEOTHERAPEUTICS, INC.

		
	 By:
	 	 /s/ Rajesh C. Strutriya

	 Name:
	 	 Rajesh C. Strutriya

	 Title:
	 	 CEO

  

			
	 GPC BIOTECH AG

		
	 By:
	 	 
	 Name:
	 	 
	 Title:
	 	 

  

			
		
	 By:
	 	 
	 Name:
	 	 
	 Title:
	 	 

  

 37 

 IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its duly authorized
officer as of the day and year first above written. 
  

			
	 NEOTHERAPEUTICS, INC.

		
	 By:
	 	 
	 Name:
	 	 
	 Title:
	 	 

  

			
	 GPC BIOTECH AG

		
	 By:
	 	 /s/ Bernd R. Seizinger

	 Name:
	 	 Bernd R. Seizenger

	 Title:
	 	 CEO

  

			
	 
		
	 By:
	 	 /s/ S. Meier-Ewert

	 Name:
	 	 S. Meier-Ewert

	 Title:
	 	 CSO

  

 38 

 EXHIBIT A 
  

J-M License Agreement 
  

 39 

 Dated August 28, 2001 
  
 JOHNSON MATTHEY PLC 
  
 and 
  
 NEOTHERAPEUTICS, INC. 
  
 LICENCE 
  
 Johnson Matthey PLC

 2-4 Cockspur Street 
 Trafalgar
Square 
 London SW1Y 5BR 
  

 40 

 LICENCE 
  
 Date: August 28, 2001 
  
 PARTIES: 
  

	1.	The LICENSOR: Johnson Matthey PLC, a company organised under the laws of England and Wales whose registered office is at 2-4 Cockspur Street, Trafalgar Square, London, SW1Y 5BQ,
England, acting for itself and for its AFFILIATES including particularly Johnson Matthey, Inc 

  

	2.	The LICENSEE: NeoTherapeutics, Inc., a corporation organised under the laws of the State of California, United States of America whose principal place of business is at 157
Technology Drive, Irvine, California 92618, United States of America, acting for itself and for its AFFILIATES 

  
 RECITALS: 
  

	(A)	The LICENSOR has developed and is the beneficial owner of a substantial body of valuable technical information relating to the use of the platinum complex JM216 in the treatment of
tumour cells, toxicity data and other valuable information and is the beneficial owner of the Patent Rights relating thereto as defined hereinafter 

  

	(B)	The LICENSEE wishes to receive and the LICENSOR is willing to grant a licence on the terms and conditions hereinafter set forth to use such information and to work under the said
Patent Rights for the purposes hereinafter provided 

  

	(C)	The parties have executed a Secrecy Agreement dated 13th March, 2001, and the LICENSOR has provided or arranged the provision of certain of LICENSOR’S INFORMATION to LICENSEE under said Secrecy Agreement 

  
 ARTICLE I DEFINITIONS 
  
 In this Agreement the following terms shall have the following meanings unless the context otherwise requires: 
  

	1.	AFFILIATE: a subsidiary company within the meaning of S.736 of the United Kingdom Companies Act 1985. 

  

	2.	EFFECTIVE DATE: the date upon which this Agreement has been executed by representatives of LICENSOR and LICENSEE. 

  

	3.	FIELD: the use of the PRODUCTS for the purpose of treating cancer in humans and the sale of the PRODUCTS for such purpose. 

  

	4.	GENERIC PRODUCT: a PRODUCT marketed by a THIRD PARTY in a country comprising the TERRITORY. 

  

 41 

	5.	IMPROVEMENTS: any new or useful invention, process or improvement, patentable or unpatentable, relating to or arising under the PATENT RIGHTS, conceived or first reduced to practice
or demonstrated to have utility by LICENSEE, LICENSOR, or LICENSEE AND LICENSOR jointly, during the TERM. 

  

	6.	JM216: the platinum complex 

 bis(acetato)amminedichloro(cyclohexylamine)platinum(IV) 
  

	7.	LICENSER’S INFORMATION: information, data, research results and clinical evaluation results relating to PLATINUM COMPLEXES and in the lawful possession of LICENSOR at the
EFFECTIVE DATE (as described in Article II.1). 

  

	8.	LICENSOR’S ONGOING INFORMATION: information, data, research results, as well as inventions made by LICENSOR subject to the PATENT RIGHTS, all coming into the lawful possession
of LICENSOR during the TERM. 

  

	9.	LICENSEE’S ONGOING INFORMATION: information, data, research results, clinical evaluation results, approval trials data and results as well as all approvals obtained by LICENSEE
during the TERM and relating to the PLATINUM COMPLEXES. 

  

	10.	NET SALES VALUE: the invoiced sales price of the PRODUCTS in an arm’s length transaction exclusively for money after deduction of normal trade discounts actually granted and of
any credits actually given by the LICENSEE for returned or defective goods and excluding or making proper deductions for any costs of packing, insurance, carriage and freight and Value Added Tax or other sales tax and, in the case of export orders,
any import duties or similar applicable governmental levies or export insurance costs expressly subject in all cases to the same being separately charged on customer invoices. In any sale or other disposal of any PRODUCTS otherwise than in an
arm’s length transaction exclusively for money, the fair market price (if higher) in the relevant country of disposal shall be substituted for the Net Sales Value 

  

	11.	MILESTONES: the objectives described in Article IV hereof 

  

	12.	ONGOING INFORMATION: together the LICENSOR’S ONGOING INFORMATION and the LICENSEE’S ONGOING INFORMATION. 

  

	13.	PATENT RIGHTS: 

  

	 	(i)	the patents and applications short particulars whereof are set out in Schedule A hereto, as well as any continuation, continuations-in-part and divisional applications, including
reissues and reexamination applications and patent term extension and reexamination certificates issuing to LICENSOR; 

  

	 	(ii)	all patent applications that may hereafter be filed by or on behalf of the LICENSOR which either are based on or claim priority from any of the foregoing patents and applications or
which are in respect of any IMPROVEMENTS to which LICENSOR is exclusively entitled; and 

  

 42 

	 	(iii)	all patents which may be granted pursuant to any of the foregoing patent applications. 

  

	14.	PLATINUM COMPLEXES: the platinum co-ordination compounds that are the subject of the PATENT RIGHTS. 

  

	15.	PRODUCTS: PLATINUM COMPLEXES formulated for administration to patients. 

  

	16.	TERM: the term commencing on the EFFECTIVE DATE and terminating three (3) years following the expiry of the last to expire of the patents granted in the United States of America or
any of the countries currently comprising the European Union which have expiration dues specified on Schedule A. The date of expiration of a patent described in this Section shall include any extension granted to LICENSOR by virtue of any
continuation, continuations-in-part and divisional applications, including reissues and reexamination applications and patent term extension and reexamination certificates issuing to LICENSOR. 

  

	17.	TERRITORY: Each country of the world. 

  

	18.	THIRD PARTY: any person or entity other than the LICENSOR and its AFFILIATES and the LICENSEE and its AFFILIATES. 

  
 ARTICLE II GRANT OF RIGHTS 
  

	1.	Subject to Article II.3 below, the LICENSOR agrees to grant and hereby grants to the LICENSEE an exclusive worldwide royalty-bearing revocable right and licence under the PATENT
RIGHTS, with rights to sub-license, to use the PLATINUM COMPLEXES, the LICENSOR’S INFORMATION and the LICENSOR’S ONGOING INFORMATION to make, have made, use, offer to sell, and have sold PRODUCTS for use within the FIELD.

  

	2.	The LICENSEE shall be entitled to sub-license any THIRD PARTY under the rights granted under Article II.1 hereof provided that: (i) the LICENSEE shall remain responsible for all
acts and omissions of such sub-licensees as though they were by the LICENSEE; and (ii) the sub-license agreement shall be in the form to be attached to this Agreement as Exhibit 1. In particular, the LICENSEE shall be responsible to the LICENSOR for
payments due in respect of sales by sub-licensees as though they were sales by the LICENSEE. The parties shall use their best endeavours to draft, negotiate and finalize the form sub-license agreement within 15 (fifteen) days of the EFFECTIVE DATE,
which form sub-license agreement shall provide that upon termination of this Agreement, any sub-licensee shall attorn to and accept the LICENSOR in the place of the LICENSEE such that any sub-license shall be deemed an agreement between the LICENSOR
and sub-licensee. 

  

	3.	 For the avoidance of doubt, it is hereby declared that the LICENSEE shall have no right hereunder to manufacture the PLATINUM COMPLEXES except in the circumstances
of Article VI.2, nor to use or sell them otherwise than for use within the FIELD and, without prejudice to the foregoing, the LICENSEE accepts that the licence hereby granted does not include the right to manufacture the PLATINUM COMPLEXES other
than in the 

  

 43 

	 	 
circumstances set forth in Article VI.2, or in accordance with the supply agreement between the LICENSOR and LICENSEE. 

  
 ARTICLE III ONGOING RESEARCH AND DEVELOPMENT 
  

	1.	The LICENSEE shall diligently perform research and development on the use of JM 216 and other PLATINUM COMPLEXES within the FIELD and on the formulation of PRODUCTS. The LICENSEE
shall exercise in the performance of such research and development technical skill and competence of a high calibre. 

  

	2.	Throughout the TERM of this Agreement, the LICENSOR shall promptly disclose to the LICENSEE all LICENSOR’S ONGOING INFORMATION developed or acquired by LICENSOR except insofar
as such disclosure would disclose information derived from and subject to confidentiality obligations in favour of a THIRD PARTY. Solely for the purposes set forth in Article VI.2, LICENSEE shall also promptly disclose to LICENSOR any LICENSEE
ONGOING INFORMATION necessary for LICENSOR to perform its obligations set forth in Article VI.2. 

  
 ARTICLE IV MILESTONES 
  
 REDACTED 
  
 ARTICLE V PAYMENT 
  
 REDACTED 
  
 REDACTED 
  

	4.	The LICENSEE shall during the TERM of this Agreement pay to the LICENSOR a royalty calculated at the rate of
[            ] of the NET SALES VALUE of all PRODUCTS sold or otherwise supplied for use whether within the FIELD or outside the FIELD for money or money’s worth by LICENSEE or any
AFFILIATE or sublicensee thereof; provided, however, that in any country in the TERRITORY where a GENERIC PRODUCT is sold in competition with the PRODUCT, the royalty payable to LICENSOR with respect to NET SALES of such PRODUCTS in such country
shall be reduced to [            ] commencing with the calendar quartet during which any such GENERIC PRODUCT first becomes available in competition with the PRODUCT in such country.

  

	5.	Payments due under Article V.4 shall be made within 30 days of the end of each calendar quarter in respect of royalties accruing on PRODUCTS invoiced in that calendar quarter.

  

	6.	All sums due to be paid to the LICENSOR under this Agreement: 

  

	 	5.1	are exclusive of any Value Added, Sales, or any other tax which shall be payable in addition; 

  

 44 

	 	5.2	shall be made in United States dollars to the credit of one or more bank accounts to be designated from time to time in writing by the LICENSOR. Conversion into United States
dollars shall be calculated where appropriate; 

  

	 	5.3	in the case of each sale in a currency other than United States dollars, the royalty shall be calculated in United States dollars at the New York foreign exchange rate quoted in
The Wall Street Journal on the date that payment is due; provided always that where any payment is made after the date provided therefor herein conversion shall be at the: foreign exchange rate on the date of payment if this is more
favourable to the LICENSOR; 

  

	 	5.4	shall be made in full without deduction of taxes charges and other duties that may be imposed except in so far as any such deduction may be credited in full by the LICENSOR against
the LICENSOR’s own tax liabilities. The parties agree to cooperate in all respects necessary to take advantage of such double taxation agreements as may be available 

  

	7.	The LICENSEE agrees during the TERM and for a period of two (2) years thereafter to keep true and accurate records and books of account containing all data necessary for the
determination of royalties payable under this Agreement, including records and books of account relating to sales of PRODUCTS by sub-licensees, which records and books of account shall upon reasonable notice by LICENSOR be open at all reasonable
times during business hours for inspection by an independent accountant appointed by LICENSOR for the purpose of verifying the accuracy of the LICENSEE’s reports hereunder. Such accountant shall be entitled to take copies solely of
LICENSEE’s records pertaining to such reports at LICENSOR’s expense. The LICENSEE shall ensure that its sub-licensees (if any) also keep true and accurate records and books of account containing all data necessary for the determination of
royalties payable in respect of their activities and shall ensure that such records and books of account shall upon reasonable notice by the LICENSOR be open at all reasonable times during business hours for inspection by such independent accountant
for the purpose of verifying the accuracy of the LICENSEE’s reports hereunder. 

  

	8.	The LICENSEE shall submit to the LICENSOR within 30 days of the end of each calendar quarter a statement setting forth with respect to the operations of the LICENSEE hereunder, as
well as with regard to each sub-licensee during that period, the quantity of PRODUCTS made and sold and the NET SALES VALUE of all PRODUCTS sold together with payments due. 

  

	9.	The accountant selected to inspect the LICENSEE’S books and records pursuant to Article V.7 shall agree in writing to maintain in confidence all financial and other information
received with respect to the LICENSEE’s operations pursuant to the foregoing Article V.7. 

  

 45 

 ARTICLE VI SUPPLY OF PLATINUM COMPLEXES 
  

	1.	The LICENSOR shall supply to the LICENSEE, LICENSEE’s reasonable requirements of the PLATINUM COMPLEXES used in the manufacture of the PRODUCTS at reasonable commercial prices
under the terms of one or more separate supply agreements the terms of which are to be agreed. 

  

	2.	Within 15 (fifteen) days of the EFFECTIVE DATE, LICENSOR shall deliver a proposal for the supply of 200 grams of the PLATINUM COMPLEXES as follows: (i) 80 grams to be delivered on
or before September 15, 2001, and 120 grams to be delivered on or before October 31, 2001. The PLATINUM COMPLEXES supplied pursuant to this Section shall be manufactured by the LICENSOR in accordance with its Standard Operation Procedures, but not
be certified as being manufactured in accordance with Good Manufacturing Practices. The obligation of the LICENSOR pursuant to this Section shall be independent of the existence of the supply agreement described in Article VI.1.

  

	3.	LICENSOR understands the requirement of LICENSSE to have security of supply. In the event that either: (i) the parties have not entered into a definitive supply agreement as
described in Article VI.1 by January 31, 2002; or (ii) the LICENSOR is unable or unwilling to supply the LICENSEE with its reasonable requirements of the PLATINUM COMPLEXES at reasonable prices, the parties agree that the LICENSEE shall have the
right and license to manufacture or have manufactured the PLATINUM COMPLEXES itself or through any THIRD PARTY, subject to the terms and conditions of this Agreement. 

  
 ARTICLE VII PATENTS 
  

	1.	The LICENSOR shall at its own cost diligently prosecute to grant all subsisting patent applications within the PATENT RIGHTS so as to secure the broadest monopoly reasonably
obtainable consistent with avoiding serious prejudice to the validity of such granted patents and shall maintain all patents within the PATENT RIGHTS in force for the full terms thereof. In the event that LICENSOR elects to abandon the prosecution
or maintenance of any such PATENT RIGHTS in any country in the Territory, LICENSOR shall give LICENSEE notice thereof at least 60 days prior to the date on which LICENSEE is required by law to make a filing in order to preserve rights to patent
protection in such country, and LICENSEE shall have the right to do so, at its own expense. In the event that LICENSOR elects to abandon the prosecution or maintenance in any country in the Territory any of its PATENT RIGHTS and LICENSEE elects to
assume such prosecution and maintenance, then LICENSOR shall assign its rights it may have therein in such country to LICENSEE. 

  

	2.	 Neither party hereto shall publish any matter forming part of the ONGOING INFORMATION that might prejudice the validity of any patent that might subsequently be
granted on it. Each party shall notify the other whether it intends to seek any relevant protection for any part of its respective ONGOING INFORMATION. If it does not wish to do so and if the other party within three (3) calendar months notifies the
first party that 

  

 46 

	 	 
it would like to seek patent or other protection then this obligation shall continue for such time as may be reasonably required to prepare and file an
application for a patent or other protection after which period it shall lapse. 

  

	3.	IMPROVEMENTS that are made by an employee or agent of LICENSEE, solely or jointly, other than with an employee or agent of LICENSOR, shall be owned by LICENSEE. IMPROVEMENTS that
are made jointly by employees or agents of LICENSOR and LICENSEE shall be jointly owned by LICENSOR and LICENSEE and treated as joint inventions under the laws applicable to joint inventions. In those countries in which the LICENSEE deems it
commercially reasonable, the LICENSEE shall process and pay for patent applications for any jointly owned IMPROVEMENTS (including the cost of filing and prosecuting applications as well as maintaining granted patents) which are to be utilised in the
FIELD. In prosecuting and filing for protection, the LICENSEE shall have the right to make any decisions which it deems necessary to carry out such filing and prosecution. While any patent issued shall be jointly owned, the LICENSEE shall have the
sole and exclusive right with regard to utilisation of the jointly owned patent in the FIELD to: (i) license such jointly owned IMPROVEMENTS to a THIRD PARTY; (ii) to enforce such patents against any THIRD PARTY; and (iii) make, have made, use,
sell, and have sold all jointly owned Improvements. In the event the term of a jointly owned patent covering an IMPROVEMENT extends beyond the TERM, the LICENSOR and LICENSEE agree to undertake best endeavours to reach an agreement on the terms
under which LICENSEE will retain the sole and exclusive rights as described in the prior sentence. 

  

	4.	Unless otherwise agreed, the costs of filing and prosecuting any application for patent and maintaining such granted patents shall rest with the party making the application.

  

	5.	 If, with respect to a given country, the LICENSEE becomes aware of substantial infringement (greater than thirty percent (30%) of the LICENSEE’S NET SALES
VALUE of PRODUCTS in such country) by a THIRD PARTY of the PATENT RIGHTS in such country the LICENSEE will promptly notify the LICENSOR and the parties will confer and attempt to agree on what action should be taken. Should the LICENSOR and the
LICENSEE agree that suit should be brought in any such country, the LICENSE shall have the right to control, bear the cost of, and retain any recovery from any such suit. Should the LICENSEE not wish to bring suit, the LICENSOR shall have the option
to do so, in which case the LICENSOR shall control, bear the cost of, and retain any recovery from any such suit and the LICENSEE shall reasonably co-operate in the effort. Should the LICENSEE provide the LICENSOR with reasonable evidence of
substantial infringement by a THIRD PARTY of the PATENT RIGHTS in any country and the parties are unsuccessful in abating the infringement within one hundred and twenty (120) days after the LICENSOR has promptly notified the infringer of the
infringement, and should the LICENSOR have failed to file suit for infringement at the end of such one hundred and twenty (120) day period, the LICENSEE shall be entitled to reduce the amount of royalty due in such country in accordance with Article
V.4 by a percentage equal to the percentage of such substantial infringement, but in no event by more than fifty percent (50%). Said reduced royalty shall continue to be the prevailing royalty rate on NET SALES VALUE of PRODUCTS in such country
until said substantial 

  

 47 

	 	 
infringement ceases and, thereafter, the royalty shall revert to the full royalty defined herein. 

  

	6.	The LICENSOR represents that it is not aware that any PRODUCTS or PLATINUM COMPLEXES infringes upon or falls within any THIRD PARTY patent rights. In the event that a THIRD PARTY
accuses or brings suit against either party alleging patent infringement, the parties shall meet and agree on the response to the THIRD PARTY and the conduct of and costs arising from any suit. 

  

	7.	In the event that any PLATINUM COMPLEXES infringe or fall within any THIRD PARTY patent rights, the LICENSOR shall at its own expense use its best endeavours either to modify the
PLATINUM COMPLEXES to be non-infringing or to obtain at its own expense for the LICENSEE a licence to continue using PLATINUM COMPLEXES, provided that in the event that the parties reasonably agree that it is not possible either to modify the
PLATINUM COMPLEXES to be non-infringing or to obtain for the LICENSEE a licence to continue using the PLATINUM COMPLEXES then the LICENSEE may terminate this Agreement and all licences granted hereunder forthwith on written notice, and the parties
shall co-operate with respect to an orderly termination of the same. Termination under this subclause shall be without prejudice to the rights of either party accrued at the date of termination. 

  

	8.	It at any time during the TERM the LICENSEE directly or indirectly opposes or assists any THIRD PARTY to oppose the grant of letters patent on any patent application within the
PATENT RIGHTS or disputes or directly or indirectly assists any THIRD PARTY to dispute the validity of any patent within the PATENT RIGHTS or any of the claims thereof the LICENSOR shall be entitled to terminate all or any of the licences granted
hereunder forthwith by notice thereof to the LICENSEE. 

  
 ARTICLE VIII CONFIDENTIALITY 
  

	1.	Any information communicated by one party to the other pursuant to this Agreement or prior to and in contemplation of it, whether technical or commercial, and which is identified on
the face of a document as confidential, or if an oral or visual communication is confirmed as confidential within 30 days, or would be reasonably be assumed as confidential in the circumstances, shall be treated by the party receiving the
information as confidential. The receiving party shall afford such confidential information the same protection as it affords its own confidential information, but no less than reasonable protection. The receiving party shall respect the
other’s proprietary rights therein, shall use the same exclusively for the purposes of this Agreement, and shall disclose the same only to those of its contractor and sub-licensees (if any) pursuant to this Agreement to whom and to the extent
that such disclosure is reasonably necessary for the purpose of this Agreement and who shall enter into obligations of confidentiality direct with the other in similar terms to this Article. 

  

 48 

	2.	The foregoing obligations of Article VIII.1 above shall not apply to information which: 

  

	 	2.1	prior to receipt thereof from one party was in the possession of the other and at its free disposal; 

  

	 	2.2	is subsequently disclosed to the recipient party without any obligations of confidence by a third party who has not derived it directly or indirectly from the other;

  

	 	2.3	is or becomes generally available to the public through no act or default of the recipient party or its agents or employees; 

  

	 	2.4	is required to be disclosed by order of a court or administrative authority but only after the owner of the information has been informed by the party subject to the order, if such
informing is possible in the circumstances. 

  

	3.	The restrictions imposed in this Article shall not apply to disclosure of information necessary for the obtaining of patents, nor shall they restrict disclosure or any other action
which is necessary for obtaining or maintaining registration or approval of the Food and Drug Administration or any other regulatory agency of the United States or any other country for the evaluation and sale of PRODUCTS. 

 
 ARTICLE IX PERFORMANCE 
  

	1.	Daring the continuance of this Agreement the LICENSEE shall: 

  

	 	1.1	use its best endeavours to obtain appropriate regulatory approvals for PRODUCTS in the United States of America or any of the countries currently comprising the European Union and
to promote the distribution and sale of PRODUCTS in the FIELD in the such countries as widely as its resources reasonably permit and will make available all necessary selling facilities to meet in full all demands for PRODUCTS for use in the FIELD
throughout such countries; 

  

	 	1.2	ensure that all literature prepared by the LICENSEE and relating to PRODUCTS bears an acknowledgement to the effect that they are subject to a licence from the LICENSOR, and attach
to all PRODUCTS a label quoting relevant patent numbers and stating that such PRODUCTS are made under licence from the LICENSOR; 

  

	 	1.3	not act as agent of the LICENSOR and specifically not give any indication that it is acting otherwise than as principal and in advertising or selling PRODUCTS not make any
representation or give any warranty on behalf of the LICENSOR; 

  

	 	1.4	advise LICENSOR immediately of all approvals granted and assist LICENSOR in all reasonable ways to obtain any form of patent term extension for medicines. 

 

 49 

 ARTICLE X LIABILITY 
  

	1.	The LICENSEE shall defend, indemnify (and keep indemnified) and hold the LICENSOR harmless from and against all claims, liabilities damages cost; and expenses (including legal
costs) which may be brought or made against or incurred by the LICENSOR arising from the use or sale of the PRODUCTS. LICENSOR acknowledges that this indemnity does not include those items for which LICENSOR is indemnifying LICENSEE below. The
LICENSOR shall as soon as reasonably practicable notify the LICENSEE of any such claims and shall give to the LICENSEE all reasonable assistance that the LICENSEE may request in connection therewith. 

  

	2.	The LICENSOR shall defend, indemnify (and keep indemnified) and hold LICENSEE harmless from and against any claims, liabilities, damages, costs and expenses (including legal costs)
arising out of or otherwise relating to any claims: (a) alleging that the PLATINUM COMPLEXES and/or the LICENSOR INFORMATION or LICENSOR’S ONGOING INFORMATION infringes upon the intellectual property rights of any THIRD PARTY, and (b) arising
out of defects present in any PLATINUM COMPLEXES supplied to the LICENSEE by this LICENSOR pursuant to Article VI herein, up to a maximum cap of $5 million. The LICENSEE shall as soon as reasonably practicable notify the LICENSOR of any such claims
and shall give to the LICENSOR all reasonable assistance that the LICENSOR may request in connection therewith. 

  
 ARTICLE XI TERM AND TERMINATION 
  

	1.	This Agreement shall commence on the EFFECTIVE DATE and shall continue in force in each country of the TERRITORY for the TERM. 

  

	2.	The LICENSOR may terminate this Agreement by written notice to the LICENSEE in the event of failure by the LICENSEE to make any of the payments specified in Article V hereof on the
due date or any reasonable and mutually agreed upon extension of any such date. 

  

	3.	The LICENSOR shall have the right to terminate this Agreement upon forty-five (45) days written notice to LICENSEE in the event of failure by the LICENSEE to attain the FIRST,
SECOND OR THIRD MILESTONES in Article IV hereof within ninety (90) days of the target date specified for such MILESTONE or any reasonable and mutually agreed upon extension of such MILESTONE target date. LICENSOR agrees that it shall grant all
reasonable requests by LICENSEE for extensions of such target dates and LICENSOR further agrees that it shall not exercise its right to terminate except where it has good faith reason to believe that LICENSEE will be unable to comply with any
requested extended dates. 

  

	4.	LICENSEE shall have the right to terminate this Agreement at any time by giving written notice to LICENSOR, which shall be effective 60 (sixty) days from the date such notice is
given. 

  

	5.	 In the event of a breach of this Agreement by either party, and if remedial action is possible the party fails to remedy such breach within a period of 45 (forty
five) days after 

  

 50 

	 	 
written notice thereof from the other party, the other party shall have the right forthwith to terminate this Agreement by giving written notice of
termination to the party in breach, except where the cause of such default is a reason of force majeure under Article XII hereof, in which event the other party shall have no such right of termination under this Article XI.5.

  

	6.	Either party shall have the right forthwith to terminate this Agreement by giving written notice of termination to the other if the other shall have a receiver or manager appointed
of its undertaking or assets or shall have an administration order made against it or shall go into liquidation whether voluntary or otherwise (other than for the purposes of and followed by an amalgamation or reconstruction) or shall enter into any
composition or arrangement with its creditors or if it shall cease to carry on business. 

  

	7.	Termination under this Article shall be without prejudice to the rights of the either party existing at the date of termination. 

  

	8.	Termination of this Agreement for any reason shall not bring to an end: 

  

	 	8.1	the secrecy obligations on the parties hereto, which shall continue for a further period of ten years after termination; 

  

	 	8.2	the LICENSEE’s obligations to pay royalties or other sums which have accrued due or which will become due is respect of sales under Article XI.9 hereof;

  

	 	8.3	Upon any termination of this Agreement, all sublicenses granted by the LICENSEE utilising the form sub-license agreement attached as Exhibit 1 to this Agreement shall be
automatically assigned to the LICENSOR which shall thereafter receive all benefits and have all obligations under the sublicenses as in the place and stead of the LICENSEE. All other sub-licenses shall terminate simultaneously with this Agreement.

  

	9.	On termination of this Agreement for any reason the LICENSEE shall continue to have the right for a period of six months from the date of termination to complete deliveries on
contracts in force at that date and to dispose of PRODUCTS already manufactured subject to payment to the LICENSOR of royalties thereon in accordance with Article V hereof. 

  

	10.	Upon termination by LICENSOR due to LICENSEE’S breach, the LICENSEE shall pass to the LICENSOR all information and data in the LICENSEE’S possession concerning the
PRODUCTS and the LICENSEE’S ONGOING INFORMATION. All regulatory approvals made or acquired by the LICENSEE with respect to the PRODUCTS shall become the sole property of the LICENSOR, and the LICENSOR shall have an exclusive royalty-free
licence without limit of time, with the right to grant sub-licences thereunder, to use all LICENSEE’s ONGOING INFORMATION and to work under all intellectual property rights in respect thereof owned by the LICENSEE or any successor in title of
the LICENSEE. 

  

 51 

	11.	After termination of this Agreement by LICENSOR due to LICENSEE’S breach, and in the event that the LICENSOR shall grant a licence to any THIRD PARTY to use PLATINUM COMPLEXES
in the manufacture of PRODUCTS for use within the FIELD and in the event that such licence includes the right to use LICENSEE’S ONGOING INFORMATION, then LICENSOR shall pay to the LICENSEE a proportion of any royalties obtained from such THIRD
PARTY, such proportion to be agreed between the parties hereto, taking into account the proportion of the value of the licensed LICENSEE’S ONGOING INFORMATION to the value of the licensed rights as a whole. 

  

	12.	Following the expiration of the TERM of this Agreement, LICENSEE shall have the royalty-free, non-exclusive, perpetual right and license to continue to use this PLATINUM COMPLEXES
to make, have made, use, sell, and have sold PRODUCTS in all countries in the TERRITORY. 

  
 ARTICLE XII FORCE MAJEURE 
  
 If the
performance of any part of this Agreement by either party is prevented, restricted, interfaced with or delayed by reason of any cause beyond the reasonable control of the party liable to perform, unless conclusive evidence to the contrary is
provided, the party so affected shall, upon giving written notice to the other party, be excused from such performance to the extent of such prevention, restriction, interference or delay, provided that the affected party shall use its reasonable
best efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. In the event that the event of Force Majeure continues uninterrupted for a period of six months,
the party not directly affected by the event may terminate this Agreement upon one month’s written notice, subject to the termination being ineffective if the even of Force Majeure ends during that notice period. 
  
 ARTICLE XIII PERSONNEL 
  

	1.	The LICENSOR agrees that it will not, nor will its AFFILIATES, for the term of this Agreement and for a period of six months after termination for whatsoever cause employ or appoint
as its partner, consultant or agent any person who has been within a period of one year from the date of such intended employment or appointment employed by the LICENSEE in research or other technical or commercial work associated with the purposes
of this Agreement. 

  

	2.	The LICENSEE agrees that it will not, nor will its AFFILIATES, for the term of this Agreement and for a period of six months after termination for whatsoever cause employ or appoint
as its partner; consultant or agent any person who has been within a period of one year from the date of such intended employment or appointment employed by the LICENSOR, in research or other technical or commercial work associated with the purposes
of this Agreement. 

  

 52 

 ARTICLE XIV GENERAL 
  

	1.	This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective legal successors but shall not otherwise be assignable by either party
without the written consent of the other party, other than to an assignee of such party of all or substantially all of such party’s business. 

  

	2.	No variation or amendment of this Agreement shall bind either party unless made in writing and agreed to in writing by duly authorised officers of both parties.

  

	3.	If any provision of this Agreement is agreed by the parties to be illegal void or unenforceable under any law that is applicable hereto or if any court or administrative authority
of competent jurisdiction in a final decision so determines this Agreement shall continue in force save that such provision shall be deemed to be excised herefrom with effect from the date of such agreement or decision or such earlier date as the
parties may agree. In such event, the parties shall endeavour to substitute the excised provision by another provision that achieves the intentions of the parties at the date hereof. 

  

	4.	The headings in this Agreement are for convenience only and are not intended to have any legal effect. 

  

	5.	A failure by either party hereto to exercise or enforce any rights conferred upon it by this Agreement shall not be deemed to be a waiver of any such rights or operate so as to bar
the exercise or enforcement thereof at any subsequent time or times. 

  

	6.	This Agreement shall not give any rights of enforcement or otherwise to any THIRD PARTY. 

  

	7.	Each of the parties acknowledges and agrees that in entering into this Agreement, and the documents referred to in it, it does not rely on, and shall have no remedy in respect of,
any statement, representation, warranty or understanding (whether negligently or innocently made) of any person (whether party to this Agreement or not) other than as expressly set out in this Agreement as a warranty or representation. The only
remedy available to it for breach of the such warranties or representations shall be for breach of contract under the terms of this Agreement. Nothing in this clause shall, however, operate to limit or exclude any liability for fraud.

  
 ARTICLE XV NOTICES 
  

	1.	Any notice required to be given hereunder by either party to the other shall be in writing and shall be served by sending the same by registered or recorded delivery post or by
telefax to the address of the other party as given herein or to such other address as that party may have previously notified to the party giving notice as its address for such service. Such notice shall be deemed to be received, if given by post,
three days after mailing, and if given by telefax, on the day of transmission. 

  

 53 

	2.	The parties’ address for service are as follows: 

  
 For the LICENSOR 
  
 Johnson Matthey PLC 
 2-4 Cockspur Street

 Trafalgar Square 
 London SW1Y
5BQ 
 United Kingdom 
 attention:
Company Secretary 
 Telefax: +44 207 269 8478 
  
 For the LICENSEE 
  
 NeoTherapeutics Inc. 
 PO Box 57052

 Irvine California 92619 – 7052 
 U.S.A. attention: President 
 Telefax: 949-788-6706 
  
 ARTICLE XVI INTEREST 
  
 Any payment required to be made by the LICENSEE under the provisions of this Agreement shall bear interest as well after as before judgment from the date the payment
becomes due until the date of actual payment at a rate equal to 3% over the base rate from time to time of Lloyds Bank PLC. 
  
 ARTICLE XVII GOVERNING LAW AND DISPUTES 
  

	1.	The construction validity and performance of this Agreement shall be governed in all respects by English Law. 

  

	2.	Subject to Article XVII 3, all disputes arising in any way out of or affecting this Agreement shall be referred to arbitration under the rules of conciliation and arbitration of the
International Chamber of Commerce whose decision shall be final. The place of arbitration shall be California if the LICENSOR is the plaintiff and London if the LICENSEE is the Plaintiff. 

  

	3.	Notwithstanding Article XVII 2, either party may seek interlocutory relief in respect of any dispute arising in any way out of or affecting this Agreement from the English courts
and the parties agree that such courts shall have non-exclusive jurisdiction in this regard. 

  

 54 

 IN WITNESS whereof the parties have caused this Agreement to be executed the day and year first above
written 
  
 SIGNED by: _____________________ 
  

			
	For and on behalf of	  	)
	JOHNSON MATTHEY PUBLIC	  	)
	LIMITED COMPANY	  	)

  
 SIGNED by:______________________

  

			
	Rajesh C. Shrotriya, M.D., President and Chief Operating Officer
	For and on behalf of	  	)
	NEOTHERAPEUTICS INC.	  	)

  

 55 

 FIRST AMENDMENT TO LICENCE AGREEMENT 
 DATED AUGUST 28, 2001 BETWEEN 
 JOHNSON MATTHEY PLC 
 AND 
 NEOTHERAPEUTICS, INC.

  
 This First Amendment to License Agreement (“FIRST
AMENDMENT”) is entered into and effective this 30th day of September 2002 by and between Johnson Matthey PLC, a company organised under the laws of England and Wales whose registered office is at 2-4 Cockspur Street, Trafalgar Square, London,
SWIY 5BQ, England, acting for itself and for its AFFILIATES including particularly Johnson Matthey, Inc (collectively, “LICENSOR”), and NeoTherapeutics, Inc., a corporation organized under the laws of the State of California, United States
of America whose principal place of business is at 157 Technology Drive, Irvine, California 92618, United States of America with reference to the following facts and on the following terms and conditions. 
  
 RECITALS 
  
 (A) Effective August 28, 2001, LICENSOR and LICENSEE entered into the License Agreement (the “LICENSE”) pursuant
to which LICENSOR granted a license for the use of technical information relating to the use of platinum complex JM216 in the treatment of tumor cells as well as for the use of the PATENT RIGHTS (as defined in the LICENSE). All defined terms in this
FIRST AMENDMENT (as set forth in capital letters) shall have the same meaning as set forth in the LICENSE. 
  
 (B) The parties now wish to amend and modify the LICENSE on the terms and conditions as set forth in this FIRST AMENDMENT. 
  

 56 

 Now therefore, for good and valuable consideration, the parties agree as follows: 
  
 (1) ARTICLE I 
  
 Paragraph 16 of Article I of the LICENSE shall be amended
to read as follows: TERM: the term commencing on the EFFECTIVE DATE and terminating on a country-by-country basis upon the expiry of the last to expire of the patents granted in each such country which have expiration dates specified on Schedule
A. The date of expiration of a patent described in this Section shall include any extension granted to LICENSOR by virtue of any continuation, continuations-in-part and divisional applications, including reissues and reexamination applications and
patents and reexamination certificates issuing to LICENSOR, 
  
 (2) ARTICLE II 
  
 Paragraph 1
of Article II of the LICENSE shall be amended to read as follows: 
  

	1.	Subject to Article II.3 below, the LICENSOR agrees to grant and hereby grants to the LICENSEE an exclusive worldwide royalty-bearing revocable right and licence, with rights to
sublicence, under the PATENT RIGHTS to use PLATINUM COMPLEXES, the LICENSOR’S INFORMATION and the LICENSOR’S ONGOING INFORMATION to make, have made, use, offer to sell, and have sold PRODUCTS for use within the FIELD.

  
 Paragraph 2 of Article II of
the LICENSE shall be amended to read as follows: 
  

	2.	 The LICENSEE shall be entitled to sub-license any THIRD PARTY under rights granted under Article II.1 hereof provided that the LICENSEE shall remain responsible for
all acts and omissions of such sub-licensee as though they were by the LICENSEE. In particular, the LICENSEE shall be responsible to the LICENSOR for payments due in respect of sales by sub-licensees as though they were sales by LICENSEE. The terms
of any sub-license agreement shall provide that upon termination of this Agreement, any 

  

 57 

	 	 
sub-licensee shall attorn to and accept the LICENSOR in place of the LICENSEE such that any sub-license shall be deemed an agreement between the LICENSOR and
sub-licensee. 

  
 (3) ARTICLE III

  
 Paragraph 1 of Article III of the LICENSE
shall be amended to read as follows: 
  

	1.	The LICENSEE, its AFFILIATES and sub-licensees shall diligently perform research and development on the use of JM 216 and other PLATINUM COMPLEXES within the FIELD and on the
formulation of PRODUCTS. The LICENSEE, its AFFILIATE and sub-licensees shall exercise in the performance of such research technical skill and competence of a high calibre. 

  
 (4) ARTICLE IV 
  
 Article IV of the LICENSE shall be amended to read as follows: 
  

	1.	The LICENSEE, its AFFILIATES and sub-licensees shall use its best efforts to test, evaluate and develop PRODUCTS so as to meet the objectives detailed hereunder:

  
 Objective 
  

	1	Submission of NDA to US FDA (hereinafter called the ‘First MILESTONE’) 

  

	2	Acceptance of NDA by US FDA (hereinafter called the ‘Second MILESTONE’) 

  

	3	Receipt of US FDA approval of NDA (hereinafter called the ‘Third MILESTONE’) 

  

	4	Approval in the first European Union state of a new drug application (hereinafter called the ‘Fourth MILESTONE’) 

  

	5	Approval by US FDA of JM216 for the first indication other than the indication approved in Objective 2. (hereinafter called the ‘Fifth MILESTONE’)

  

 58 

	6	Approval in the first European Union state of JM216 for the first indication other than the indication approved in Objective 3.(hereinafter called the ‘Sixth MILESTONE’)

  
 (5) ARTICLE V 
  
 Paragraphs 1 through 5, inclusive of Article V of the
LICENSE shall be amended to read as follows: 
  

	1.	The LICENSOR acknowledges receipt of US$100,000 which was paid by LICENSOR on the EFFECTIVE DATE; 

  

	2.	The LICENSOR acknowledges receipt of US$150,000 as required by Article V.2 of the LICENSE. 

  

	3.	Within 30 (thirty) days of the date of the attainment of each MILESTONE by the LICENSEE, an AFFILIATE or sub-licensee, the LICENSEE shall pay to the LICENSOR the following sums:

  

	 	(i)	the First MILESTONE:        [Intentionally Redacted] 

  

	 	(ii)	the Second MILESTONE:   [Intentionally Redacted] 

  

	 	(iii)	the Third MILESTONE:       [Intentionally Redacted] 

  

	 	(iv)	the Fourth MILESTONE:     [Intentionally Redacted] 

  

	 	(v)	the Fifth MILESTONE:        [Intentionally Redacted] 

  

	 	(vi)	the Sixth MILESTONE:        [Intentionally Redacted] 

  
 In no event will LICENSEE be liable for more than one payment upon the occurrence of each MILESTONE. 
  

	4.	 The LICENSEE shall during the TERM of this Agreement pay to the LICENSOR a royalty calculated at the rate set forth below of the NET SALES VALUE of all PRODUCTS
sold or otherwise supplied for use whether within the FIELD or outside the FIELD for money or money’s worth by LICENSEE or any AFFILIATE or sublicensee 

  

 59 

	 	 
thereof; provided, however, that in any country in the TERRITORY where a GENERIC PRODUCT is sold in competition with the PRODUCT, the royalty payable to
LICENSOR with respect to NET SALES of such PRODUCTS in such country shall be reduced to 0%, commencing with the calendar quarter during which any such GENERIC PRODUCT first becomes available in competition with the PRODUCT in such country.

  

			
	 Royalty Rate

	 	 NET SALES during calendar year

  
 [Intentionally
Redacted] 
  

	5.	Payments due under Article V.4 shall be made within 45 days of the end of each calendar quarter in respect of royalties accruing on PRODUCTS invoiced in that calendar quarter.

  
 Paragraphs 7 and 8 of
Article V of the LICENSE shall be amended to read as follows: 
  

	7.	 The LICENSEE agrees during for a period of three (3) years following the accrual of any royalty it will keep and maintain accurate records and books of account
containing all data necessary for determination of royalties payable under this Agreement, including records and books of account relating to sales of PRODUCTS by sub-licensees, which records and books of account of LICENSEE shall upon reasonable
notice by LICENSOR be open at all reasonable times during reasonable business hours for inspection by an independent accountant appointed by LICENSOR for the purpose of verifying the accuracy of the LICENSEE’s reports hereunder. Such accountant
shall be entitled to take copies solely of LICENSEE’s records pertaining to such reports as LICENSOR’s expense. The LICENSEE shall ensure that its sub-licensees (if any) also keep true and accurate records and books of account containing
all data necessary for the determination of royalties payable in respect of their activities and shall ensure that such records and books of account shall upon reasonable notice by the LICENSOR be open for inspection 

  

 60 

	 	 
at all reasonable times during business hours for inspection by such independent accountant no less than once per year for purposes of verifying the accuracy
of the LICENSEE’S reports hereunder. 

  

	8.	The LICENSEE shall submit to the LICENSOR within 45 days of the end of each calendar quarter a statement setting forth with respect to the operations of the LICENSEE hereunder, as
well as with regard to each sub-licensee during that period, the quantity of PRODUCTS made and sold and the NET SALES VALUE of all PRODUCTS sold together with payments due. 

  
 (6) ARTICLE VII 
  
 Paragraph 6 of Article VII of the LICENSE shall be amended by inserting the following after the first sentence: 
  
 LICENSOR further represents and warrants that it is not aware of any
patents, whether granted to LICENSOR, an AFFILIATE, or any THIRD PARTY, which would be infringed by: (i) the making, using and selling of any PRODUCT; (ii) or utilization of any PLATINUM COMPLEX by LICENSEE in accordance with the license granted by
this AGREEMENT; or (iii) the metabolites of JM216. To the best of LICENSOR’s knowledge and belief, the practice of the PATENT RIGHTS and the exercise of the rights granted LICENSEE under Article II.1 do not infringe upon or conflict with any
patent, copyright or other proprietary right of any THIRD PARTY. 
  

 61 

 (7) ARTICLE IX 
  

The first sentence of Paragraph 1 of Article IX of the LICENSE shall be amended by to read as follows: 
  

	 	1.	During the continuance of this Agreement the LICENSEE, its AFFILIATES, and its sub-licensees shall: 

  
 (8) ARTICLE XI 
  
 Paragraph 3 of Article XI shall be amended to read as follows 
  

	 	3.	Intentionally deleted. 

  
 Subparagraph 8.3 of Article XI shall be amended to read as follows: 
  

	 	8.3	Upon any termination of this Agreement, sublicenses granted by the LICENSEE shall be automatically assigned to the LICENSOR which shall thereafter receive all benefits and have all
obligations under the sublicenses as in place and stead of the LICENSEE. 

  
 (9) [Intentionally Redacted] 
  
 The redacted provisions of this Section deal exclusively with the issuance of shares of NeoTherapeutics common stock to LICENSOR upon the achievement of a MILESTONE. 
  
 (10) GENERAL PROVISIONS 
  
 (a) This FIRST AMENDMENT may be executed in two or more counterparts, including facsimile signatures, each of which will be deemed an
original, but all of which together will constitute one and the same instrument. 
  
 (b) This FIRST AMENDMENT and the AGREEMENT constitute the complete and integrated agreement of the parties with respect to the subject
matter hereof and thereof. Except as provided in this FIRST AMENDMENT, the AGREEMENT will remain in full force and effect and unchanged in all other respects. 
  

(c) LICENSOR represents that it is not aware of any default by LICENSEE under the Agreement, or aware of any event or omission which
with the passage of time might be reasonable foreseen to lead to a default under the Agreement. 
  

 62 

 The parties have caused this FIRST AMENDMENT to be executed by their respective authorized
representatives effective as of the date first set forth above. 
  

									
	 LICENSOR
 Johnson Matthey PLC
	 	 	 	 LICENSEE
 NeoTherapeutics, Inc.

					
	By:	 	 	 	 	 	By:	 	 
	Its:	 	 	 	 	 	Its:	 	 

  

 63 

 (b) This FIRST AMENDMENT and the AGREEMENT constitute the complex and integrated
agreement of the parties with respect to the subject matter hereof and thereof. Except as provided in this FIRST AMENDMENT, the AGREEMENT will remain in full force and effect and unchanged in all other respects. 
  
 (c) LICENSOR represents that it is not aware of any default
by LICENSEE under the Agreement. 
  
 The parties have caused this
FIRST AMENDMENT to be executed by their respective authorized representatives effective as of the date first set forth above. 
  

									
	 LICENSOR
 Johnson Matthey PLC
	 	 	 	 LICENSEE
 NeoTherapeutics, Inc.

					
	By:	 	 	 	 	 	By:	 	 
	Its:	 	 	 	 	 	Its:	 	 

  

 64 

 EXHIBIT B 
  

Patent Rights 
  

 65 

 SCHEDULE A 
  
 Patent Rights 
  

									
	 1.
	  	Case MBUS 1044	  	 	  	 	  	 
	 	  	 County

	  	 Application No.

	  	 Patent No.

	  	 Expiration

	 	  	Austria	  	EP891300787	  	0328274	  	26Jan09
	 	  	Belguim	  	“	  	“	  	26Jan09
	 	  	France	  	“	  	“	  	26Jan09
	 	  	Germany	  	“	  	“	  	26Jan09
	 	  	Great Britain	  	“	  	“	  	26Jan09
	 	  	Greece	  	“	  	“	  	26Jan09
	 	  	Italy	  	“	  	“	  	26Jan09
	 	  	Luxembourg	  	“	  	“	  	26Jan09
	 	  	Netherlands	  	“	  	“	  	26Jan09
	 	  	Spain	  	“	  	“	  	26Jan09
	 	  	Sweden	  	“	  	“	  	26Jan09
	 	  	Switzerland	  	“	  	“	  	26Jan09
	 	  	Australia	  	28971/89	  	618310	  	31Jan09
	 	  	Brazil	  	1100963-2	  	1100963-2	  	14May17
	 	  	Canada	  	589796	  	1340286	  	22Dec15
	 	  	Denmark	  	0491/89	  	—  	  	1Feb09
	 	  	Finland	  	89/0512	  	91260	  	1Feb09
	 	  	Hungary	  	52289	  	205767	  	3Feb09
	 	  	Hungary	  	P/P00163	  	210872	  	9Dec08
	 	  	Ireland	  	31989	  	65503	  	 31Jan06 (can be
 extended to
31Jan09)

	 	  	Israel	  	89119	  	89119	  	29Jan09
	 	  	Japan	  	01/24751	  	2781403	  	1Feb09
	 	  	S. Korea	  	89/1069	  	147270	  	15May13
	 	  	Mexico	  	9203596	  	181357	  	10Dec08
	 	  	New Zealand	  	227839	  	227839	  	1Feb09
	 	  	Norway	  	89/0426	  	177569	  	1Feb09
	 	  	Portugal	  	89608	  	89608	  	2Feb09
	 	  	Romania	  	C-20256	  	—  	  	2Feb08
	 	  	South Africa	  	89/0831	  	89/0831	  	1Feb09
	 	  	Taiwan	  	78/100752	  	51931	  	2Oct06
	 	  	USA	  	07/602931	  	5072011	  	9Dec08
	 	  	USA	  	07/723971	  	5244919	  	14Sep10

  

 66 

									
	 2.
	  	Case MBUS 1192	  	 	  	 	  	 
	 	  	 County

	  	 Application No.

	  	 Patent No.

	  	 Expiration

	 	  	Austria	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Belgium	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Denmark	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	France	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Germany	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Greece	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	GB	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Holland	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Ireland	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Italy	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Portugal	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Spain	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Sweden	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Switzerland	  	EP 95302629.1	  	0 679 656	  	19Apr15
	 	  	Australia	  	17661/95	  	692521	  	23Apr15
	 	  	Canada	  	2147567	  	—  	  	20Apr15
	 	  	Japan	  	7-100870	  	—  	  	24Apr15
	 	  	USA	  	08/428444	  	5519155	  	24Apr15

  

 67 

 EXHIBIT C 
  

Initial Members of Joint Development Committee 
  

			
	 GPC Designees:
	  	 Marcel Rozencweig, Chairman
 Michael
Petrone
 Ed McNiff

		
	NEOTHERAPEUTICS	  	 
	Designees:	  	 Gino Lenaz
 Ashok Gore
 Shanta Chawla

  

 68 

 EXHIBIT D 
  

Registration Rights Agreement 
  

 69 

 NEOTHERAPEUTICS, INC. 
  
 REGISTRATION RIGHTS AGREEMENT 
  
 This Registration Rights Agreement (this “Agreement”) is made as of
                 , 2002, between NeoTherapeutics, Inc., a Delaware corporation (the “Company”), and GPC Biotech AG, a company organized
under the laws of the Federal Republic of Germany (the “GPC”). 
  
 RECITALS 
  
 The
Company and GPC are parties to a Co-Development and License Agreement (the “License Agreement”) dated as of September             , 2002, pursuant to which the
Company has agreed to sell to GPC and GPC has agreed to purchase from the Company shares of the Company’s Common Stock, upon the attainment of certain milestones under the License Agreement. As a condition to GPC’s obligation to purchase
shares of Common Stock under the License Agreement, the Company and GPC are required to enter into this Agreement in order to provide GPC with certain rights to register for resale the shares of the Company’s Common Stock purchased under the
License Agreement. 
  
 AGREEMENT 
  
 The parties agree as follows: 
  

	1.	Definitions; Registration Rights. 

  
 1.1. Definitions. For purposes of this Agreement: 
  

(a) “Common Stock” means the common stock, par value $0.001 per share, of the Company. 
  
 (b) “Exempt Registration” means a
registration statement relating to the sale of securities by the Company pursuant to a stock option, stock purchase or similar benefit plan or an SEC Rule 145 transaction or any other registration statement that would not customarily provide for the
secondary sale of equity shares for cash. 
  
 (c)
“Holder” means (i) GPC and (ii) any person owning Registrable Securities to whom the rights under this Section 1 have been transferred in accordance with Section 1.9 of this Agreement. 
  
 (d) “person” means any individual,
corporation, partnership, limited liability company, trust, business, association or government or political subdivision thereof, governmental agency or other entity. 
  
 (e) “register,” “registered,” and “registration” refer to
a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act and the declaration or ordering of effectiveness of such registration statement or document. 
  
 (f) The term “Registrable Securities” means
(i) the shares of Common Stock issued under the License Agreement, and (ii) any other shares of Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend
or other distribution with respect to, or in exchange for or in replacement of, the shares listed in clause (i) and this clause (ii); provided, however, that the foregoing definition shall exclude in all cases any Registrable
Securities sold or transferred by a Holder in a transaction in which such Holder’s rights under this Agreement are not assigned. Notwithstanding the foregoing, securities shall 

  

 70 

 
only be treated as Registrable Securities if and so long as they have not been (A) sold to or through a broker or dealer or underwriter in a public
distribution or a public securities transaction, or (B) sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof so that all transfer restrictions, and restrictive
legends with respect thereto, if any, are removed upon the consummation of such sale. 
  
 (g) “SEC” means the Securities and Exchange Commission or any other federal agency at the time administering the
Securities Act. 
  
 (h) “Securities
Act” means the Securities Act of 1933, as amended. 
  
 1.2. Company Registration. 
  
 (a) Initiation. If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its stock in connection with
the public offering of such securities solely for cash (other than an Exempt Registration), the Company shall, at such time, promptly give each Holder notice of such proposed registration. Upon the written request of each Holder given within 20 days
after receipt by such Holder of the Company’s notice, the Company shall, subject to the provisions of Section 1.2(b), cause to be registered all of the Registrable Securities that each such Holder has requested to be registered. 
  
 (b) Underwritten Offering. In connection with any
offering involving an underwriting of shares of the Company’s capital stock, the Company shall not be required under Section 1.2(a) to include any of the Holders’ securities in such underwriting unless they accept the terms of the
underwriting as agreed upon between the Company and the underwriters selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters determine in their sole discretion will not jeopardize
the success of the offering by the Company. If the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the
underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the
underwriters determine in their sole discretion will not jeopardize the success of the offering (the securities so included to be apportioned pro rata (to the nearest 100 shares) among the selling stockholders according to the total amount of
securities entitled to be included therein owned by each selling stockholder or in such other proportions as shall mutually be agreed to by such selling stockholders). For purposes of the preceding apportionment, for any participating Holder that is
a partnership, limited liability company or corporation, the partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of any such partners, members, 

  

 71 

 
retired partners or members and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling
stockholder,” and any pro-rata reduction with respect to such “selling stockholder” shall be based upon the aggregate amount of shares carrying registration rights owned by all Persons included in such “selling
stockholder,” as defined in this sentence. 
  
 (c) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 1.2 prior to the effectiveness of such registration whether or not any Holder has
elected to include Registrable Securities in such registration. 
  
 1.3. Obligations of the Company. Whenever required under this Section 1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
  
 (a) Prepare and file with the SEC a registration statement
with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective. 
  
 (b) Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the provisions of the Securities Act. 
  
 (c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements
of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of such Registrable Securities. 
  
 (d) Use its reasonable best efforts to register and qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions. 
  
 (e) In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement with the managing underwriter of such offering in usual and customary form and consistent
with the other provisions of this Agreement. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 
  
 (f) Promptly notify each Holder covered by the registration statement at any time when the Company becomes
aware of the happening of any event as a result of which the registration statement or the prospectus included in such registration statement or any supplement to the prospectus (as then in effect) contains any untrue statement of a material fact or
omits to state a material fact necessary to make the statements there in (in the case of the prospectus, in light of the circumstances under which they were made) not misleading or, if for any other reason it shall be necessary during such time
period to amend or supplement the 

  

 72 

 
registration statement or the prospectus in order to comply with the Securities Act, whereupon, in either case, each Holder shall immediately cease to use
such registration statement or prospectus for any purpose and, as promptly as practicable thereafter, the Company shall prepare and file with the SEC, and furnish without charge to the appropriate Holders and managing underwriters, if any, a
supplement or amendment to such registration statement or prospectus which will correct such statement or omission or effect such compliance and such copies thereof as the Holders and any underwriters may reasonably request. 
  
 (g) Cause all such Registrable Securities registered
pursuant hereunder to be listed on each securities exchange or market on which similar securities issued by the Company are then listed or traded, if applicable. 
  
 (h) Use its reasonable best efforts to furnish, at the request of any Holder requesting registration of
Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through
underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated such date, of the counsel representing the Company for
the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii)
a letter dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to
the underwriters, if any, and to the Holders requesting registration of Registrable Securities (to the extent the then applicable standards of professional conduct permit said letter to be addressed to the Holders). 
  
 1.4. Furnish Information. It shall be a condition precedent to
the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities
held by it, and the intended method of disposition of such securities as shall be required to effect the registration of such Holder’s Registrable Securities. 
  
 1.5. Expenses of Registration. All expenses other than underwriting discounts and commissions incurred in
connection with registrations initiated pursuant to Section 1.2, including without limitation all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable
fees and disbursements of one counsel for the Holders, shall be borne by the Company. 
  
 1.6. Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with
respect to the interpretation or implementation of this Section 1. 
  

 73 

 1.7. Indemnification. In the event any Registrable Securities are included in a
registration statement under this Section 1: 
  
 (a) Indemnification by the Company. To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls
such Holder or underwriter within the meaning of the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), against any losses, claims, damages, or liabilities (joint or several) to which they may
become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements,
omissions or violations (collectively a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus
contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or
alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will pay to each such
Holder, underwriter or controlling person, as incurred, any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however, that
the indemnity agreement contained in this Section 1.7(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not
be unreasonably withheld), nor shall the Company be liable to any Holder, underwriter or controlling person for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation (x) which occurs in
reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Holder, underwriter or controlling person or (y) which occurs in any preliminary prospectus if a final, amended or
supplemental prospectus which corrects such Violation is delivered by the Company to such person at or prior to the written confirmation of the sale giving rise to such loss, claim, damage, liability, or action. 
  
 (b) Indemnification by the Holders. To the extent
permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the
Securities Act, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages, or liabilities (joint or several) to which
any of the foregoing persons may become subject, under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any
Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration statement; and each
such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intended to be indemnified pursuant to this Section 1.7(b), in connection with investigating or defending any such loss, claim, damage, liability, or
action; provided, however, that the indemnity agreement contained in this Section 1.7(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the
consent of the Holder, which consent shall not be unreasonably withheld; provided, that in no event shall any indemnification by a Holder under this Section 1.7(b) exceed the net proceeds from the offering received by such Holder, except in
the case of willful fraud by such Holder. 
  

 74 

 (c) Procedures. Promptly after receipt by an indemnified party under this Section
1.7 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.7, deliver to the indemnifying party a
written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense
thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to
retain one separate counsel, with the reasonable fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential
differing interests between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action,
if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.7, but the omission so to deliver written notice to the indemnifying party will not
relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.7. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to
entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. The
indemnity agreements contained in this Section 1.7 shall not apply to amounts paid in settlement of any loss, claim, damage, liability or action if such settlement is effected without the consent of the indemnifying party, such consent not to be
unreasonably withheld. 
  
 (d)
Contribution. If the indemnification provided for in this Section 1.7 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein,
then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is
appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as
any other relevant equitable considerations; provided, that in no event shall any contribution by a Holder under this Section 1.7(d) exceed the net proceeds from the offering received by such Holder, except in the case of willful fraud by
such Holder. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material
fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. 
  

 75 

 (e) Underwriting Agreement. Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall
control. 
  
 (f) Survival. The obligations
of the Company and Holders under this Section 1.7 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise. 
  
 1.8. Reports Under Exchange Act. With a view to making available to the Holders the benefits of Rule 144
promulgated under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration, the Company agrees to: 
  
 (a) make and keep public information available, in
accordance with SEC Rule 144, at all times after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public so long as the Company remains subject to the periodic reporting
requirements under Sections 13 or 15(d) of the Exchange Act; 
  
 (b) file with the SEC in a timely manner all reports and other documents as may be required of the Company under the Securities Act and the Exchange Act; and 
  
 (c) furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144, the Securities Act and the Exchange Act (at any time after it has become subject to such
reporting requirements), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of
any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 
  
 1.9. Assignment of Registration Rights. The rights to cause the Company to register securities granted Holders under Section 1.2 may not be
assigned to a transferee or assignee of Registrable Shares without the prior written consent of the Company, except that such rights may be freely transferred to any party controlling, controlled by or under common control with a Holder without such
consent; provided, that the Company is provided with prompt notice of the name and address of such transferee and such transferee agrees in writing to be bound by the provisions of this Agreement. 
  
 1.10. Termination of Registration Rights. No Holder shall be
entitled to exercise any registration right provided for in this Section 1 after such time as Rule 144(k) or another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares without limitation as to
volume or manner of sale. 
  

	2.	Miscellaneous. 

  
 2.1. Entire Agreement. This Agreement constitutes the entire agreement among the parties hereto pertaining to the subject matter hereof, and
any and all other written or oral 

  

 76 

 
agreements relating to the subject matter hereof existing among any of the parties hereto are expressly canceled. 
  
 2.2. Recapitalizations, Etc. The provisions of this Agreement
(including any calculation of share ownership) shall apply, to the full extent set forth herein with respect to the Registrable Securities and to the Common Stock, to any and all shares of capital stock of the Company or any capital stock,
partnership or member units or any other security evidencing ownership interests in any successor or assign of the Company (whether by merger, consolidation, sale of assets or otherwise) that may be issued in respect of, in exchange for, or in
substitution of the Registrable Securities by reason of any stock dividend, split, combination, recapitalization, liquidation, reclassification, merger, consolidation or otherwise. 
  
 2.3. Successors and Assigns. Except as otherwise provided in this Agreement, the terms and conditions of this
Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
  
 2.4. Amendments and Waivers. Any term of this Agreement may be amended or waived only with the written consent
of the Company and the holders of at least a majority of the Registrable Securities then outstanding. GPC and its successors and assigns acknowledge that by operation of this Section 2.4, the holders of at least a majority of the then outstanding
Registrable Securities, when acting together with the Company, will have the right and power to diminish or eliminate any rights or increase any or all obligations under this Agreement. 
  
 2.5. Notices. Any notice required or permitted by this Agreement shall be in writing and shall be deemed
sufficient upon delivery, when delivered personally or by overnight courier or sent by electronic mail or fax, or forty-eight (48) hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, addressed (a) if
to the Company or NeoTherapeutics, to 157 Technology Drive, Irvine, California 92618, Attention: Chief Executive Officer or via facsimile to (949) 788-6706, with a copy to Latham & Watkins, 650 Town Center Drive, Suite 2000, Costa Mesa,
California 92626-1925, Attention: Alan W. Pettis, or via facsimile to (714) 755-8290, or (b) if to GPC, to Fraunhoferstrasse 20, D-82152 Martinsried/Munich, Germany, Attention: Chief Executive Officer or via facsimile to 49-89-8565-2610, with a copy
to Ropes & Gray, One International Place, Boston, Massachusetts 02110, Attention: Marc A. Rubenstein, or via facsimile to (617) 951-7050. 
  
 2.6. Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to
renegotiate such provision in good faith. Until the parties have agreed upon an enforceable replacement for such provision, (a) such provision shall be excluded from this Agreement, (b) the balance of the Agreement shall be interpreted as if such
provision were so excluded and (c) the balance of the Agreement shall be enforceable in accordance with its terms. 
  
 2.7. Delays or Omissions; Remedies Cumulative. No delay or omission to exercise any right, power or remedy accruing to any party under this
Agreement, upon any breach or 

  

 77 

 
default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be
construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or
conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not
alternative. 
  
 2.8. Attorney’s Fees. If any
action at law or in equity (including arbitration) is necessary to enforce or interpret the terms of any this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any
other relief to which such party may be entitled. 
  
 2.9.
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without
regard to the principles of conflicts of law thereof. The Company and GPC hereby irrevocably submit to the exclusive jurisdiction of the state and federal courts sitting in Orange County, California, for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any
such court, or that such suit, action or proceeding is improper. Each of the Company and GPC hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by receiving a copy
thereof sent to the Company at the address in effect for notices to it under this instrument and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit
in any way any right to serve process in any manner permitted by law. 
  
 2.10. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 2.11. Titles and Subtitles. The titles and subtitles used in
this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
  
 2.12. Aggregation of Stock. All shares of Company stock held or acquired by affiliated Persons (including former and current partners,
former and current members and former and current stockholders) shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 
  
 2.13. Confidentiality. Each Holder agrees that, except with the prior written permission of the applicable
party, it shall at all times keep confidential and not divulge, furnish or make accessible to anyone any confidential information, knowledge or data concerning or relating to the business or financial affairs of the Company or any other party to
which such 

  

 78 

 
Holder has been or shall become privy by reason of this Agreement. The provisions of this Section 2.13 shall be in addition to, and not in substitution for,
the provisions of any separate nondisclosure agreement executed by the parties hereto with respect to the transactions contemplated hereby. 
  
 [Signature Page Follows] 
  

 79 

 The parties have executed this Registration Rights Agreement as of the date first above written.

  

									
	 NEOTHERAPEUTICS, INC.
	 	 	 	 GPC BIOTECH AG

					
	By:	 	 	 	 	 	By:	 	 
					
	Name:	 	 	 	 	 	Name:	 	 
					
	Title:	 	 	 	 	 	Title:	 	 

  

 80Collaboration and License Agreement, dated April 15, 1999

 Exhibit 10.2 
  
 Confidential treatment has been requested for portions of this Exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as ***. A complete version of this Exhibit has been filed separately with the Securities and Exchange Commission. 
  
 EXECUTION COPY 
  
 COLLABORATION AND LICENSE AGREEMENT 
  
 This Collaboration and License Agreement (“Agreement”) is made effective as of April 15, 1999 (“Effective Date”) by and between GPCAG-GENOME PHARMACEUTICALS CORPORATION, a German stock corporation
having its principal place of business at Fraunhofer Strasse 20, 82152 Martinsried, Munich, Germany (“GPC”), and MORPHOSYS AG, a German stock corporation with its principal place of business at Am Klopferspitz 19, 82152 Martinsried,
Munich, Germany (“MORPHOSYS”). MORPHOSYS and GPC are each hereafter referred to individually as a “Party” and together as the “Parties”. 
  
 WHEREAS, GPC and MORPHOSYS desire to collaborate in the discovery and development of human monoclonal antibodies against
certain specified GPC Targets, whereby MORPHOSYS will use its HuCAL technologies to generate and characterize such antibodies and GPC will use its expertise with respect to antibodies and targets in pre-clinical settings; 
  
 WHEREAS, GPC desires to receive licenses to the MORPHOSYS Technologies and
resulting discoveries on the terms set forth herein; and 
  
 WHEREAS, GPC and MORPHOSYS desire to initiate the performance of the above-described activities by MORPHOSYS and GPC and therefore agree to undertake the foregoing, all under the terms and conditions set forth in this Agreement. 

 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein,
and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Parties hereby agree as follows: 
  
 1. DEFINITIONS 
  
 Whenever used in the Agreement with an initial capital letter, the terms defined in this Section 1 shall have the meanings specified below. 
  

 1 

 1.1 “Affiliate” shall mean any corporation, firm, limited liability company, partnership
or other entity which directly or indirectly controls or is controlled by or is under common control with a Party to this Agreement. “Control” means ownership, directly or through one or more Affiliates, of fifty percent (50%) or more of
the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, status as a general partner in any partnership,
or any other arrangement whereby a Party controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity. 
  
 1.2 “Agreement Year” shall mean an annual period commencing on the Effective Date or any anniversary
thereof. 
  
 1.3 “Antibody Optimization” shall
mean the modification of an antibody intended to achieve higher affinity and/or improved specificity, including the replacement or modification of CDRs of the antibody. 
  
 1.4 “Antibody Products” shall mean whole antibodies or fragments thereof directed to a Target, including
ScFvs, Fabs and IgGs, alone or in combination with other materials. 
  
 1.5 “BMBF” shall mean the German Federal Ministry for Education, Science and Technology. 
  
 1.6 “Bona Fide Request” shall mean (i) a firm offer from a third party regarding a license to an Antibody Product to a GPC Target, which
offer has been evidenced by a written term sheet or (ii) a notice from a third party of its desire to exercise a right to obtain such a license under the terms of an existing contractual arrangement with MORPHOSYS. 
  
 1.7 “Collaboration Data” shall mean any data generated using
MORPHOSYS Technologies by MORPHOSYS or GPC in the performance of the Collaboration Program. 
  
 1.8 “Collaboration Invention” shall mean either a MORPHOSYS Collaboration Invention or a GPC Collaboration Invention. 
  

 2 

 1.9 “Collaboration Material” shall mean any proprietary materials, including but not
limited to Deliverables, identified or developed by either Party in the performance of the Collaboration Program through the use of MORPHOSYS Technologies. 
  
 1.10 “Collaboration Plan” shall mean the written description of the research and development efforts with respect to the identification
and optimization of candidate Licensed Products to be performed by MORPHOSYS and GPC under this Agreement, as further described in Section 2.1.3. 
  
 1.11 “Collaboration Program” shall mean the activities to be performed by MORPHOSYS and GPC under this Agreement with respect to the
identification and optimization of candidate Licensed Products during the Collaboration Term as described in the Collaboration Plan and amendments thereto. 
  
 1.12 “Collaboration Term” shall have the meaning set forth in Section 2.3.1. 
  
 1.13 “Deliverables” shall mean information and materials,
including but not limited to Antibody Products, to be delivered to GPC by MORPHOSYS hereunder, as further set forth in Section 2.1.1. 
  
 1.14 “Field” shall mean the development and commercialization of Antibody Products for human or animal therapeutic and prophylactic use,
for use in clinical settings for patient screening to support development of Licensed Products, and, to the extent set forth in Section 3.7, for diagnostic uses. 
  
 1.15 “FTE” shall mean the equivalent of one researcher involved in one year of research on a full-time
basis comprising at least thirty-two (32) hours per week of scientific effort in support of the Collaboration Program for 52 weeks per year, less vacations and holidays. 
  
 1.16 “GPC Antigen” shall mean the protein antigen on which the GPC Target epitopes are found, which is
known as ***. 
  
 1.17 “GPC Collaboration
Invention” shall mean any discovery, invention, know-how and/or trade secret first conceived or made solely by employees of GPC through the direct and material 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 3 

 use of Collaboration Data or Collaboration Materials or other proprietary information or materials obtained by GPC from
MORPHOSYS hereunder. 
  
 1.18 “GPC Proprietary
Material” shall mean antigens or other GPC Targets provided by GPC to MORPHOSYS for the purposes of performing the Collaboration Program. 
  
 1.19 “GPC Target” shall mean a Target for which an exclusive license is granted hereunder, which GPC Targets are specified in Appendix
A. 
  
 1.20 “IgG Success Date” shall mean the
earlier of (a) the first date of confirmation by GPC that an IgG antibody delivered by MORPHOSYS to GPC hereunder meets the relevant Success Criteria for a GPC Target, or (b) the date of the first payment by GPC pursuant to Section 4.4(b).

  
 1.21 “Joint Steering Committee” or
“JSC” shall have the meaning set forth in Section 2.2. 
  
 1.22 “Licensed Product” shall mean an Antibody Product which binds to a GPC Target and which is consisting of or directly and materially derived from a Deliverable. 
  
 1.23 “MORPHOSYS Background Inventions” shall mean all
inventions, discoveries, patent rights, trade secrets and know-how, including without limitation, laboratory scientific information and procedural techniques owned or controlled by MORPHOSYS and relating to the MORPHOSYS Technologies, which
MORPHOSYS has the right to license and which would be infringed by the activities of GPC permitted by this Agreement and whether existing now or obtained in the future; provided, however, that MORPHOSYS Background Inventions shall expressly exclude
any inventions, discoveries, patent rights, trade secrets or know-how arising from any MORPHOSYS collaboration with a third party, except to the extent expressly permitted thereby. 
  
 1.24 “MORPHOSYS Collaboration Invention” shall mean any discovery, invention, know-how and/or trade secret
first conceived or made solely by employees of MORPHOSYS, or jointly by employees of both MORPHOSYS and GPC, in the performance of the Collaboration Program, but excluding any of the foregoing to the extent relating to the operation, use, or
improvement of the MORPHOSYS Technologies. 
  
 1.25
“MORPHOSYS Technologies” shall mean the MORPHOSYS HuCAL library and associated technologies described on Exhibit A attached hereto. 
  

 4 

 1.26 “Net Sales” shall mean the gross invoiced sales price of any Licensed Product
charged by GPC, its Affiliates or its Sublicensees for the sale of a Licensed Product in arm’s length sales to unrelated third parties, less eight percent (8%) of such gross invoiced sales price to provide an allowance for standard discounts
and deductions with respect to such sale of Licensed Product, and less any sales or other excise taxes levied on the sale or delivery of a Licensed Product (including any tax such as a value added or similar tax or government charge) borne by the
seller thereof, other than franchise or income tax of any kind whatsoever. Net Sales shall not include sales or transfers between GPC and its Affiliates or Sublicensees, unless the Licensed Product is consumed by the Affiliate or Sublicensee.

  
 In the event that a Licensed Product under this Agreement is
sold in combination with another active ingredient or component having independent therapeutic effect, then “Net Sales,” for purposes of determining royalty payments on the combination, shall be calculated using one of the following
methods: 
  

	 	(a)	By multiplying the Net Sales of the combination by the fraction A/A+B, where A is the gross selling price, during the royalty paying period in question, of the Licensed Product sold
separately, and B is the gross selling price, during the royalty period in question, of the other active ingredients or components sold separately; or 

  

	 	(b)	In the event that no such separate sales are made of the Licensed Product or any of the active ingredients or components in such combination package during the royalty paying period
in question, Net Sales, for the purposes of determining royalty payments, shall be calculated by dividing the Net Sales of the combination by the number of active ingredients or components (including Licensed Products) contained in the combination.

  
 Notwithstanding the foregoing, for Net Sales of
Sublicensees, any commercially reasonable definition included in a written agreement between GPC and such Sublicensee and used in calculating remuneration to GPC pursuant to such sublicense agreement shall be used in lieu of the above definition for
the purposes of calculating amounts due to MORPHOSYS hereunder as a result of such sublicense 

  

 5 

 
agreement. Such definitions of Net Sales shall be provided to MORPHOSYS upon execution of any such sublicense agreement. 
  
 1.27 “Patent Rights” means the rights and interests in and
to issued patents and pending patent applications in any country, including, but not limited to, all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and all
reissues, reexaminations and extensions thereof, whether owned solely or jointly by a Party or licensed in by a Party, with the right to sublicense, now or in the future, wherein at least one claim of such patent right is directly based, in whole or
in part, on a Collaboration Invention. 
  
 1.28
“Sublicensee” shall mean any non-Affiliate third party licensed or sublicensed under the license granted to GPC hereunder by GPC to develop, have developed, make, have made, use, have used, offer to sell, sell, have sold, import or
have imported any Licensed Product. 
  
 1.29 “Success
Criteria” shall mean the characteristics of each Antibody Product to be delivered by MORPHOSYS pursuant to the Collaboration Program, as specified and agreed in the Collaboration Plan and as initially described in Appendix C attached
hereto. 
  
 1.30 “Target” shall mean (i) a
defined molecule such as a biological receptor, an enzyme, or a macromolecule, (ii) an entity tentatively identified through its reaction with a specific antibody or another reagent, or (iii) a molecule which is encoded by a particular gene.

  
 1.31 “Term” shall have the meaning set forth
in Section 8.1. 
  
 1.32 “Territory” shall mean
the world. 
  
 1.33 “Third Party Payment” shall
have the meaning set forth in Section 4.6. 
  
 2.
COLLABORATION PROGRAM 
  
 2.1 Implementation of the
Collaboration Program. 
  
 2.1.1 Basic
Provisions. The objectives of the Collaboration Program will be to utilize MORPHOSYS Technologies to generate human-like antibodies against GPC Targets and to deliver such Antibody Products to GPC for confirmation of achievement of the Success
Criteria, all according to a mutually agreed Collaboration Plan. In order to enable MORPHOSYS to commence its activities 

  

 6 

 
hereunder, GPC shall deliver to MORPHOSYS GPC Proprietary Material in such form and meeting such specifications as set forth in the Collaboration Plan.
Pursuant to the Collaboration Plan, MORPHOSYS shall use all commercially reasonable efforts to develop and deliver to GPC the following items: Antibody Product sequence information; DNA encoding the Antibody Product sequence, and bacterial cells
containing the same; Antibody Products cloned as ScFvs, Fabs or IgGs; and purified protein, all as further described and specified in the Collaboration Plan for each GPC Target, as well as relevant documentation reasonably requested by GPC (the
“Deliverables”). MORPHOSYS and GPC shall each use all commercially reasonable efforts to perform such other tasks as are assigned to them in the Collaboration Plan, including the provision of such facilities, samples and materials
(including GPC Proprietary Material), equipment and consultants as each deems necessary to the achievement of such Collaboration Plan. In carrying out the Collaboration Program, MORPHOSYS and GPC shall devote such staffing resources as are
reasonably necessary to achieve the objectives of the Collaboration Program as specified in the Collaboration Plan; provided, however, that MORPHOSYS shall in no event be required to devote more than one FTE of effort to work relating to any single
GPC Target, nor an aggregate of more than two (2) FTEs in any calendar year to the Collaboration Program without MORPHOSYS’ prior written consent; and provided further that GPC shall in no event be required to devote more than one FTE of effort
of work relating to any single GPC Target, nor an aggregate of more than two (2) FTEs in any calendar year, to the Collaboration Program without GPC’s prior written consent. Each Party shall bear expenses incurred by it pursuant to this
Agreement unless otherwise expressly set forth herein. 
  
 2.1.2 Collaborative Efforts and Reports. 
  
 (a) The Parties agree that the successful execution of the Collaboration Program will require the collaborative use of both Parties’ areas of expertise. The Parties shall keep the JSC fully informed, in the
manner provided herein, about the status of the portions of the Collaboration Program they respectively perform. In particular, without limitation, each Party shall furnish to the JSC monthly written reports within ten (10) business days after the
end of each calendar month, describing the progress of its activities under the Collaboration Program in reasonable detail. 
  

 7 

 (b) Researchers at MORPHOSYS and GPC shall cooperate in the performance of the
Collaboration Program and, subject to any confidentiality obligations to third parties, shall exchange information and materials as necessary to carry out the Collaboration Program, subject to the provisions of Section 5. Each Party will attempt to
accommodate any reasonable request of the other Party to send or receive personnel for purposes of collaborating or exchanging information under the Collaboration Program. Such visits and/or access will have defined purposes relating specifically to
the Collaboration Program and be scheduled in advance. 
  
 2.1.3 Collaboration Plan. The Collaboration Plan shall be agreed upon by the Parties prior to execution of this Agreement. The Collaboration Plan shall include specifications for GPC Proprietary Material to be delivered to MORPHOSYS,
mutually agreed Success Criteria and specifications for Deliverables for each GPC Target prior to the initiation of work on such GPC Target by MORPHOSYS hereunder. The Collaboration Plan shall also specify time lines for the performance of work by
each Party pursuant to the Collaboration Plan. Every four (4) months during the Collaboration Term, or at any time on request of either GPC or MORPHOSYS, the Collaboration Plan shall be updated by MORPHOSYS and GPC and shall be approved by the JSC
no later than thirty (30) days before the end of each such four (4) month period. The JSC will consider adjustments in the Collaboration Plan at any time upon the request of GPC or MORPHOSYS. 
  
 2.1.4 Permitted Activities. 
  
 (a) MORPHOSYS agrees that MORPHOSYS will not use and/or
replicate any GPC Proprietary Material for any purpose other than as provided herein. During the Term of this Agreement, MORPHOSYS will not collaborate with any other party with respect to the development or commercialization of Antibody Products in
the Field directed to a GPC Target. 
  
 (b) GPC
agrees that GPC will not utilize Collaboration Data, Collaboration Material, Collaboration Inventions, Deliverables, or Patent Rights or the MORPHOSYS Technologies, other than as expressly provided herein. Notwithstanding any other provision of this
Agreement, GPC shall in no event use or commercialize any Antibody Product consisting of or directly derived from a Deliverable other than pursuant to a license expressly granted herein and in no event shall GPC engineer 

  

 8 

 
an Antibody Product consisting of or directly derived from a Deliverable so as to bind to a Target which is not a GPC Target without the prior written
consent of MORPHOSYS. 
  
 2.1.5 Failure to
Achieve Success Criteria. If, despite using the efforts and resources specified in Section 2.1.1, MORPHOSYS fails to deliver an antibody to GPC which is determined to meet the relevant Success Criteria for any GPC Target, along with the related
Deliverables, during the Collaboration Term, all relevant licenses and obligations hereunder shall terminate with respect to such GPC Target with the consequences as set forth in Section 8.3, unless the Parties otherwise mutually agree. In the event
that efforts are unsuccessful with respect to both GPC Targets, this Agreement shall terminate in its entirety upon the expiration of the Collaboration Term. 
  
 2.2 Joint Steering Committee. 
  
 2.2.1 Establishment and Functions of JSC. 
  

(a) MORPHOSYS and GPC shall establish a “Joint Steering Committee” (the “JSC”). The JSC will act on behalf of the
two companies and will be responsible for the planning and monitoring of the Collaboration Program. In particular, the activities of the JSC shall include reviewing progress in the Collaboration Program and approving necessary adjustments to the
Collaboration Program, including any modifications to the Collaboration Plan deemed desirable based on results, as the research and development progresses. 
  
 (b) In planning and monitoring the Collaboration Program, the JSC shall assign tasks and responsibilities taking into account the terms of
this Agreement and each Party’s respective specific capabilities and expertise in order in particular to avoid duplication and enhance efficiency and synergies; provided that neither Party shall be required by any modification in the
Collaboration Program to expend additional effort under the Collaboration Program without the consent of all of such Party’s representatives on the Joint Steering Committee. 
  
 2.2.2 JSC Membership. MORPHOSYS and GPC each shall appoint, in their sole discretion, two (2) members
to the JSC, which shall include a Co-Chair to be designated by GPC and a Co-Chair to be designated by MORPHOSYS. Substitutes or alternates for the Co-Chairs or other JSC members may be appointed at any time by notice in writing to the other Party.
The Parties may 

  

 9 

 
mutually agree to change the size of the JSC as long as there shall be an equal number of representatives of each Party on the JSC. The initial Co-Chairs and
other JSC members shall be designated by the Parties upon execution of this Agreement. MORPHOSYS shall appoint a Project Coordinator, who shall be reasonably satisfactory to GPC, to serve as the principal liaison with GPC for the Collaboration
Program. Such Project Coordinator will be one of MORPHOSYS’ members of the JSC. GPC shall appoint a Project Coordinator, who shall be reasonably satisfactory to MORPHOSYS, to serve as the principal liaison with MORPHOSYS for the Collaboration
Program. Such Project Coordinator will be one of GPC’s members of the JSC. 
  
 2.2.3 Meetings. The JSC shall meet at least every four (4) months, with such meetings to be held in Munich, Germany, or in such
other manner as the Parties mutually agree. Any additional meetings shall be held at places or by video conference and on dates as selected by the Co-Chairs of the JSC. In addition, the JSC may act without a formal meeting by a written memorandum
signed by the Co-Chairs of the JSC. Whenever any action by the JSC is called for hereunder during a time period in which the JSC is not scheduled to meet, the Co-Chairs of the JSC shall cause the JSC to take the action in the requested time period
by calling a special meeting or by action without a meeting. Subject to the obligations set forth in Section 5, representatives of each Party or of its Affiliates, in addition to the members of the JSC, may attend JSC meetings at the invitation of
either Party with the prior approval of the other Party, which shall not be unreasonably withheld. 
  
 2.2.4 Minutes. The JSC shall keep accurate minutes of its deliberations which record all proposed decisions and all actions
recommended or taken. Drafts of the minutes shall be delivered to the Co-Chairs of the JSC within ten (10) days after the meeting. The Party hosting the meeting shall be responsible for the preparation and circulation of the draft minutes or, in the
event of meetings by video conference, such responsibility shall be as agreed by the Parties. Draft minutes shall be edited by the Co-Chairs and shall be issued in final form only with their approval and agreement as evidenced by their signatures on
the minutes. 
  
 2.2.5 Quorum; Voting;
Decisions. At each JSC meeting, at least two (2) member(s) appointed by each Party present in person or by telephone shall constitute a quorum and decisions shall be made by majority vote. Each JSC member shall have one vote on all matters
before the JSC, 

  

 10 

 
provided that the member or members of each Party present at any JSC meeting shall have the authority to cast the votes of any of such Party’s members
on the JSC who are absent from the meeting. Notwithstanding the foregoing, the objective of the Parties to this Agreement is that decisions of the JSC shall be made by consensus. Any matter in dispute hereunder shall be resolved, if possible, by the
Chief Executive Officers of each Party using good faith efforts. 
  
 2.2.6 Expenses. MORPHOSYS and GPC shall each bear all expenses of their respective JSC members related to their participation on the JSC and attendance at JSC meetings. 
  
 2.3 Collaboration Term. 
  
 2.3.1 Term of the Collaboration Program. The
Collaboration Program shall expire either (i) fourteen (14) months after the Effective Date or (ii) upon the date on which the Success Criteria are determined to be met for each GPC Target and all corresponding Deliverables have been delivered to
GPC in good condition, whichever shall first occur, unless extended as provided below or unless this Agreement is earlier terminated by either Party pursuant to the provisions of Article 8 (the “Collaboration Term”). In no event shall
MORPHOSYS have any obligation to perform any activities with respect to the development or optimization of Antibody Products after such date, except as specified in Section 2.3.2 or Section 4.2 hereof. 
  
 2.3.2 Extension of the Collaboration Program. The
Collaboration Program and the Collaboration Term may be extended for one or more additional six (6) month periods by mutual agreement of the Parties upon three (3) months prior written notice given to MORPHOSYS by GPC on the terms hereof.

  
 2.4 Exclusive Use of Collaboration Material and
Data. During the Collaboration Term, and for a period of three (3) years thereafter, MORPHOSYS: (a) shall not utilize Collaboration Material and Collaboration Data relating specifically to any GPC Target for any purpose other than conducting
the Collaboration Program hereunder, and (b) shall keep such Collaboration Data and Collaboration Material confidential in accordance with the provisions of Section 5.1 hereof and will not disclose or transfer such Collaboration Data or
Collaboration Material to third parties by publication or otherwise, without the prior written consent of GPC. Notwithstanding the foregoing, nothing in this 

  

 11 

 
Section 2.4 shall limit any rights expressly granted to either Party in Article 3 hereof, nor shall it in any way diminish any exclusive rights granted to
GPC pursuant to Article 3. To the extent that MORPHOSYS utilizes for commercial purposes any Collaboration Material or Collaboration Data generated solely by GPC or generated jointly by MORPHOSYS and GPC, it shall pay a royalty to GPC on net sales
of products resulting directly and materially from such utilization on commercially reasonable terms to be negotiated in good faith by the Parties. 
  
 2.5 Other Collaborations. MORPHOSYS and GPC hereby acknowledge that, unless otherwise provided herein, MORPHOSYS may grant exclusive rights
to utilize the MORPHOSYS Technologies with respect to the development and commercialization of products (i) within or outside the Field directed to any Target which is not a GPC Target, and (ii) outside the Field directed to any Target, to any other
party at any time and that, unless otherwise provided herein, MORPHOSYS shall have the right, alone or in conjunction with a third party, to utilize the MORPHOSYS Technologies with respect to any Target for any such purpose, or to grant licenses to
third parties with respect thereto, subject to compliance with the provisions of Section 2.4. Nothing contained in this Agreement shall in any way restrict MORPHOSYS’ right to perform research or collaborate with third parties and to grant to
third parties the right to exploit the results of any such research or collaborations without restriction other than as expressly provided in Sections 2.1.4 and 2.4, or in Article 3. 
  
 2.6 Other Targets. Notwithstanding the foregoing, in the event that GPC identifies another Target to which a
Licensed Product binds that is not a GPC Target, then GPC may give notice to MORPHOSYS identifying such Target and notifying MORPHOSYS that it elects to exercise its first negotiation right, as provided hereinbelow, with respect to such Target. Upon
receipt of a notice described in the preceding sentence, MORPHOSYS shall, to the extent permitted by contractual arrangements with third parties, negotiate exclusively with GPC with respect to the grant of rights to GPC for the use of the Licensed
Product in connection with the Target identified in such notice for a period of not less than 120 days. If, at the end of such 120-day period, GPC and MORPHOSYS have not reached an agreement on the terms of such grant of rights, then MORPHOSYS shall
be free to grant such rights to any other party; provided that, MORPHOSYS shall not, for a period of two years, 

  

 12 

 
grant such rights to any other party on terms which are, in the aggregate, any more favorable to such party than those last offered by GPC. 
  
 3. GRANT OF RIGHTS 
  
 3.1 License Grant. 
  
 (a) For each GPC Target listed on Appendix A,
MORPHOSYS hereby grants to GPC an exclusive license in the Territory to make, have made, use, have used, sell, have sold, offer for sale, import and have imported Licensed Products directed to such GPC Target for use in the Field under MORPHOSYS
Background Inventions, and under MORPHOSYS’ rights in all Patent Rights, Collaboration Inventions, Collaboration Material, and Collaboration Data pertaining to such GPC Target and Licensed Products or the uses thereof. Such license shall be
perpetual unless terminated in accordance with the terms of this Agreement. Such license includes a transfer of certain rights licensed from DYAX CORPORATION and PROTEIN ENGINEERING CORPORATION by MORPHOSYS, which transfer shall be acknowledged by
the execution of Appendix B attached hereto. 
  
 (b) Upon written request of GPC, MORPHOSYS shall, to the extent permitted by contractual arrangements with third parties, grant to GPC a non-exclusive license in the Territory to make and use any specified Licensed Product directed against
a GPC Target in a clinical setting for patient screening to support the development by GPC of human or animal therapeutic or prophylactic products which are not Licensed Products. Such license shall be personal to GPC and non-assignable and may only
be sublicensed to third parties performing patient screening on behalf of GPC. In the event of any such grant, the Parties shall execute an amendment to this Agreement to effect such grant and the sole payments therefor shall be the payments to be
made to MORPHOSYS according to the terms of Sections 4.4(f) through (h) hereof. 
  
 3.2 Due Diligence. Commencing upon confirmation of achievement of the Success Criteria with respect to each GPC Target, GPC shall use commercially reasonable efforts, itself or in collaboration with a
third party, to diligently test, obtain regulatory approval of, market and sell at least one Licensed Product. Commencing upon the expiration of the Collaboration Term, GPC shall provide 

  

 13 

 
annual reports to MORPHOSYS summarizing its progress hereunder with respect to each Licensed Product on or before each subsequent anniversary of the
Effective Date. Subject to Sections 9.12 and 9.18 hereof, failure to use diligent efforts as set forth herein under each license with respect to a GPC Target shall give MORPHOSYS the right, but not the obligation, to terminate GPC’s license
hereunder solely with respect to such Licensed Product and related GPC Target pursuant to the provisions of Section 8.2(a). 
  
 3.3 Sublicenses. GPC shall have the right to grant licenses or sublicenses to all or any portion of its rights under any license granted
pursuant to Section 3.1 to any Affiliate or Sublicensee for the purposes of developing, having developed, making, having made, using, having used, offering to sell, selling, having sold, importing or having imported any relevant Licensed Product;
provided, however, that GPC shall remain obligated to ensure payment of royalty and milestone obligations as set forth in Article 4 and that no right to use the MORPHOSYS Technologies may be granted, and no access to the MORPHOSYS Technologies may
be provided, by GPC to any third party. 
  
 3.4 Research
License to GPC. MORPHOSYS hereby grants to GPC a non-exclusive, royalty-free research license under MORPHOSYS Background Inventions and MORPHOSYS’ interests in any Collaboration Material and Collaboration Inventions, solely during the
Collaboration Term and as further described below, to the extent necessary to allow GPC to perform its obligations under the Collaboration Program. Such license (a) shall be personal to GPC and non-sublicensable without the prior written consent of
MORPHOSYS, (b) shall not include the right to utilize any MORPHOSYS Technologies or to perform antibody development, screening, engineering or optimization with respect to any Target which is not a GPC Target, (c) shall not include the right to have
on-site access to the MORPHOSYS Technologies, and (d) shall not include the right to develop or commercialize any products other than as set forth in Section 3.1 hereof. 
  
 3.5 Antibody Optimization. GPC shall have the option, exercisable in its sole discretion, during the Term
hereof to have Antibody Optimization performed by MORPHOSYS outside of the Collaboration Program, with the expenses of any such Antibody Optimization to be paid by GPC as set forth in Section 4.2. GPC may exercise the option described in this
Section by providing written notice 

  

 14 

 
to MORPHOSYS describing the Antibody Optimization to be performed. Notwithstanding the foregoing, GPC shall have no obligation to use MORPHOSYS for Antibody
Optimization. 
  
 3.6 Grantback of Rights. GPC
hereby grants to MORPHOSYS a perpetual, worldwide, royalty-free license, with the right to sublicense, under GPC’s rights if any, in Collaboration Data, Collaboration Material, Collaboration Inventions and Patent Rights thereon (a) to operate,
utilize or improve the MORPHOSYS Technologies, which license to MORPHOSYS shall be exclusive, and (b) to develop and/or commercialize and/or utilize Antibody Products developed utilizing the MORPHOSYS Technologies, other than such Licensed Products
as are exclusively licensed to GPC hereunder, which license to MORPHOSYS shall be non-exclusive, provided that MORPHOSYS’ exercise of any such rights shall be subject to the restrictions and/or obligations set forth in Sections 2.4, 2.6 and 3.1
hereof. 
  
 3.7 Right of First Negotiation. In the
event that MORPHOSYS desires to negotiate the terms of a license with respect to the use of any Licensed Product for diagnostic purposes (“Diagnostic Rights”) with any third party, MORPHOSYS shall first notify GPC. GPC shall have 90 days
from receipt of such notice to negotiate in good faith with MORPHOSYS the terms of a license of such Diagnostic Rights from MORPHOSYS. If GPC does not notify MORPHOSYS of its desire to negotiate such a license or if the Parties do not, despite good
faith efforts, agree on the terms of any such license within such 90-day period, MORPHOSYS shall thereafter be free to grant a license of such Diagnostic Rights to any third party; provided that, MORPHOSYS shall not, for a period of two years, grant
such rights to any other party on terms which are, in the aggregate, any more favorable to such party than those last offered by GPC. 
  
 3.8 No Other Rights. GPC shall receive no rights to Targets, Collaboration Data, or Collaboration Material under MORPHOSYS Background
Inventions or under MORPHOSYS’ rights in Patent Rights or Collaboration Inventions or rights with respect to use of MORPHOSYS Technologies except as expressly set forth herein. Nothing in this Agreement shall be deemed to require MORPHOSYS to
provide GPC with on-site access to the MORPHOSYS Technologies. MORPHOSYS shall receive no rights under GPC’s ownership interest in any Collaboration Data, 

  

 15 

 
Collaboration Material, Collaboration Inventions or Patent Rights or any other proprietary rights of GPC except as expressly set forth herein. 
  
 4. FINANCIAL TERMS 
  
 4.1 Initiation Fee. GPC agrees to pay to MORPHOSYS a
collaboration initiation and license fee of DM *** upon execution of this Agreement. 
  
 4.2 Research Funding. In the event that GPC exercises its option described in Section 3.5 to have MORPHOSYS perform Antibody Optimization, GPC will pay MORPHOSYS non-refundable research payments of DM
*** per year per FTE for any FTEs performing Antibody Optimization on Deliverables, as approved by the JSC. Such payments will be made by payment of *** DM monthly within 30 days of receipt by GPC of an itemized invoice. MORPHOSYS will fund
all of its other activities under the Collaboration Program and GPC will fund all of its own activities under the Collaboration Program, and all activities required pursuant to Section 3.2. 
  
 4.3 Exclusivity. The exclusive licenses granted to GPC pursuant
to Section 3.1(a) shall terminate on the following dates unless GPC makes the specified payment to MORPHOSYS prior to such date: 
  

			
	 Date

	  	Exclusivity Continuation Payment

		
	Six month anniversary of the IgG Success Date	  	DM ***
		
	Thirty month anniversary of the IgG Success Date	  	DM ***
		
	 Total Exclusivity Payment
	  	DM ***

  
 In addition, if at any
time following the twelve-month anniversary of the IgG Success Date and prior to the receipt of the Total Exclusivity Payment indicated above, MORPHOSYS receives a Bona Fide Request for a license for an Antibody Product to a GPC Target from a third
party, MORPHOSYS shall notify GPC in writing of such Bona Fide Request and the licenses granted to GPC 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 16 

 pursuant to Section 3.1 may be terminated by MORPHOSYS as provided below unless GPC pays to MORPHOSYS the balance of any
unpaid Total Exclusivity Payment within thirty (30) days of written notice to GPC from MORPHOSYS of such Bona Fide Request. 
  
 In the event any payment pursuant to this Section 4.3 is not made in a timely manner, this Agreement may be terminated in its entirety by MORPHOSYS as of
the date such payment was due upon written notice to GPC.  
  
 4.4 Milestone Payments. GPC shall make the following milestone payments to MORPHOSYS once for each GPC Target, upon the first achievement of such milestone by a Licensed Product directed to such GPC Target: 
  
 (a) *** Deutschmarks (DM ***) within thirty
(30) days of confirmation by GPC that an ScFv antibody delivered by MORPHOSYS meets the Success Criteria for the relevant GPC Target; 
  
 (b) *** Deutschmarks (DM ***) within thirty (30) days of confirmation by GPC that an IgG antibody delivered by MORPHOSYS
meets the Success Criteria for the relevant GPC Target; 
  
 (c) *** Deutschmarks (DM ***) within thirty (30) days following the date GPC or an Affiliate commences a Phase I clinical trial in any country for the Licensed Product; 
  
 (d) *** Deutschmarks (DM ***) within thirty
(30) days following the date GPC or an Affiliate commences a Phase III clinical trial or other clinical trial designed to generate data sufficient for the filing of an NDA (e.g., a Phase II/III clinical trial) in any country for the Licensed
Product; and 
  
 (e) *** Deutschmarks
(DM ***) within thirty (30) days following the date GPC or an Affiliate receives an FDA (or equivalent foreign regulatory agency) approval of the Licensed Product for commercial sale. 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 17 

 In addition, solely in the event that the non-exclusive license provided in Section 3.1(b) is granted to
GPC by specific amendment of this Agreement, GPC shall make the following milestone payments to MORPHOSYS upon each occurrence of the listed event: 
  
 (f) *** Deutschmarks (DM ***) per Licensed Product within thirty (30) days of execution of an amendment granting any license
for use of such specified Licensed Product in a clinical setting for patient screening to support the development of a non-Licensed Product; 
  
 (g) *** Deutschmarks (DM ***) within thirty (30) days of the date of commencement of each clinical trial using a Licensed
Product for patient screening to support the development of a non-Licensed Product; and 
  
 (h) *** Deutschmarks (DM ***) within thirty (30) days of the date GPC or an Affiliate first receives regulatory approval to
commence sales of any non-Licensed Product developed using Licensed Products in a clinical setting for patient screening. 
  
 4.5 Royalties on Licensed Products . GPC shall pay to MORPHOSYS a royalty on Net Sales of Licensed Products sold by GPC or its Affiliates as
follows: 
  
 ***% on annual gross sales under DM
***; 
  
 ***% on annual gross sales between
DM *** and DM ***; 
  
 ***% on
annual gross sales over DM ***; 
  
 4.6 Third Party
Payments. 
  
 (a) In the event that any
license fees, royalty payments or milestone payments are owed to any third party under any license agreement relating to the general operation or use of the MORPHOSYS Technologies which was entered into by either GPC or MORPHOSYS (all such payments,
“Third Party Payments”) in order to permit the Parties to perform their obligations under this Agreement and/or to make, have made, use, offer for sale, sell and/or import Licensed Products, GPC shall be responsible for making all such
Third Party Payments for itself, if a party to such agreement, or on MORPHOYSYS’ behalf, if MORPHOSYS is a party to such agreement. The Parties shall notify each other in writing of all Third Party Payment obligations which exist on the
Effective Date and will only assume future obligations with the prior written consent of the other Party, such consent to not be unreasonably withheld. Notwithstanding anything else contained herein, in no event will GPC be required to make any
payments to Cambridge Antibody Technology (“CAT”) other than royalty and 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 18 

 milestone payments or a reasonable pro rata portion of any license fee due to CAT (as determined in good
faith by the Parties based on the number of other licensees benefiting from any such CAT license) in order to fully exercise its rights hereunder. Any payments owed to Cambridge Antibody Technology other than the license fees, milestone and royalty
payments described above shall be paid by MORPHOSYS, including without limitation, any payments due as damages resulting from any legal action. 
  
 (b) For Licensed Products which have not been sublicensed by GPC, GPC may reduce the corresponding royalty and milestone payments
otherwise due and payable to MORPHOSYS pursuant to Sections 4.4 and 4.5 by *** (***%) of any relevant Third Party Payments actually paid, but in no event shall any such payments to MORPHOSYS hereunder be reduced by more than ***
(***%). In the event any such Third Party Payment is due for a milestone or royalty which does not correspond to a milestone or royalty payment due to MORPHOSYS hereunder, GPC shall be entitled to carry forward any credit permitted above to
the subsequent milestone or royalty payments for such Licensed Product which become due to MORPHOSYS hereunder. For Licensed Products which have been sublicensed by GPC, the provisions of Section 4.7 shall govern credits of relevant Third Party
Payments from the date of execution of such sublicense. 
  
 4.7
Sublicenses. 
  
 (a)
Notwithstanding the provisions of Section 4.4, in the event that GPC sublicenses a Sublicensee to commercialize a Licensed Product, GPC shall, in lieu of paying the milestones specified in Section 4.4 for such Licensed Product, pay to MORPHOSYS the
percentages specified below of any license or milestone fees or other non-royalty compensation but excluding research and development funding (whether such funding relates to work performed at GPC or work performed elsewhere) and equity investments
(“Sublicense Income”) from such Sublicensee, depending upon when any such sublicense agreement is executed with respect to the development of the relevant Licensed Product as follows: 
  

				
	 •      Before completion of pre-clinical studies
	  	***	%
		
	 •      After filing of IND
	  	***	%
		
	 •      After completion of first phase II study
	  	***	%
		
	 •      After completion of first phase III study
	  	***	%

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 19 

 Notwithstanding the foregoing, prior to computation of the above percentages, Sublicense
Income shall be reduced by the amount of all Third Party Payments (other than royalties) previously paid by GPC with respect to the relevant Licensed Product and by relevant payments actually made to BMBF by GPC.  
  
 (b) In lieu of the payments specified in Section 4.5, and in
light of GPC’s obligation to make all Third Party Payments to the relevant third parties as provided in Section 4.6, for Licensed Products sold by Sublicensees GPC shall pay to MORPHOSYS a royalty on Net Sales based on the following
formula: 
  

	
	***
	
	 Where: A = Royalties on Net Sales of Sublicensees to be received by MORPHOSYS;

	
	     B = Royalties on Net Sales received by GPC from Sublicensee;

	
	     C = Royalties payable as Third Party Payments; and

	
	     Z = Time dependent royalty sharing percentage according to the following table:

  

			
	 Time of Sublicense
	  	Royalty Share Z for MORPHOSYS
	 •      Before completing pre-clinical studies
	  	***%
		
	 •      After completion of pre-clinical studies but before completion of first Phase II clinical
study.
	  	***%
		
	 •      After completion of first Phase II clinical study but prior to completion of first Phase III or
Phase II/III clinical study
	  	***%
		
	 •      After completion of first Phase III or Phase II/III clinical study
	  	***%

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 20 

 (c) Notwithstanding the foregoing, in no event shall MORPHOSYS receive less than
***% of the Net Sales of any Sublicensee of such Licensed Product, unless the Parties otherwise mutually agree; provided, however, that the Parties shall agree to a lower amount if necessary to ensure that the share of Net Sales to be
retained by GPC, after payment of all Third Party Payments due thereon, shall not be less than ***. 
  
 4.8 One Royalty. Only one royalty, calculated at the highest applicable royalty rate hereunder, shall be payable to MORPHOSYS hereunder for
each sale of a Licensed Product. 
  
 4.9 Payment
Terms. 
  
 (a) Royalty payments shall be
made to MORPHOSYS in EUROs quarterly within forty-five (45) days following the end of each calendar quarter for which royalties are due. Each royalty payment shall be accompanied by a report summarizing the total gross sales of Licensed Products,
credits allowed pursuant to Section 1.25, and total Net Sales for each Licensed Product during the relevant three-month period and the calculation of royalties, if any, due thereon pursuant to this Article 3. 
  
 (b) All royalties shall be payable in full in Germany in
EUROs, regardless of the countries in which sales are made. For the purpose of computing Net Sales for Licensed Products sold in a currency other than EUROs, such currency shall be converted into EUROs at the exchange rate for buying EUROs set forth
in The Frankfurter Allgemeine Zeitung for the last business day of the calendar quarter. Such payments shall be without deduction of exchange, collection or other charges. 
  
 4.10 Royalty Term. GPC shall pay royalties with respect to each Licensed Product on a country by country basis
until (i) the expiration or revocation or complete rejection of the last to expire or to be revoked or to be completely rejected of any Patent Right or of any other patent or patent 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 21 

 
application licensed to GPC by MORPHOSYS hereunder covering such Licensed Product in such country, or (ii) twelve (12) years from the first commercial sale
of such Licensed Product in such country, whichever is later. Following such period, GPC shall have a fully paid-up, irrevocable license in such country under the relevant Patent Rights, Collaboration Inventions and MORPHOSYS Background Inventions
to make, have made, use, have used, sell, have sold, offer for sale, import and have imported such Licensed Product in such country. 
  
 4.11 Overdue Royalties. Royalties not paid within the time period set forth in this Article 4 shall bear interest quarterly at an
annual rate equal to the German federal discount rate plus two percent (2%) from the due date until the date paid in full. 
  
 4.12 Records Retention. Audits. GPC, its Affiliates and Sublicensees shall keep for three (3) years from the date of each payment of
royalties complete and accurate records of sales by GPC and its Affiliates and Sublicensees of each Licensed Product in sufficient detail to allow the accruing royalties to be determined accurately. MORPHOSYS shall have the right for a period of
three (3) years after receiving any report or statement with respect to royalties due and payable to appoint an independent certified public accountant reasonably acceptable to GPC to inspect the relevant records of GPC and its Affiliates and
Sublicensees to verify such report or statement. GPC and its Affiliates and Sublicensees shall each make its records available for inspection by such independent certified public accountant during regular business hours at such place or places where
such records are customarily kept, upon reasonable notice from MORPHOSYS, solely to verify the accuracy of the reports and payments. Such inspection right shall not be exercised more than once in any calendar year nor more than once with respect to
sales of any Licensed Product in any given payment period. MORPHOSYS agrees to hold in strict confidence and to cause its accountants to hold in strict confidence all information concerning royalty payments and reports, and all information learned
in the course of any audit or inspection, except to the extent necessary for MORPHOSYS to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law, regulation or judicial order. The results of
each inspection, if any, shall be binding on both Parties. MORPHOSYS shall pay for such inspections, except that in the event there is any upward adjustment in aggregate royalties payable 

  

 22 

 
for any year shown by such inspection of more than five percent (5%) of the amount paid, GPC shall pay for such inspection. 
  
 4.13 Taxes. If withholding taxes in the country of sale
of Licensed Products are levied on the amounts payable to MORPHOSYS under this Agreement, GPC shall pay such withholding taxes and deduct the amount paid to the tax authorities from the amount to be paid to MORPHOSYS. GPC shall provide MORPHOSYS
with the relevant certifications of any such tax payment and shall cooperate with MORPHOSYS in seeking a refund or waiver from the relevant tax authorities. 
  
 5. TREATMENT OF CONFIDENTIAL INFORMATION 
  
 5.1 Confidential Information. During the Term of this Agreement, each Party may disclose to the other Party proprietary information,
materials and technical and business information, including but not limited to MORPHOSYS Background Inventions, Collaboration Inventions, and Collaboration Material and information disclosed pursuant to Section 9.1 (which information shall be deemed
Confidential Information of MORPHOSYS) (collectively, “Confidential Information”). For a period of five (5) years after the end of the Collaboration Term, except as expressly permitted hereunder, the receiving Party shall keep confidential
all such Confidential Information of the other Party and will not disclose such Confidential Information of the other Party to third parties by publication or otherwise. Each Party further agrees not to use Confidential Information of the other
Party for any purpose other than conducting research hereunder or exercising any rights granted to it or reserved by it hereunder. Upon any termination or expiration of this Agreement, upon request, a Party shall return to the requesting Party all
copies of any of such requesting Party’s Confidential Information which is not the subject of a surviving license hereunder. Notwithstanding the foregoing, it is understood and agreed that the receiving Party’s obligations of
confidentiality and nonuse herein shall not apply to any information which: 
  
 (a) is, at the time of disclosure by the disclosing Party hereunder, or thereafter becomes, a part of the public domain or publicly known or available through no fault or negligence of the receiving Party or any of
its Affiliates; or 
  

 23 

 (b) was otherwise in the receiving Party’s lawful possession prior to disclosure by
the disclosing Party other than under an obligation of confidentiality; or 
  
 (c) was independently discovered or developed by the receiving Party or any of its Affiliates, without use of the other Party’s Confidential Information, as can be demonstrated by competent proof; or 

 
 (d) is lawfully disclosed to the receiving Party or any
of its Affiliates on a non-confidential basis by a third party that is not in violation of an obligation of confidentiality to the disclosing Party relative to such information. 
  
 Information disclosed that is not in written or electronic form shall be subject to the terms of this Section 5.1 for a
period of at least thirty (30) days and shall be subject to Section 5.1 for a continuing period only if confirmed in writing to the other Party within thirty (30) days of initial disclosure and specifying with particularity that Confidential
Information disclosed other than in written or electronic form which is to continue to be subject to the provisions of this Section 5.1. Each Party may disclose the other’s Confidential Information to the extent such disclosure is reasonably
necessary in (i) prosecuting patent applications and maintaining patents, or (ii) prosecuting or defending litigation, or (iii) complying with applicable governmental regulations provided, however, that if a Party is required to make any disclosure
of the other Party’s Confidential Information, it will give reasonable advance notice to the other Party of such disclosure requirement and will use reasonable efforts to secure confidential treatment of such information required to be
disclosed. 
  
 5.2 Publications. It is expected that
each Party may wish to publish the results of its research under the Collaboration Program. In order to safeguard intellectual property rights, the Party wishing to publish or otherwise publicly disclose the results of such research shall first
submit a draft of the proposed manuscripts to the Joint Steering Committee for review, comment and consideration of appropriate patent action at least eight (8) weeks prior to any submission for publication or other public disclosure. Within thirty
(30) days of receipt of the pre-publication materials, the Joint Steering Committee will advise the Party seeking publication as to whether a patent application will be prepared and filed or whether trade secret protection should be pursued and, if
so, the Joint Steering Committee 

  

 24 

 
will, in cooperation with both Parties, determine the appropriate timing and content of any such publications. 
  
 5.3 Publicity. Neither Party shall issue a press release
announcing the execution of this Agreement other than the press release attached hereto as Exhibit B. In addition to the issuance of such press release, the Parties shall also be permitted hereunder to disclose the general nature of this Agreement
to the extent reasonably necessary to obtain financing from third parties or potential collaborators, and to make such other disclosures as mutually agreed by the Parties. Once any written statement is approved for disclosure by both Parties, either
Party may make subsequent public disclosures of the contents of such statement without the further approval of the other Party. 
  
 6. INTELLECTUAL PROPERTY RIGHTS 
  
 6.1 Proprietary Material. 
  
 (a) GPC Proprietary Material. GPC Proprietary Material shall remain the property of GPC and MORPHOSYS shall use such GPC
Proprietary Material only for the purpose of conducting the Collaboration Program hereunder and shall not transfer GPC Proprietary Material to any other person or entity. Derivatives of GPC Proprietary Material shall remain GPC Proprietary Material.

  
 (b) Collaboration Material and
Deliverables. All Collaboration Material and Deliverables shall be the property of MORPHOSYS, subject only to any licenses granted to GPC hereunder. Derivatives of Collaboration Material shall remain Collaboration Material. 
  
 6.2 Collaboration Inventions. Except as set forth
in Section 6.1, all Collaboration Inventions shall be solely owned by a Party if solely invented by employees or representatives of such Party as determined under applicable patent laws, and shall be jointly owned if jointly invented by the
employees or representatives of both Parties as determined under applicable patent laws, and Patent Rights thereon shall be owned as determined in accordance with applicable patent laws. Each Party shall promptly disclose in writing to the other
Party all Collaboration Inventions made during the Collaboration Term. The rights and interests of MORPHOSYS and GPC in Collaboration Inventions shall be subject to the provisions of Section 2.1.4 and Article 3 and this Article 6. 
  

 25 

 7. PROVISIONS CONCERNING THE FILING, 
 PROSECUTION AND MAINTENANCE OF PATENT RIGHTS 
  
 7.1 Applicability. The provisions of this Section 7 shall be applicable to all Collaboration Inventions and Patent Rights thereon.

  
 7.2 Patent Prosecution. 
  
 (a) GPC shall have the first right (but not the obligation)
to prepare, file, prosecute, obtain and maintain patent applications and patents on Collaboration Inventions using patent counsel reasonably acceptable to MORPHOSYS with the expenses for any such preparation, filing, prosecution and maintenance to
be borne by GPC. GPC agrees that MORPHOSYS shall be kept fully informed of the progress of all patent prosecution and shall be provided with copies of all material documents pertaining thereto, and shall be provided with the reasonable opportunity
to comment thereon prior to filing, which comments shall be incorporated by GPC to the extent reasonably practical. MORPHOSYS agrees to provide reasonable assistance and cooperation to GPC to facilitate any such filing, prosecution and maintenance.

  
 (b) GPC may elect not to exercise its first
right to prepare, file, prosecute, obtain or maintain patent applications and patents on Collaboration Inventions as described in Section 7.2(a) above at any time for any such patent applications and patents. For all MORPHOSYS Collaboration
Inventions and for those GPC Collaboration Inventions having claims covering the composition or utility of Antibody Products discovered through the use of the MORPHOSYS Technologies for which such election is made, GPC shall give written notice
thereof to MORPHOSYS. Such notice shall specifically identify the invention(s), patent application(s) and/or patent(s) for which GPC wishes to relinquish such first right. Following the receipt of such notice, MORPHOSYS shall have the right at its
sole expense to prepare, file, prosecute, obtain and maintain the patent application(s) and patent(s) identified in the notice all for its own benefit, and such patent applications and patents shall be removed from the operation of this Agreement.

  
 (c) The Parties shall mutually agree before
permitting any patent application or patent within Patent Rights to lapse as well as before authorizing any amendment to any patent 

  

 26 

 
application or patent within Patent Rights that would irrevocably limit the lawful scope of the Patent Rights. 
  
 (d) No Party shall have any obligation under this Agreement
to pay any fees or costs: (i) for bringing a lawsuit or other action to enforce any of the Patent Rights against an actual or suspected infringement or (ii) for the other Party to obtain for its own benefit independent business or legal advice
concerning any of the Patent Rights. 
  
 (e) Each Party agrees to provide reasonable cooperation, at the other Party’s expense, in the preparation, filing and prosecution of any Patent Rights being prepared, filed or prosecuted by such other Party in accordance with the terms
of this Agreement, including, but not limited to, executing all papers and instruments, or requiring its employees or agents to execute such papers and instruments, so as to facilitate any such actions. 
  
 7.3 Notice of Infringement. If either Party learns of
any suspected infringement or threatened infringement by a third party of the patents within Patent Rights, such Party shall promptly notify the other Party and shall provide such other Party with its available information regarding such suspected
infringement. 
  
 7.4 Infringement. 
  
 (a) GPC shall have the first right (but not the obligation),
at its own expense, to bring suit (or other appropriate legal action) against any actual or suspected infringement of Patent Rights exclusively licensed to GPC hereunder. If GPC does not take such action within one hundred twenty (120) days after
written notice from MORPHOSYS of such infringement, MORPHOSYS shall have the right (but not the obligation), at its own expense, to bring suit against such infringement. Any amount recovered, whether by judgment or settlement, shall first be applied
to reimburse the costs and expenses (including attorneys’ fees) of the Party bringing suit, then to the costs and expenses (including attorneys’ fees), if any, of the other Party. Any amounts remaining shall be allocated three-quarters
(3/4) to the Party bringing suit and one-quarter (1/4) to the other Party or shall be allocated one-half to each Party if the suit is brought jointly. 
  

 27 

 (b) MORPHOSYS shall have the sole right to defend and enforce any claims relating to
infringement of MORPHOSYS Background Inventions licensed to GPC hereunder. 
  
 (c) GPC shall have the sole right to defend and enforce any claims relating to infringement of patent rights owned solely by GPC, other than any Patent Rights inuring solely to the benefit of MORPHOSYS as set forth in
Section 7.2(b). 
  
 7.5 Cooperation. Each
Party shall execute all papers and perform such other acts as may be reasonably required to maintain any infringement suit brought in accordance with Section 7.4 above (including giving legal consent for bringing such suit, and agreeing to be named
as a plaintiff or otherwise joined in such suit), and at its option and expense, may be represented in such suit by counsel of its choice. 
  
 8. TERM AND TERMINATION 
  
 8.1 Term. The term of this Agreement shall extend to the date neither Party has any further obligation pursuant to this Agreement,
unless this Agreement is otherwise terminated in accordance with the provisions hereof (the “Term”). 
  
 8.2 Termination. 
  
 (a) This Agreement and the rights and options granted herein may be terminated by either Party upon any material breach by the other Party
of any material obligation or condition, effective thirty (30) days after giving written notice to the alleged breaching Party of such termination in the case of a payment breach and sixty (60) days after giving written notice to the breaching Party
of such termination in the case of any other alleged breach (other than a breach of Section 3.2, for which the applicable time period shall be ninety (90) days), which notice shall describe such alleged breach in reasonable detail; provided,
however, that a breach of Section 3.2 shall only give rise to the termination rights specified therein. The foregoing notwithstanding, if such alleged default or breach is cured or shown to be non-existent within the aforesaid time period, the
notice shall be deemed automatically withdrawn and of no effect. For the purposes of this Section, (i) the failure of MORPHOSYS to use timely and diligent efforts, as specified in the Collaboration Plan, to develop Deliverables shall be deemed a
material breach of this Agreement giving rise to a right of GPC to terminate this Agreement 

  

 28 

 
pursuant to this Section 8.2(a), and (ii) the failure of GPC to use timely and diligent efforts, as specified in the Collaboration Plan, to determine whether
or not Deliverables meet the relevant Success Criteria shall be deemed a material breach of this Agreement giving rise to a right of MORPHYSYS to terminate this Agreement pursuant to this Section 8.2(a) with respect to the relevant GPC Target;
provided, however, that such a material breach may be cured by GPC by making the relevant payment to MORPHOSYS specified in Section 4.4(a) or (b) within ten (10) days of notice of any such breach, rather than upon the due date specified in Section
4.4(a); and provided further that MORPHOSYS shall not be permitted to give any such notice for a period of six months following delivery of the relevant Deliverables to GPC. In addition, if the existence of any breach of this Agreement is disputed
in good faith by either Party, the period set forth above shall be tolled pending resolution of any such good faith dispute pursuant to the provisions of Section 9.18. 
  
 (b) If either Party files for protection under bankruptcy laws, makes an assignment for the benefit of
creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency act or has any such petition filed against it which is not discharged within sixty (60) days of the filing
thereof, then the other Party may terminate this Agreement by notice to such Party. 
  
 (c) In the event that (i) MORPHOSYS is prevented from licensing and screening its antibody libraries as a result of a court order or any
other reason, (ii) MORPHOSYS is required to obtain a license from Cambridge Antibody Technology (“CAT”) to perform its obligations hereunder and is unable to obtain such license, or (iii) GPC, and not MORPHOSYS, is required to obtain a
license from CAT in order to allow GPC to fully exercise its rights hereunder and GPC is unable to obtain such a license on commercially reasonable terms, then GPC may terminate this Agreement by notice to MORPHOSYS. 
  
 (d) Obligations after Termination. Upon termination
of this Agreement pursuant to Section 4.3, 8.2, 8.4 or 2.1.5, neither Party shall have any further obligation to the other Party hereunder except as set forth in Section 8.6. Notwithstanding the foregoing, GPC shall remain liable for all payment
obligations accruing prior to the effective date of any such termination, but shall have no obligation to make any payment that has not accrued prior to the effective date of any such termination. 
  

 29 

 8.3 Effect of Termination. 
  
 (a) Upon termination of this Agreement pursuant to Section 4.3, Section 8.2, Section 8.4 or Section 2.1.5,
the relevant GPC Target(s) shall be removed from Appendix A and GPC shall cease sales, if any, of all Licensed Products covered by the terminated license(s) and all rights included in the relevant licenses granted by MORPHOSYS to GPC
hereunder with respect to the relevant GPC Target(s) shall immediately and automatically revert to MORPHOSYS. Without limiting the generality of the foregoing, all relevant licenses and sublicenses granted by MORPHOSYS to GPC hereunder shall
terminate automatically and GPC shall promptly transfer to MORPHOSYS all related documents, instruments, records and data relevant to the development or commercialization of the relevant Licensed Product(s) generated or developed by or on behalf of
GPC during the term of this Agreement along with all related Collaboration Data, and Collaboration Material in its possession, and MORPHOSYS shall promptly return to GPC all GPC Proprietary Material in its possession, in each case without retaining
any copies of any of the foregoing. In addition, upon any termination by MORPHOSYS pursuant to Section 8.2(a) or (b) or pursuant to Section 4.3, (i) GPC shall be deemed to have granted to MORPHOSYS a non-exclusive, worldwide royalty-free license
(including the right to grant sublicenses) under GPC’s ownership interest, if any, in Collaboration Data, Collaboration Inventions and Patent Rights related to the terminated license to develop, have developed, make, have made, use, have used,
offer for sale, sell, have sold, import and have imported Antibody Products binding to the terminated GPC Target and developed utilizing the MORPHOSYS Technologies for use in all fields, and (ii) upon written request of MORPHOSYS, GPC shall
negotiate the terms of an exclusive license to MORPHOSYS under GPC’s ownership interest, if any, in such Collaboration Data, Collaboration Inventions and Patent Rights, and under other proprietary rights owned or controlled by GPC necessary or
useful to allow MORPHOSYS to develop, have developed, make, have made, use, have used, offer for sale, sell, have sold, import and have imported Antibody Products binding to the terminated GPC Target for use in all fields, upon commercially
reasonable terms to be negotiated in good faith by the Parties. Upon any termination by GPC within 18 months of the Effective Date pursuant to Section 8.2(a) or by GPC pursuant to Section 8.2(c), MORPHOSYS shall, within thirty (30) days of such
termination, refund to GPC all amounts previously paid by GPC hereunder. 
  

 30 

 (b) Documentation. At the request of MORPHOSYS, GPC shall execute and deliver such
bills of sale, assignments and licenses and other documents as may be necessary to fully vest in MORPHOSYS all right, title and interest to which it is entitled as aforesaid pursuant to this Section 8.3. 
  
 (c) Payment Obligations. GPC shall have no obligation
to make any milestone or royalty payment to MORPHOSYS that has not accrued prior to the effective date of such termination, but shall remain liable for all obligations accruing prior to termination. 
  
 8.4 Termination by GPC. Unless earlier terminated pursuant to
the other provisions hereof, GPC may terminate this Agreement, and the rights and obligations hereunder, or may remove any GPC Target and the licenses related thereto from operation of this Agreement, in its sole discretion at any time following the
first anniversary of the expiration of the Collaboration Term by giving written notice thereof to MORPHOSYS. Such termination shall be effective fifteen (15) days following the date such notice is received by MORPHOSYS and shall have all
consequences as set forth in Section 8.3 above, but only with respect to such removed GPC Target, as if this Agreement had been terminated by MORPHOSYS pursuant to Section 8.2(a). 
  
 8.5 Remedies. If either Party shall fail to perform or observe or otherwise breaches any of its
material obligations under this Agreement, in addition to any right to terminate this Agreement, the non-defaulting Party may elect to obtain other relief and remedies available under law. 
  
 8.6 Surviving Provisions. Notwithstanding any provision
herein to the contrary, the rights and obligations set forth in Sections 2.1.4, 2.1.5, 2.4, 2.5, 3.6, 3.8, 4.8, 4.10, 4.11, 4.12, 4.13, 5.1, 5.2, 5.3, 6.1, 6.2, 7.2(d), 7.2(e), 7.5, 8.2(d), 8.3, 8.5, 8.6, 9.3, 9.4, 9.16 and 9.18 hereof shall survive
the expiration or termination of the Term of this Agreement. 
  
 9.
MISCELLANEOUS 
  
 9.1 MORPHOSYS
Representations. MORPHOSYS represents and warrants that: (a) the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all appropriate MORPHOSYS corporate
action; (b) MORPHOSYS is under no obligation which is inconsistent with this Agreement, and (c) 

  

 31 

 
MORPHOSYS has the full right and legal capacity to grant the rights to GPC pursuant to Article 3 without violating its obligations to or the rights of any
third party, (d) upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of MORPHOSYS enforceable in accordance with its terms, except as enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally, (e) except as otherwise disclosed to GPC, there are no material adverse proceedings, claims or actions
pending, or to the best of MORPHOSYS’ knowledge, threatened, relating to any MORPHOSYS Technology or know-how owned or controlled by MORPHOSYS or its Affiliates as of the date of this Agreement which would materially interfere with
MORPHOSYS’ performance of its obligations under this Agreement; and, further, MORPHOSYS will promptly inform GPC of any material adverse proceedings, claims or actions that may arise during the Term relating to any such property or relating to
Patent Rights, Collaboration Data or Collaboration Material (to the extent the foregoing are owned by MORPHOSYS), which would materially interfere with any rights granted to GPC hereunder or with the performance of MORPHOSYS’ obligations under
this Agreement, (f) the rights, information and property licensed by MORPHOSYS to GPC pursuant to this Agreement have not been obtained by MORPHOSYS in violation of any material contractual obligations to which MORPHOSYS is or was a party, or by
misappropriation of the trade secrets of any third party; and (g) to the best of MORPHOSYS’ knowledge and belief, and except as otherwise disclosed to GPC, the performance of MORPHOSYS’s obligations under this Agreement, including without
limitation the delivery to GPC of the Deliverables, will not infringe any issued patent or valid copyright of any Third Party. 
  
 9.2 GPC Representations. GPC represents and warrants that: (a) the execution and delivery of this Agreement and the performance of the
transactions contemplated hereby have been duly authorized by all appropriate GPC corporate action; (b) GPC is under no obligation which is inconsistent with this Agreement, and (c) GPC has the full right and legal capacity to grant the rights to
MORPHOSYS pursuant to Article 3 without violating its obligations to or the rights of any third party, (d) upon the execution and delivery of this Agreement, this Agreement shall constitute a valid and binding obligation of GPC enforceable in
accordance with its terms, except as enforceability may be 

  

 32 

 
limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights
generally. 
  
 9.3 No Warranties. 
  
 (a) Nothing in this Agreement is or shall be construed as:

  

	 	(i)	a warranty or representation by either Party as to the validity or scope of any application or patent licensed hereunder; 

  

	 	(ii)	a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted pursuant to this Agreement is or will be free from infringement of
patents, copyrights, and other rights of third parties; 

  

	 	(iii)	obligating either Party to commercialize inventions made hereunder or to perform any additional work beyond that set forth in the Collaboration Plan and in Section 3.2.

  
 (b) Except as expressly set
forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR OF
NON-INFRINGEMENT OF ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS, OR ANY OTHER EXPRESS OR IMPLIED WARRANTIES. 
  
 9.4 Liability. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY WILL BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER
OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR (I) ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS OR (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR
SERVICES 
  
 9.5 Notices. Any notices, requests,
deliveries, approvals or consents required or permitted to be given under this Agreement to GPC or MORPHOSYS shall be in writing and shall be personally 

  

 33 

 
delivered or sent by telecopy (with written confirmation to follow via United States first class mail), overnight courier providing evidence of receipt or
certified mail, return receipt requested, postage prepaid, in each case to the respective address specified below (or to such address as may be specified in writing to the other Party hereto): 
  

			
	 MORPHOSYS:
	  	Am Klopferspitz 19
	 	  	82152 Martinsried
	 	  	Munich, Germany
	 	  	Attn: Chief Executive Officer
	 	  	Telecopy: 011-49-89-899-27-222
		
	 With a copy to:
	  	Jeffrey M. Wiesen, Esq.
	 	  	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	 	  	One Financial Center
	 	  	Boston, MA 02111
	 	  	Telecopy: 617-542-2241
		
	 GPC:
	  	GPC AG - Genome Pharmaceuticals Corporation
	 	  	Fraunhofer Strasse 20
	 	  	82152 Martinsried
	 	  	Munich, Germany
	 	  	Attn: Chief Executive Officer
	 	  	Telecopy: 011-49-89-8565-2610
		
	 With a copy to:
	  	Michael Lytton, Esq.
	 	  	Marc Rubenstein, Esq.
	 	  	Palmer & Dodge, LLP
	 	  	One Beacon Street
	 	  	Boston, MA 02108
	 	  	Telecopy: 617-227-4420

  
 Such notices shall be
deemed to have been sufficiently given on: (a) the date sent if delivered in person or transmitted by telecopy, (b) the next business day after dispatch in the case of overnight courier or (c) in all other cases, the date actually received.

  

 34 

 9.6 Governing Law. This Agreement will be construed, interpreted and applied in accordance
with the laws of the State of Delaware (excluding its body of law controlling conflicts of law), and where appropriate, the United States of America. 
  
 9.7 Limitations. Except as set forth elsewhere in this Agreement, neither Party grants to the other Party any right or license to any of its
intellectual property. 
  
 9.8 Entire Agreement.
This is the entire Agreement between the Parties with respect to the subject matter hereof and supersedes all prior agreements between the Parties with respect to the subject matter hereof. No modification shall be effective unless in writing with
specific reference to this Agreement and signed by the Parties. 
  
 9.9 Waiver. The terms or conditions of this Agreement may be waived only by a written instrument executed by the Party waiving compliance. The failure of either Party at any time or times to require performance of any
provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either Party of any condition or term shall be deemed as a continuing waiver of such condition or term or of another condition or term.

  
 9.10 Headings. Section and subsection headings
are inserted for convenience of reference only and do not form part of this Agreement. 
  
 9.11 Assignment. This Agreement may not be assigned by either Party without the consent of the other, except that each Party may, without such consent, assign this Agreement and the rights, obligations
and interests of such Party, in whole or in part, to any of its Affiliates, to any purchaser of all or substantially all of its assets in the line of business to which this Agreement pertains or to any successor corporation resulting from any merger
or consolidation of such Party with or into such corporations. 
  
 9.12 Force Majeure. Neither Party shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to
natural disasters or any causes beyond the reasonable control of such Party. In event of such force majeure, the Party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder.

  

 35 

 9.13 Construction. The Parties hereto acknowledge and agree that: (i) each Party and its
counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the
interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the
preparation of this Agreement. 
  
 9.14
Severability. If any provision(s) of this Agreement are or become invalid, are ruled illegal by any court of competent jurisdiction or are deemed unenforceable, in whole or in part, under then current applicable law from time to time
in effect during the Term hereof, it is the intention of the Parties that the remainder of this Agreement shall not be affected thereby provided that a Party’s rights under this Agreement are not materially affected. The Parties hereto covenant
and agree to renegotiate the affected portions of any such term, covenant or application thereof in good faith in order to provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or the application thereof
that is invalid, illegal or unenforceable, it being the intent of the Parties that the basic purposes of this Agreement are to be effectuated. 
  
 9.15 Status. Nothing in this Agreement is intended or shall be deemed to constitute a partner, agency, employer-employee, or joint venture
relationship between the Parties. 
  
 9.16
Indemnification. 
  
 (a) GPC shall
indemnify, defend and hold harmless MORPHOSYS, its Affiliates and their respective directors, officers, employees, and agents and their respective successors, heirs and assigns (the “MORPHOSYS Indemnitees”), against any liability, damage,
loss or expense (including reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon the MORPHOSYS Indemnitees, or any of them, in connection with any claims, suits, actions, demands or judgments of third parties,
including without limitation personal injury and product liability matters (except in cases where such claims, suits, actions, demands or judgments result from a willful material breach of this Agreement, gross negligence or willful misconduct on
the part of MORPHOSYS) arising out of or relating to the manufacture, use or sale of Licensed Products by GPC or any Affiliate, licensee, sublicensee, distributor or agent of GPC under this Agreement or breach of any representation or warranty by
GPC. 
  

 36 

 MORPHOSYS shall promptly notify GPC of any action or claim for which it is to be
indemnified hereunder and GPC shall have the sole right to defend, settle or compromise any such action or claim. 
  
 (b) MORPHOSYS shall indemnify, defend and hold harmless GPC, its Affiliates and their respective directors, officers, employees, and
agents and their respective successors, heirs and assigns (the “GPC Indemnitees”), against any liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon the GPC
Indemnitees, or any of them, in connection with any claims, suits, actions, demands or judgments of third parties, including without limitation personal injury and product liability matters (except in cases where such claims, suits, actions, demands
or judgments result from a willful material breach of this Agreement, gross negligence or willful misconduct on the part of GPC) arising out of or relating to (i) the manufacture, use or sale of products by MORPHOSYS or any Affiliate, licensee,
sublicensee, distributor or agent of MORPHOSYS under any license granted to MORPHOSYS by GPC pursuant to this Agreement, (ii) any legal action against MORPHOSYS which has commenced, in whole or in part, prior to the Effective Date, or (iii) any
breach of a representation or warranty by MORPHOSYS. GPC shall promptly notify MORPHOSYS of any action or claim for which it is to be indemnified hereunder and MORPHOSYS shall have the sole right to defend, settle or compromise any such action or
claim. 
  
 9.17 Further Assurances. Each Party
agrees to execute, acknowledge and deliver such further instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  
 9.18 Dispute Resolution. 
  
 (a) The Parties recognize that disputes as to certain
matters may from time to time arise during the term of this Agreement which relate to either Party’s rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes
arising under this Agreement in an expedient matter by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Section 9.18 if and when a dispute arises under
this Agreement between the Parties or among the Joint Steering Committee. 
  

 37 

 (b) If the Parties or the Joint Steering Committee cannot resolve any such dispute by
good faith negotiations, which both Parties agree to undertake within 20 days of formal request by either Party to the other, any Party may, by written notice to the other, have such dispute referred to the Chief Executive Officers of both Parties
for attempted resolution by good faith negotiations within 30 days after such notice is received. 
  
 (c) Any such dispute, except disputes relating to patent validity, enforceability and/or infringement, arising out of or relating to this
Agreement which is not resolved between the Parties or the Joint Steering Committee or the Chief Executive Officers of the Parties pursuant to Section 9.18(b), shall be resolved by final and binding arbitration conducted in Boston, Massachusetts
under the then current rules of the American Arbitration Association (“AAA”). The arbitration shall be conducted by one arbitrator who is knowledgeable in the subject matter which is at issue in the dispute and who is selected by mutual
agreement of the Parties, or, failing such agreement, shall be selected according to the AAA rules. In conducting the arbitration, the arbitrator shall be able to decree any and all relief of an equitable nature, including but not limited to such
relief as a temporary restraining order, a preliminary injunction, a permanent injunction, or replevin of property. The arbitrator shall also be able to award actual damages, but shall not award any other form of damages (e.g., consequential,
incidental, punitive or exemplary damages). The Parties shall share equally the arbitrator’s fees and expenses pending the resolution of the arbitration unless the arbitrator, pursuant to his or her right but not his or her obligations,
requires the non-prevailing Party to bear all or any portion of the costs of the prevailing Party. The decision of the arbitrator shall be final and may be sued on or enforced by the Party in whose favor it runs in any court of competent
jurisdiction at the option of such Party. 
  
 IN WITNESS WHEREOF,
the Parties have caused this Agreement to be executed by their duly authorized representative in two (2) originals. 
  

									
	 GPC AG - GENOME
 PHARMACEUTICALS CORPORATION
	 	 	 	 MORPHOSYS AG

					
	 By:
	 	 /s/ Bernd R. Seizinger
	 	 	 	 By:
	 	 /s/ Thomas von Rüden

	 Title:
	 	 President and Chief Executive Officer
	 	 	 	 Title:
	 	 CSO

					
	 By:
	 	 /s/ Elmar Maier
	 	 	 	 By:
	 	 /s/ Dave Lemus

	 Title:
	 	 Senior Vice President Business Development
	 	 	 	 Title:
	 	 CFO

  

 38 

 APPENDIX A 
  
 GPC Target List 
  
 The target molecule is the class II human major histocompatibility (MHC) moleculed termed HLA-DR (DR). The DR molecule consists of two chains: the 35 kD
alpha encoded in the DRA locus and 28 kD beta encoded in the DRB locus. The DRA locus is practically monomorphic, it has one major allele DRA1*0101 and a minor allele DRA1*0102,***. In contrast, the beta chains are encoded in the highly polymorphic
DRB1 locus with ~ 60 alleles. ***. There are three additional loci encoding beta chains, namely, DRB3 with four, DRB4 with one, DRB5 with four, and DRB6 with three alleles. *** 
  
 Both DR alpha and beta chains consist of two extraceullular, a transmembrane,
and an intracytoplasmic domain. *** Two different antibody activities are searched for: one that is immunosuppressive, i.e., inhibits the activation of CD4+ T helper cells, and another that is apoptotic for proliferating DR+ cells including
DR+ malignant cells. Both of these activities have been associated with specificities for the *** antibodies tested thus far have not caused either immunosuppression or apoptosis. However, *** immunosuppressive antibodies have been
demonstrated, and the same applies to apoptotic antibodies, although the strongest known apoptotic antibody is ***. Therefore, based on presently available information, specific epitopes within the alpha and beta first domains cannot be
assigned for these two activities. 
  
 Thus, in summary, GPC
Targets shall include the ***. 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 39 

 APPENDIX B 
  
 Acknowledgment of Third Party Interest 
  
 [Follows] 
  

 40 

 APPENDIX C 
  
 Success Criteria 
  
 CONFIDENTIAL 
  

	1.	Immunosuppressive mAb 

  
 scFv. Kd = or < ***, T cell inhibition IC50 = or < ***, reactivity with *** (panel test). 
  
 IgG. Kd and T cell inhibition ***. Lack of toxicity in DR-tg mice. Inhibition of *** in DR-tg mice by a single i.v. injection of <*** mg/kg.

  

	2.	Apoptotic mAb 

  
 scFv. Killing of <*** at 37°C, when ***. No affinity criteria (except maybe as a guideline). Reactivity with *** (panel test). 
  
 IgG. Lack of toxicity in DR-tg mice. Killing (<***) of a selected panel of ***. 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 41 

 EXHIBIT A 
  
 MORPHOSYS TECHNOLOGIES 
  

Human Combinatorial Antibody Library (HuCAL) 
  
 MORPHOSYS will utilize vectors for phage display and antibody expression and the HuCAL antibody libraries for cloning, screening, expression and purification of HuCAL
derived antibodies. 
  
 Design of HuCAL antibody genes 
  

	 	•	49 fully synthetic human antibody genes, 

  

	 	•	single chain Fv(scFv) format with the orientation VH-Linker-VL, 

  

	 	•	signal sequence derived from the E. coli phoA gene, 

  

	 	•	an N-terminal detection tag derived from the FLAGTM epitope, 

  

	 	•	a 20 amino acid linker between VH and VL, 

  

	 	•	unique restriction sites facilitating cloning of HuCAL genes and elements thereof, 

  

	 	•	unique restriction sites for CDR randomisation. 

  
 HuCAL Libraries 
  
 MORPHOSYS will utilize the following library: 
  

	 	•	HuCAL *** library: a collection of all 49 HuCAL *** master genes cloned in the HuCAL phagemid vector *** used for antibody selection by phage display and panning. Both
the light chain and heavy chain CDR3s are randomized. The total library size was determined to be at least *** independent colonies. The library will be provided as a glycerol stock of transformed E. coli TG1 cells. 

 
 Expression vectors 
  
 Expression vectors contain a ColEI origin, an antibiotic resistance gene, an operon for recombinant protein expression under control of the
inducible lac promoter/operator region, a lac repressor gene, unique restriction sites for insertion of genes and an in-frame region encoding at least one tag useful for detection and purification of expressed genes. 

 

	 	•	*** this expression vector is derived from the pMorph series and can be used to express monomeric proteins such as ***. It provides chloramphenicol resistance. HuCAL

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 42 

 derived *** inserted into this vector will be carrying an *** tag derived from the
*** tag useful for detection in Western blots using the commercially available anti-*** antibody ***, and two tags at the C-terminus: the original *** tag useful for detection in ELISA assays using the commercially
available anti-*** antibody ***, followed by a *** useful for *** purification using ***. 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 43 

 EXHIBIT B 
  
 PRESS RELEASE 
  
 [Follows] 
  

 44

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]